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ABSTRACT 
 
The  MLL gene, located on 11q23, is involved in a large number of 
chromosomal translocations, including t(9;11)(p22;q23) and t(11;19)(p22;q23). 
These translocations encode the MLL-AF9 and MLL-ENL fusion transcription 
factors and are prevalent in infant acute leukaemia and therapy-related leukaemia. 
Leukaemias associated with these translocations have a particularly poor outcome. In 
order to conditionally express the MLL-AF9 fusion oncogene in primary 
haematopoietic progenitor cells, retroviral delivery of the Tet-off expression system 
was used. Progenitors were purified from murine bone marrow and co-infected with 
MSCV-TRE-fMLL-AF9 and MSCV-tTA retroviral supernatants. Using this 
approach, eight independent cell lines with conditional expression of MLL-AF9 and 
three independent cell lines with constitutive MLL-AF9 expression were generated. 
Treatment of the conditional cells with Doxycycline caused a decrease in MLL-AF9 
mRNA and protein expression, and resulted in terminal differentiation of the cells. 
By analysing global changes in gene expression after treatment of cells with 
Doxycycline, using Mouse genome Affymetrix Gene Chips (430 2.0), we have 
identified a number of potential transcriptional target genes of the MLL-AF9 and 
MLL-ENL fusion oncogenes. In order to examine the importance of target genes for 
MLL-fusion mediated transformation, up-regulated target genes were knocked down 
in vitro. Knock-down of a small proportion of the target genes analysed caused 
MLL-ENL and MLL-AF9 immortalised cells to die. These data illustrate novel 
approaches to interfering with MLL-fusion activity in leukaemia. In order to 
establish the importance of MLL-fusion activity for leukaemia in vivo, and hence its 
dependence on the transcriptional target genes identified, MLL-ENL immortalised 
cell lines were chosen to be injected into primary recipients. Conditionally MLL-  4
ENL immortalised cell lines were found to induced leukaemia in vivo. Leukaemic 
cells isolated from primary recipient mice were shown to have acquired additional 
genetic abnormalities and, when transplanted into secondary recipients, induced 
leukaemia with shortened latencies. However, the leukaemic cells remained 
dependent on MLL-ENL expression in vitro and in vivo, and its ablation resulted in 
regression of established leukaemias. 
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CHAPTER I  - INTRODUCTION 
 
1.1.  Haematopoiesis 
 
Haematopoiesis, the development of blood cells, has been well described in 
the mouse and serves as a model for human haematopoiesis. In vertebrates, 
establishment of a haematopoietic system starts early in the embryo and functions 
throughout embryonic and adult life. The extra-embryonic yolk sac produces the first 
haematopoietic cells, a process known as primitive haematopoiesis (reviewed in 
Orkin, 2000). Following this, the production of blood cells progresses to an intra-
embryonic site defined as the aorta-gonad-mesonephros (AGM) and then to the 
foetal liver. After birth, haematopoietic precursors seed the bone marrow, which 
becomes the main site of haematopoietic activity (reviewed in Keller et al., 1999). 
Haematopoiesis within the embryo is referred to as definitive haematopoiesis 
(reviewed in Orkin, 2000). Haematopoiesis takes place in a hierarchical order with 
haematopoietic stem cells (HSC) as the origin of multiple lineages. HSC have two 
characteristic capacities, they have the potential to self-renew and they can 
differentiate into various haematopoietic progenitor cells (HPC). HPC give rise to 
lineage specific precursors, which ultimately differentiate into mature blood cells 
(reviewed in Orkin, 2000). In murine haematopoiesis, HSC exist in a small fraction 
of bone marrow cells not expressing lineage-associated surface marker (Lin
-) but 
expressing high Sca1 and c-Kit (Lin
-Sca1
+c-kit
hi; LSK). Within the LSK fraction 
long-term self-renewal HSC (LT-HSC) reside in the CD34
-CD38
+ compartment and 
HSC with short-term self-renewal capacity (ST-HSC) reside in the CD34
+CD38
- 
compartment (Randall et al., 1996).    25
The classical model of the haematopoietic hierarchy (Figure 1) proposes that 
ST-HSC give rise to strictly lineage committed progenitor cells, either the common 
lymphoid progenitor (CLP) or the common myeloid progenitor (CMP). It has been 
shown that the interleukin-7 receptor α-chain (IL-7Rα) marks the CLP and that cells 
in the Lin
-Sca1
loc-Kit
loIL-7Rα
+ compartment give rise to T-Cells, B-Cells and natural 
killer (NK)-Cells (Kondo et al., 1997). The CMP do not express IL-7Rα and reside 
in the Lin
-Sca1
-c-Kit
+ fraction. By including expression profiles of the Fcγ receptor-
II/III (FcγRII/III), a marker for myeloid progenitors, and expression of CD34, this 
fraction can be further divided. CMP are FcγRII/III
loCD34
+ and give rise to 
FcγRII/III
loCD34
-  megakaryocyte-erythrocyte restricted progenitors (MEP) and 
FcγRII/III
hiCD34
+ granulocyte-macrophage restricted progenitors (GMP) (Akashi et 
al., 2000). GMP and MEP produce only granulocyte-macrophage or megakaryocyte-
erythrocyte lineage cells, respectively. 
 
Contrary to this classical model of haematopoietic development, two 
alternative models have been proposed, which do not support an early division into 
lineage restriction of the progenitor cells (Adolfsson et al., 2005). By including 
FMS-like tyrosine kinase 3 (Flt3) as a marker for a compartment of the LSK cells, it 
was shown that LSKFlt3
+ cells had the potential to produce granulocyte, 
macrophage, B-cell and T-cell lineage cells but no megakaryocyte-erythrocyte 
lineage cells (Adolfsson et al., 2005). The LSKFlt3
+ cells were termed lymphoid-
primed multipotent progenitors (LMPP) and asymmetric cell division of the ST-HSC 
into MEP and LMPP was proposed as the alternative model of haematopoietic 
development which does not include the existence of a CMP (Figure 2) (Adolfsson et 
al., 2005).    26
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Figure 1: Classical model of adolescent haematopoiesis 
Long-term haematopoietic stem cells (LT-HSC) have the potential to self renew and 
give rise to short-term HSC (ST-HSC) with limited self-renewal capacity. ST-HSC 
give rise to the common myeloid progenitors (CMP) and the common lymphoid 
progenitors (CLP). CMP can generate megakaryocyte-erythrocyte resricted 
progenitors (MEP) and granulocyte-macrophage restricted progenitors (GMP) which 
in turn give rise to the mature myeloid lineage cells. CLP can generate NK cells, B-
cell progenitors (Pro-B) and T-cell progenitors (Pro-T) which in turn give rise to the 
mature lymphoid lineage cells (adapted from Traver et al., 2001).   27
 
 
 
LT-HSC
ST-HSC
MEP LMPP
CLP GMP
Pro-B Pro-T
LT-HSC
ST-HSC
CMP LMPP
CLP GMP
Pro-B Pro-T
MEP
Alternative Model Composite Model
 
 
 
 
Figure 2: Alternative and composite model of haematopoiesis 
The alternative model describes a less lineage restricted haematopoietic development 
by introducing a lymphoid-primed multipotent progenitors (LMPP). The alternative 
model was combined with the classical model into the composite model, in order to 
include the coexistence of the CMP and LMPP (adapted from Iwasaki and Akashi, 
2007).   28
However, since it has been shown that CMP exist in the Lin
-Sca1
-Kit
+IL-7Rα
-
FcγRII/III
loCD34
+  compartment (Akashi et al., 2000), a composite model of 
haematopoiesis has been proposed (Figure 2). In the composite model, upon 
asymmetric cell division, the ST-HSC give rise to CMP and LMPP. CMP retain the 
potential to produce granulocyte-macrophage or megakaryocyte-erythrocyte lineage 
cells and LMPP have the potential to produce granulocyte-macrophage as well as B-
cell and T-cell lineage cells (Adolfsson et al., 2005; reviewed in Iwasaki and Akashi, 
2007). 
 
1.2.  Transcriptional control of haematopoiesis 
 
Self-renewal, lineage commitment and differentiation of HSC are complex 
processes that are orchestrated by expression of lineage specific transcription factors. 
The lineage specific function of any given transcription factor is analysed by loss-of-
function or overexpression studies (reviewed in Iwasaki and Akashi, 2007). 
Experiments using these approaches have revealed transcription factors which are 
essential for haematopoiesis, such as the Mixed lineage leukaemia ( MLL),  Acute 
myeloid leukaemia 1 ( AML1) and translocation-Ets-leukaemia ( TEL) genes. Mll 
deficient mice (Mll
-/-) were generated by homologous recombination in embryonic 
stem cells (Yu et al., 1995; Yagi et al., 1998). Mll deficiency was embryonic lethal, 
by embryonic day E10.5 (Yu et al., 1995) or between E11.5-E14.5 (Yagi et al., 
1998). HPC isolated from both the yolk sac (Hess et al., 1997) and foetal liver (Yagi 
et al., 1998) of Mll
-/- mice demonstrated impaired clonogenic capacity in vitro. It was 
shown that the number of colony-forming unit-granulocyte, erythroid, macrophage, 
megakaryocyte (CFU-GEMM), colony-forming unit-macrophage (CFU-M) and 
burst-forming unit-erythroid (BFU-E) was reduced in Mll
-/- cultures (Hess et al.,   29
1997). However, Mll
-/- cultures developed all cell types (Hess et al., 1997). These 
studies indicate that Mll affects early haematopoiesis and functions in the control of 
HPC but is not required for later stages of differentiation. Two conditional Mll 
knock-out studies showed that Mll function is important for stem cell self-renewal 
capacity and promoting proliferation in progenitors (McMahon et al., 2007; Jude et 
al., 2007). 
 
Another transcription factor, AML1, and its dimerising partner, core binding 
factor  β ( CBFβ), form a complex and are two of the most frequent targets of 
chromosomal rearrangements in human leukaemia. AML1 deficient mice (AML1
-/-) 
showed a complete absence of foetal liver-derived haematopoiesis and were 
embryonic lethal around day E12.5 (Okuda et al., 1996). These results indicate that 
AML1 regulates target genes that are essential for definitive haematopoiesis of all 
lineages. Surprisingly, a conditional AML1 knock-out study has recently shown that 
AML1 is not required for maintenance of HSC in adult haematopoiesis. However, it 
is necessary for maturation of megakaryocytes and differentiation of lymphocytes 
(Ichikawa et al., 2004). 
 
Tel encodes an Ets family transcription factor and is expressed in 
haematopoietic cells (Wang et al., 1998). Tel deficient mice (Tel
-/-) are embryonic 
lethal at day E11.5 because of yolk sac angiogenic defect (Wang et al., 1997). It was 
shown that in chimeras, Tel deficient embryonic stem cells contribute to foetal liver 
haematopoiesis but do not contribute to bone marrow myelopoiesis, erythropoiesis 
and lymphopoiesis (Wang et al., 1998). Therefore, Tel function seems to be essential 
for the establishment of haematopoiesis of all lineages in the bone marrow. A 
conditional  Tel knock-out model further showed that haematopoiesis in the bone   30
marrow depends on Tel expression. However Tel does not function as a master 
regulator but is specifically required for maturation of megakaryocytes and for 
survival of HSC in the bone marrow (Hock et al., 2004). 
 
Lineage specific gene expression depends on the presence of a combination 
of transcription factors. The main transcriptional regulators required for myeloid cell 
development include PU.1, GATA-1 and CCAAT/enhancer binding protein (C/EBP). 
The transcription factor PU.1, an ETS family member, is only expressed in 
haematopoietic cells. High levels of PU.1 are found in monocytic, granulocytic and 
B lymphoid lineages, whereas low levels are found in mature erythrocytes (reviewed 
in Gupta et al., 2009). PU.1 deficient mice lack mature macrophages, neutrophils, B- 
and T-cells and die shortly after birth (McKercher et al., 1996). Different levels of 
PU.1 gene expression are responsible for differentiation into macrophages, 
granulocytes or lymphocytes (reviewed in Gupta et al., 2009). PU.1 knock-down 
mice developed a block in macrophage and B-cell development (Rosenbauer et al., 
2004). These studies revealed that control of PU.1 expression is important for normal 
haematopoietic development. A variety of other transcription factors have been 
shown to interact with PU.1 and determine haematopoietic cell development. Among 
these are the megakaryocyte-erythroid transcription factor, GATA-1, and C/EBPα, 
which is expressed in immature myeloid cells (reviewed in Gupta et al., 2009). PU.1 
has been shown to block transcription of genes required for commitment to MEP 
lineage by blocking GATA-1 DNA binding (reviewed in Zhang et al., 2000). The 
transcription factor C/EBPα, a basic leucine zipper transcription factor, is expressed 
in multiple haematopoietic lineages. C/ebpα  deficient mice developed a myeloid 
differentiation block at the myeloblast stage. It was suggested that PU.1 and C/EBPα   31
in combination regulate the differentiation of GMP into either granulocytes or 
monocytes (reviewed in Gupta et al., 2009). 
 
1.3.  Wnt signalling in haematopoiesis 
 
The Wnt signalling pathway is a highly conserved signalling system that 
plays a crucial role in embryonic development and regeneration of adult tissues, 
regulating processes such as proliferation, survival and differentiation (Figure 3). 
Transcriptional target genes of the Wnt signalling pathway act either as tumour 
suppressors or proto-oncogenes. It has been shown that aberrant activation of the 
Wnt signalling pathway, by inappropriate stabilisation and accumulation of 
cytoplasmic  β-Catenin, is linked to a variety of cancers (reviewed in Klaus and 
Birchmeier, 2008). Following accumulation, β-Catenin translocates to the nucleus 
and constantly activates transcription of genes that are associated with cell 
proliferation and survival, such as c-Myc and CyclinD1 (reviewed in Klaus and 
Birchmeier, 2008). Studies have shown that aberrant accumulation of β-Catenin can 
be caused by mutations in factors controlling β-Catenin degradation, such as APC, 
axin or β-Catenin itself. Also, activating mutations of the Wnt-ligand co-receptor 
LRP5 can cause aberrant accumulation of β-Catenin (reviewed in Klaus and 
Birchmeier, 2008). Wnt signalling has also been shown to play a role in self-renewal 
of HSC as well as development of T- and B-cells. TCF-GFP reporter assays were 
used to demonstrate active Wnt signalling in HSC (Willert et al., 2003). Deletion of 
β-Catenin in HSC showed that the distribution in cell cycle, multilineage 
differentiation and homing ability are unchanged in β-Catenin-deleted HSC but their 
self-renewal ability was impaired (Zhao et al., 2007).   32
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Figure 3: Wnt signalling pathway 
A) In the absence of Wnt ligands β-Catenin (Ctnnb1) is linked with a destruction complex 
consisting of axis inhibitor (axin), adenomatous polyposis coli (APC), casein kinase 1 (CK1) 
and glycogen-synthase kinase 3 β (GSK3β), and N-terminally phosphorylated by CK1 and 
GSK3β. Upon N-terminal phosphorylation, Ctnnb1 is recognised by the E3 ubiquitin ligase, 
β-transducin-repeat-containing family (β-TRCP), and ubiquitylated, followed by 
proteasomal degradation. As a result levels of cytoplasmic Ctnnb1 are low and its 
transcriptional targets are repressed by intranuclear binding of the co-repressor Groucho 
(GRG) to the lymphoid enhancer factor/T-cell factor (LEF/TCF) transcription factor. B) Wnt 
ligand binding to the frizzled (Fzd) receptor and low-density-lipoprotein-receptor-related 
protein 5 and 6 (LRP5/LRP6) co-receptors, results in phosphorylation of LRP5/LRP6 by 
CK1 and GSK3β. Dishevelled (DVL) is then engaged on the plasma membrane with the Fzd 
receptor and axin, which also interacts with LRP5/LRP6. The degradation of cytoplasmic 
Ctnnb1 is inactivated and Ctnnb1 can accumulate in the cytoplasm and translocate into the 
nucleus. In the nucleus Ctnnb1 replaces GRG and activates transcription by forming a 
transcriptionally active complex with LEF/TCF (adapted from Staal and Cleevers, 2004; 
Klaus and Birchmeier, 2008).   33
Expression of a constitutively active form of β-Catenin in murine Bcl2-
transgenic mice resulted in an increased number of HSC with enhanced ability to 
reconstitute lethally irradiated mice (Reya et al., 2003). In contrast, a separate study 
showed that upon constitutive activation of β-Catenin, multilineage differentiation 
was negatively affected and numbers of HSC were depleted, following a transient 
increase in their number (Scheller et al., 2006; Kirstetter et al., 2006). These studies 
highlight the importance of maintaining the correct level of Wnt signalling in HSC. 
Furthermore, deregulated Wnt signalling has also been reported to be involved in the 
development of AML, CLL, CML and E2A-PBX1 induced pre-B-ALL. Müller-
Tidow et al. showed that γ-Catenin was induced by the AML-associated 
translocation products, AML1-ETO, PML-RARα and PLZF- RARα (Müller-Tidow 
et al., 2004). Another group reported that LEF1 and its down-stream target CyclinD1 
were overexpressed in cells from patients with CLL (Lu et al., 2004). Wnt signalling 
activation has been shown in blast crises of CML, using TCF-GFP reporter assays in 
BCR-ABL CML patients (Jamieson et al., 2004). E2A-PBX1 has been shown to 
activate expression of WNT16 (McWhirter et al., 1999). 
 
These studies show that Wnt signalling may contribute to the development of 
some haematological malignancies. β-Catenin has also been shown to interact with 
MLL. Sierra et al. reported that the C-terminal β-Catenin activation domain 
selectively associates with nuclear remodelling subunits of the TRRAP histone 
acetyltransferase (HAT) and the MLL histone methyltransferase (HMT) complexes 
and that β-Catenin promotes H3K4 histone trimethylation at the c-Myc gene (Sierra 
et al., 2006). 
   34
1.4.  Acute leukaemia in infants 
 
Acute leukaemia is a cancer that arises in cells of the haematopoietic system 
and is the most common form of childhood cancer. Acute lymphoblastic leukaemia 
(ALL), a clonal expansion of lymphoblasts in the bone marrow or blood, is more 
frequent in children than acute myeloid leukaemia (AML), accounting for more than 
50% of paediatric haematopoietic malignancies (reviewed in Downing and Shannon, 
2002). Acute myeloid leukaemia is defined as a clonal expansion of myeloid blasts 
that comprise more than 20% of the nucleated cells in the bone marrow or blood, 
frequently resulting in haematopoietic insufficiency (reviewed in Downing and 
Shannon, 2002). AML is a heterogeneous disease, consisting of many recognized 
morphologic and biological subtypes. Acute myeloid leukaemias are divided by the 
French-American-British (FAB) classification into eight subtypes (Table 1), 
designated M0 through M7, based on the type of cell from which the leukaemia 
developed (Cancer Society, Cancer Reference Information, www.cancer.org). 
 
Table 1: The French-American-British classification of human AML 
FAB 
Subtype 
Name Associated 
translocation, gene 
M0 Undifferentiated  AML  inv(3q26),  EVI1 
M1  Myeloblastic leukaemia with minimal maturation  n.a. 
M2  Myeloblastic leukaemia with maturation  t(8;21), AML1-ETO 
M3 Promyelocytic  leukaemia  t(15;17),  PML-RARα 
M4 Myelomonocytic  leukaemia  11q23,  MLL 
M4 eos  Myelomonocytic leukaemia with eosinophilia  inv(16), CBFβ-MYH11 
M5 Monocytic  leukaemia  11q23,  MLL 
M6 Erythroid  leukaemia  unknown 
M7 Megakaryoblastic  leukaemia  unknown 
 
The table lists the FAB subtypes of AML and the known associated translocations and genes.   35
A World Health Organisation (WHO) classification of AML has also been 
published (Table 2). The WHO classification of acute myeloid leukaemia attempts to 
be more clinically useful and to produce more meaningful prognostic information 
than the FAB criteria. 
 
Table 2: WHO subtypes of AML 
Name Description 
AML with characteristic genetic 
abnormalities 
  AML with translocations between Chr 8 
and 21 t(8;21); AML1-ETO 
  AML with inversions in Chr 16 inv(16); 
CBFβ-MYH11 
  AML with translocations between Chr 15 
and 17 t(15;17); RARα-PML 
AML with multilineage dysplasia    patients who have had a prior 
myelodysplastic syndrome (MDS) or 
myeloproliferative disease (MPD) that 
transforms into AML 
AML and MDS, therapy-related    patients who have had prior 
chemotherapy and/or radiation and 
subsequently develop AML or MDS 
  leukaemias may be characterized by 
specific chromosomal abnormalities 
AML not otherwise categorized    subtypes of AML that do not fall into the 
above categories 
 
The table lists the WHO subtypes of AML and the associated subtypes. 
 
Cytogenetic abnormalities are found in 80% of AML and ALL cases. 
Chromosomal rearrangements involving chromosome band 11q23 make up 60% of 
infant AML cases and 80% of infant ALL cases (Pui et al., 1995) and they are 
prevalent in therapy-related secondary leukaemias (t-AML) (Felix, 1998). The 
rearrangements affecting the MLL gene are associated with poor outcome in ALL but   36
also in AML (reviewed in Felix and Lange, 1999). The young age at diagnosis 
(average six months for ALL) and studies of identical twins, concordant for infant 
ALL, suggest that MLL gene rearrangements arise in utero (reviewed in Eguchi et 
al., 2003). Identification of a clonal but non-inherited breakpoint suggested that the 
clone containing the translocation is passed on from one twin to the other via the 
placenta. Furthermore, analysis of Guthrie neonatal bloodspots confirmed that 
translocations were already present at the time of birth (reviewed in Felix and Lange, 
1999; Eguchi et al., 2003). It has been suggested that a possible predisposition to 
develop leukaemia in utero could be the exposure of the mother to naturally 
occurring topoisomerase-II inhibitors, such as dietary bioflavonoids (Ross et al., 
1994). 
 
1.5.  MLL and its functional domains 
 
The MLL gene is located on human chromosome 11, band q23. MLL is a 
large protein with several functional domains (Figure 4). The N-terminal part of 
MLL contains three AT hooks, two sub-nuclear localisation domains (SNL1 and 
SNL2), a DNA methyltransferase 1 homology domain (DNMT1), plant homology 
domains (PHD finger) and a bromodomain. The three AT hooks, located nearest to 
the N-terminus, recognize DNA structure and mediate binding to the minor groove of 
AT-rich regions (reviewed in Eguchi et al., 2003; Ayton and Cleary 2001). These 
may stabilize protein-DNA complexes or mediate protein-protein interaction through 
binding to DNA (reviewed in Ayton and Cleary 2001). Two sub-nuclear localisation 
domains, SNL1 and SNL2, direct the punctuate localisation pattern of the protein to 
the nucleus.    37
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Figure 4: Domain organisation of the MLL protein 
A) Three N-terminal AT hooks mediate binding to the minor groove of AT-rich 
DNA regions. Two small regions SNL1 and SNL2 specify the sub-nuclear 
localisation of the MLL protein. The DNA methyltransferase 1 homology domain 
(DNMT1) enables MLL to bind unmethylated CpG sequences with high specifity. 
The region around the DNMT1 domain has transcriptional repression activity 
through interaction with histone deacetylases (HDAC) or polycomb groub proteins 
HPC2 and Bmi-1. The PHD finger domain mediate protein-protein interactions. The 
bromodomain (BROM) binds to acetylated lysines on histones. The Transactivation 
domain (TA) is located between the PHD domain and the SET domain. TA enhances 
transcriptional activation through binding of MLL to cAMP binding protein (CBP). 
The SET (Su(var)3-9, enhancer of zeste and trithorax) domain possesses histone H3 
lysine 4 specific methyltransferase activity. B) The mature MLL protein is cleaved in 
the cytoplasma by taspase-1 into an N-terminal p320 peptide (AT hooks, DNMT1 
repression and PHD domain) and a C-terminal p180 peptide (TA and SET domain). 
The fragments translocate into the nucleus where they remain non-covalently 
associated through the FYRN and FYRC domain (adapted from Hess, 2004; Daser 
and Rabbitts, 2005).    38
These domains are two of the evolutionary conserved regions between 
Drosophila trx and MLL, suggesting an important functional role for the ability of 
MLL and trx to localise to specific regions within the nucleus (reviewed in Eguchi et 
al., 2003). The DNMT1 domain is a cysteine-rich CXXC domain that enables DNA 
binding of MLL to unmethylated CpG sequences with high specifity. This interaction 
with unmethylated CpG islands allows MLL to associate with active genes. The 
region around the DNMT1 domain has transcriptional repression activity through 
interaction with histone deacetylases (HDAC) or polycomb group (PcG) proteins; for 
example polycomb 2 homolog (HPC2) and BMI1 polycomb ring finger oncogene 
(BMI1) (reviewed in Eguchi et al., 2003). The PHD fingers of MLL mediate 
protein-protein interactions, such as binding to methylated histones (Muntean et al., 
2008; reviewed in Eguchi et al., 2003). The nuclear cyclophilin Cyp33 has been 
shown to bind the PHD fingers, mediating an enhanced binding of HPC2 and BMI1 
to the transcriptional repression domain (Muntean et al., 2008). This region also 
recruits histone deacetylases HDAC1 and HDAC2 to mediate transcriptional 
repression (reviewed in Daser and Rabbitts, 2005). Proximal to the PHD finger 
domains is the bromodomain, a domain that binds to acetylated lysines on histones 
(reviewed in Dou and Hess, 2007). The C-terminal part of MLL contains the 
transactivation domain (TA) and the ‘Su(var)3-9, enhancer of zeste and trithorax’ 
(SET) domain. The transactivation domain binds to cAMP binding protein (CBP), a 
histone acetyltransferase that activates gene expression. CBP in turn, mediates 
binding of cAMP responsive element-binding protein (CREB) to promote 
transcriptional activation (reviewed in Eguchi et al., 2003). The SET domain at the 
C-terminus is a highly conserved domain with histone methyltransferase activity, that 
specifically methylates histone H3 at lysine 4 (H3K4) (reviewed in Dou and Hess, 
2007). The mature MLL protein is proteolytically cleaved between the bromodomain   39
and the TA domain in the cytoplasm by the taspase-1 protease, into an N-terminal 
peptide (MLL
N 320kDa) and a C-terminal peptide (MLL
C 180kDa). Taspase-1 is the 
only protease in vertebrates that can cleave MLL (Takeda et al., 2006). MLL
N and 
MLL
C fragments remain non-covalently associated through FYDN and FYDC 
domains after cleavage to avoid degradation and confer stability (reviewed in Eguchi 
et al., 2003; Dou and Hess, 2007). 
 
1.6.  Transcriptional regulation by MLL 
 
Post-translational histone modifications, including acetylation, methylation, 
phosphorylation, ubiquitination and sumoylation, alter chromatin accessibility and 
allow transcription factors to be recruited (reviewed in Linggi at al., 2005). These 
histone modifications can have an activating, repressing or combined transcriptional 
role, creating a complex histone code. This histone code is created by histone 
modifiers such as kinases, histone methyltransferases and histone acetyltransferases 
and is then recognized by transcription factors. MLL is a histone-modifying factor 
that acts as a member of a macromolecular methyltransferase complex. It is recruited 
to target genes through interactions with menin and LEDGF and mediates 
trimethylation of histone H3K4 within the promoter region of genes occupied by 
RNA polymerase II (reviewed in Krivtsov and Armstrong, 2007). Trimethylation of 
histone H3K4 is generally associated with transcriptional activation and subsequent 
transcription of MLL target genes such as homeobox ( Hox) genes (reviewed in 
Krivtsov and Armstrong, 2007).  
 
The MLL
N and MLL
C fragments have different molecular functionalities to 
facilitate methylation, acetylation and DNA binding. The C-terminal part of MLL   40
interacts with a macromolecular complex with methyltransferase activity, including 
the WD-repeat protein 5 (WDR5), retinoblastoma binding protein 5 (RbBP5) and 
ash2 (absent, small, or homeotic)-like protein (ASH2L) (Figure 5 A) (reviewed in 
Dou and Hess, 2007). The protein WDR5, together with RbBP5, mediates 
association with the C-terminus of MLL, whereas ASH2L associates with RbBP5 
only and mediates stabilisation of the complex (reviewed in Crawford and Hess, 
2006). WDR5 binds preferentially to dimethylated histone 3 lysine 4 (H3K4) in order 
to facilitate MLL induced histone H3K4 trimethylation (reviewed in Berger, 2007). It 
has been shown that MLL requires the WDR5/RbBP5/ASH2L complex in order to 
trimethylate histone H3K4 and activate transcription (reviewed in Crawford and 
Hess, 2006). The N-terminal part of MLL directs targeting of the MLL complex. The 
tumour suppressor gene MEN1 product, menin, is part of the MLL associated 
macromolecular complex. In contrast to most of the other MLL-interacting proteins, 
menin binds to the N-terminal domain of MLL (Hughes et al., 2004; Yokoyama et 
al., 2004). A high-affinity N-terminal conserved menin binding motif (RXRFP) has 
been identified in MLL, spanning amino acids six to ten (Yokoyama et al., 2005). 
Recently, it was shown that menin and MLL interact with lens epithelium derived 
growth factor (LEDGF) to facilitate interaction with chromatin (Yokoyama and 
Cleary, 2008).  
 
Following MLL induced trimethylation of histone H3K4 at the promoter, 
positive transcription elongation factor b (pTEFb) is associated with the active AF4-
ENL/AF9 complex and recruited to the transcription machinery (Figure 5 B) (Bitoun 
et al., 2006). pTEFb, a dimer of cyclin dependent kinase 9 (CDK9) and cyclin T, 
overcomes transcriptional pausing by phosphorylating the C-terminal domain (CTD) 
of RNA polymerase II at serine-2 (S2).   41
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Figure 5: Transcriptional regulation by the MLL complex 
A) MLL is a member of a macromolecular complex that mediates histone H3K4 
trimethylation of the promoter regions of genes occupied by RNA pol II. The SET 
domain at the C-terminal part of MLL interacts with WDR5, RbBP5 and ASH2L 
forming a H3K4 specific methyltransferase complex. The N-terminal part of MLL 
interacts with menin which then interact with LEDGF to facilitate interaction with 
chromatin (adapted from Krivtsov and Armstrong, 2007; Dou and Hess, 2008). B) 
Following MLL mediated histone H3K4 trimethylation the pTEFb complex is 
recruited to phosphorylate the RNA pol II CTD at serine-2 (S2). AF4-ENL/AF9 
complex associates with histone H3 and recruits AF10. This complex in turn can 
recruit the histone H3K79 specific methyltransferase DOT1L to the elongating RNA 
pol II and methylation of histone H3K79. The MLL complex separates from RNA 
polymerase II (adapted from Bitoun et al., 2006).    42
Concurrently, ENL/AF9 associates with histone H3 and recruits AF10 to the 
AF4-ENL/AF9 complex. DOT1L is then recruited to elongating RNA polymerase II 
via interaction with ENL/AF9 and AF10 in order to methylate histone H3K79. As 
productive elongation continues the MLL complex dissociates from RNA 
polymerase II (Bitoun et al., 2006). 
 
1.7.  Normal function of MLL 
 
MLL is widely expressed during embryonic development, in most adult 
tissues, including myeloid and lymphoid cells (reviewed in Hess 2004). The MLL 
gene is a member of the trithorax group, a conserved family of proteins, and is 
homologous to the Drosophila trithorax (Trx) gene (reviewed in Hess 2004). Trx 
positively regulates homeotic (HOM-C) gene expression during development and is 
opposed by the polycomb group (PcG) proteins, which repress HOM-C gene 
expression (reviewed in Hess 2004). Mutations of the Trx gene cause loss or 
abnormal patterns of HOM-C gene expression resulting in segment identity defects 
(Breen and Harte, 1993). The Mll gene in mice has been disrupted and studied by 
homologous recombination (Yu et al., 1995; Yu et al., 1998; Yagi et al., 1998; 
Ayton et al., 2001). Mll
-/- homozygous mice were embryonic lethal with completely 
absent expression of HoxA7 and HoxC9. Mll heterozygous mice had retarded growth, 
axial skeletal abnormalities and disturbed pattern of HoxA7 and HoxC9 expression. 
Furthermore, heterozygous mice displayed haematopoietic abnormalities (Yu et al., 
1995). Later it was shown that HoxA7 was initiated in Mll
-/- embryos before E8.5 but 
not maintained (Yu et al., 1998). Two conditional Mll knock-out models have shown 
that wild-type MLL is required for normal haematopoiesis and haematopoietic stem 
cell activity (Jude et al., 2007; McMahon et al., 2007).   43
MLL has a global role in transcription by associating along with RNA 
polymerase II to the 5’ end of actively transcribed genes (as previously described). 
Studies with Mll knockout mice have shown that the transcriptional function of MLL 
includes Hox gene regulation (Yu et al., 1995; Yu et al., 1998). Hox genes encode 
transcription factors that are regulators of proliferation and differentiation of 
haematopoietic cells (Thorsteindottir et al., 1997). 39 different Hox genes are 
clustered into four groups (HoxA, HoxB, HoxC and HoxD) on four different 
chromosomes (human/mouse: Chr7/Chr6, Chr17/Chr11, Chr12/Chr15 and 
Chr2/Chr2, respectively) and numbered from 1 to 13. No cluster contains a full set 
(Sauvageau et al., 1994). Hox genes have expression patterns specific for the stage 
and lineage of progenitor cell development with a general down-regulation of Hox 
gene expression as the progenitors differentiate into mature blood cells (Sauvageau et 
al., 1994). Generally, gene expression of 3’ Hox genes within HoxA and HoxB 
clusters are found in the most immature haematopoietic cells. These genes are 
subsequently down-regulated and the Hox loci closer to the 5’ end are expressed in 
the early stages of differentiation. Hox gene expression is lost upon terminally 
differentiation (Sauvageau et al., 1994). It has been reported that the MLL protein 
interacts with the promoters of the HoxA7, HoxA9 and HoxA10 genes (Guenther et 
al., 2005). However, transcriptional regulation extends beyond Hox gene regulation. 
MLL was found to be associated with many promoters in cell-line studies, suggesting 
a more global role in regulation of transcription (Guenther et al., 2005). 
 
1.8.  MLL oncogenic rearrangements 
 
Chromosomal rearrangements involving MLL are common in patients with 
AML and can take several forms such as balanced translocations, inversions and   44
duplications of 11q23 (reviewed in Dou and Hess, 2008). Balanced translocations are 
the most common rearrangement disrupting the MLL gene (Figure 6). The genomic 
breakpoints are located within an 8.3 kb breakpoint cluster region (bcr), spanning 
exons 8 to 12. It has been shown that breaks including the PHD fingers, located C-
terminal of the bcr, are not compatible with transformation of HPC (Muntean et al., 
2008). The breakpoint cluster regions are always located within introns, invariably 
generating a novel in-frame chimaeric gene. Rearrangements result in the deletion of 
the PHD fingers and all other downstream domains of MLL (reviewed in Hess 
2004). The bcr region contains topoisomerase-II-binding sites as well as Alu 
sequences and is thought to be prone to DNA double strand cleavage in response to 
topoisomerase-II inhibitors environmental exposure (reviewed in Eguchi et al., 
2003). Alternatively it was suggested that upon initiation of the apoptotic 
programme, double strand breaks in the MLL gene and the partner gene are generated 
and joined together by the error-prone non-homologous end joining (NHEJ) DNA 
repair pathway (reviewed in Greaves 2003). In the event that the apoptotic response 
is aborted, cells carrying the MLL rearrangement would survive (Betti et al., 2001).  
 
Balanced translocations fuse the genomic region encoding the N-terminal 
portion of MLL to sequences encoding the C-terminal portion of one of a number of 
translocation partners. This fusion generates an in-frame chimaeric gene that codes 
for a novel fusion protein with leukaemogenic potential (reviewed in Hess, 2004). 
Various studies have used retroviral gene transfer assays to assess the transforming 
capacities of MLL-fusions.    45
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Figure 6: Balanced MLL translocation 
The translocation breakpoints of MLL occur within a breakpoint cluster region (bcr) 
spanning exons 8 to 12. The translocation results in the deletion of the C-terminal 
portion of MLL including the PHD, TA and SET domains. The remaining N-
terminal portion of MLL is fused to the C-terminal portion of one out of more than 
40 fusion partners. As the result of this translocation, an in-frame chimeric fusion 
protein is generated (adapted from Hess, 2004).   46
We and others have shown that the fusion genes MLL-AF9 and MLL-ENL 
transform murine HPC in vitro and result in leukaemia development in vivo when 
transplanted into a mouse model (Lavau et al., 1997; Ayton and Cleary, 2003; 
Cozzio et al., 2003; Zeisig et al., 2004; Horton et al., 2005; Krivtsov et al., 2006; 
Somervaille et al., 2006; Horton, Walf-Vorderwülbecke et al., 2009). Others have 
shown that the fusion genes MLL-GAS7 and MLL-AF4 also transform murine HPC 
in vitro and result in leukaemia in vivo (So et al., 2003; Krivtsov et al., 2008). Since 
heterozygous Mll knock-out mice do not have an increased incidence of leukaemia 
and neither the N-terminal region of MLL or wild-type ENL on their own had 
transforming capacities, a gain of function has been proposed as the mechanism by 
which MLL-fusion proteins transform HPC (Lavau et al., 1997; reviewed in Ayton 
and Cleary 2001; Eguchi et al., 2003; Hess 2004). Furthermore the generation of 
viable MLL-AF9 mutant mouse germlines confirmed that MLL function, vital for 
embryogenesis, is not blocked by MLL-AF9 in vivo (Dobson et al., 1999). 
 
It has been suggested that a subset of HoxA genes and myeloid ecotropic viral 
integration site 1 (Meis1) are required for MLL-fusion proteins to transform HPC 
(Zeisig et al., 2004; Horton et al., 2005; reviewed in Dou and Hess, 2008). Meis1 is a 
member of the three amino acid loop extension (TALE) family of homeodomain-
containing proteins. Meis1 is closely related to the pre B-cell leukaemia homeobox 
(Pbx) proteins. DNA binding by Hox transcription factors is enhanced by forming 
heterooligomeric complexes with the Pbx and Meis families (Mann and Chan, 1996). 
Despite persistent MLL expression during normal haematopoietic differentiation, 
Hox and Meis1 gene expression are generally down-regulated as the progenitors 
differentiate (Sauvageau et al., 1994). However, this regulation is disturbed by MLL-
fusion proteins, leading to maintenance of high expression levels of HoxA7, HoxA9   47
and  Meis1. Furthermore, murine models for MLL-AF9 and MLL-ENL fusion 
oncogenes showed that overexpression of a HoxA code (HoxA4 – HoxA11) appear to 
be important for MLL mediated leukaemogenesis (Kumar et al., 2004; Horton et al., 
2005). This aberrant expression of HOXA genes and MEIS1 is also observed in 
human leukaemias with MLL rearrangements (reviewed in Dou and Hess, 2008). 
 
1.9.  MLL translocation partner 
 
Over 50 fusion partners of MLL have been identified. A few of the MLL 
partner proteins can be classified into either nuclear factors involved in 
transcriptional regulation (such as AF4, AF9, AF10, ENL, ELL) or signalling 
molecules that are localised in the cytoplasm (such as GAS7, EEN, AF1p, AF6) 
(reviewed in Ayton and Cleary, 2001). Some of the nuclear factors can be grouped 
into common gene families such as AF9/ENL, AF4/AF5q31/LAF4 and AF10/AF17 
(Nakamura et al., 1993; Chaplin et al., 1995; Nilson et al., 1997; Taki et al., 1999). 
Table 3 lists examples for the identified MLL fusion partner genes with their known 
function and localisation. 
 
The AF9 (ALL1 fused gene from chromosome 9) gene at chromosome 9, band 
p22, and the ENL (eleven nineteen leukaemia) gene at chromosome 19, band p13, 
encode proteins with a 56% amino acid identity and are among the most common 
fusion partners (Nakamura et al., 1993; Rubnitz et al., 1994). The mouse Af9 gene 
has been shown to be a controller of embryo patterning presumably via control of 
Hox gene regulation, which is similar to the role of Mll (Collins et al., 2002).    48
Table 3: MLL fusion partner genes 
Gene Chr. 
Location 
Function Localisation
AF4*  4q21 transcriptional  activator  N 
AF6*  6q27  maintenance of cell-cell junctions  C 
AF9*  9p22 transcription  factor  N 
AF10*  10p12 transcription  factor  N 
ELL*  19p13.1  RNA pol II transcription elongation   N 
ENL*  19p13.3 transcriptional  activator  N 
AFX  Xq13  forkhead transcription factor  N 
Septin6  Xq22 Septin  family  C 
AF1p  1p32  regulation of endocytosis  C, N 
LAF4  2q11 transcriptional  activator  N 
GMPS  3q25 Guanosine  monophosphatase  synthetase  C 
LPP  3q28  cell motility and focal adhesion  C, N 
AF5q31  5q31 transcriptional  activator  ? 
GRAF  5q31  negative regulator of RhoA  C 
FKHRL1  6q21  forkhead transcription factor  N 
AF9q34  9q34  Ras GTPase-activating protein  C 
ABI1  10p11.2 cell  motility  C 
CALM  11q14-q21  regulation of endocytosis  C, N 
LARG  11q23.3  activator of Rho GTPases  C 
CBL  11q23.3  neg. regulator of receptor tyrosine kinase  C 
GPHN  14q24  Gly and GABA receptors assembly  C 
CBP  16p13 histone  acetylase  N 
GAS7  17p13 Actin  assembly  C 
AF17  17q21 transcription  factor  N 
AF17q25  17q25 Septin  family  C 
EEN  19p13.3  regulation of endocytosis  ? 
AF22  22q11 Septin  family  C 
p300  22q13 histone  acetylase  N 
 
The table lists MLL fusion partner genes with known function and localisation. N indicates nuclear 
localisation, C cytoplasmic localisation and ? not known localisation. The most common translocation 
partner are marked with * (adapted from Eguchi et al., 2003). 
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AF9 is a 568 amino acid protein containing a serine-rich and a proline-rich 
domain as well as a nuclear localisation signal domain. ENL is a 559 amino acid 
protein containing multiple serine- and proline-rich domains. Both proteins contain 
an N-terminal YEATS domain with unknown function (Figure 7) (reviewed in 
Schulze  et al., 2009). However, the YEATS domain of ENL was found to bind 
histone H3 and histone H1 in vitro, suggesting a chromatin-modifying effect for 
YEATS domain-containing proteins (Zeisig et al., 2005). The C-terminus of both 
AF9 and ENL proteins has been described to contain a domain possessing 
transcriptional activation properties. This domain is retained in the MLL fusion 
proteins (Rubnitz et al., 1994). 
 
As described in section 1.6., the MLL fusion partners have been shown to be 
involved in normal transcriptional elongation (Bitoun et al., 2006). AF9 has been 
shown to interact with AF4, another MLL translocation partner, suggesting that the 
different MLL fusion partners may form a protein network in normal cells (Erfurth et 
al., 2003). Interaction of MLL fusion partners has been further investigated by 
identifying ENL-associated proteins (Mueller et al., 2007). The RNA polymerase II 
CTD kinase, pTEFb, associates with DOT1L, a non SET domain containing histone 
3 lysine 79 (H3K79) specific methyltransferase. DOT1L also associates with the 
MLL translocation partner complex, ENL and AF4/AF5q31/LAF4, to promote 
transcriptional elongation (Bitoun et al., 2006; Mueller et al., 2007). These findings 
suggest a function of ENL and AF4 in histone modification and transcriptional 
elongation. In mice, it has also been shown that Af4 interacts with Af9 and/or Enl to 
recruit Af10 and mediate binding of Dot1l.    50
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Figure 7: MLL-AF9 and MLL-ENL fusion protein 
A) The domain organisations of the MLL protein is shown in grey, of the AF9 
protein is shown in green and of the ENL protein is shown in blue. AF9 and ENL 
contain an N-terminal YEATS domain, multiple proline- (P) and serine-rich (S) 
domains and a C-terminal domain with transcriptional activation properties (TA). 
AF9 also contains a nuclear localisation signal (NLS). The breakpoint cluster region 
(bcr) of MLL and the corresponding fusion points within AF9 and ENL are 
highlighted in red. B) The figure illustrates the structure of the MLL-AF9 (grey-
green) and MLL-ENL (grey-blue) fusion proteins.   51
Dot1l is able to methylate histone H3K79, which leads in conjunction with 
histone H3K4 methylation to active chromatin, and allows RNA polymerase II 
elongation (Meyer et al., 2006; Bitoun et al., 2007). Hence, the four most frequent 
MLL fusion partner AF4, AF9, AF10 and ENL have been found to interact in a 
protein network involved in histone H3K79 methylation and the transcriptional 
elongation processes. 
 
1.10. Regulation of gene expression by MLL-fusion 
 
The disruption of the wild-type MLL protein in infant and therapy-related 
leukaemia results in the loss of the C-terminal SET domain with histone H3K4 
methyltransferase activity and its associated co-factors (reviewed in Krivtsov and 
Armstrong 2007). MLL fusion proteins always contain the AT hooks and the 
DNMT1 domain of MLL
N, which are required for MLL association with chromatin. 
Therefore, of the known associated co-factors only menin and LEDGF remain 
associated with the disrupted MLL fusion proteins (Yokoyama et al., 2004; 
Yokoyama and Cleary, 2008). MLL fusion proteins interact with menin through 
multiple domains within the N-terminus including a high-affinity N-terminal 
conserved binding motif (RXRFP). It has been shown, that this high-affinity menin 
interaction domain is required for the fusion proteins MLL-ENL, MLL-GAS7 and 
MLL-AF10 to induce and maintain oncogenic transformation of myeloid progenitors 
(Yokoyama et al., 2005). 
 
Because of the particularly large number of possible translocation partner, a 
common mechanism of transformation for MLL-fusions has not been elucidated. 
However, a principle of transcriptional regulation for the most common nuclear   52
translocation partners, such as AF9, ENL, AF4 and AF10, has been proposed. As 
described earlier, the MLL fusion partners AF4, AF9/ENL and AF10 are part of a 
protein network that interacts with the DOT1L H3K79 histone methyltransferase 
(reviewed in Krivtsov and Armstrong, 2007). Methylation of histone H3K79 has also 
been linked with positive regulation of transcription (Lachner et al., 2003). It has 
been shown that the C-terminal region of ENL, essential for DOT1L binding, is also 
required for the transformation ability of MLL-ENL and therefore maintained in 
MLL-fusion proteins (Mueller et al., 2007). Furthermore, high levels of histone 
H3K79 methylation at HoxA9 locus has been observed in MLL-ENL and MLL-AF9 
transformed cells (Milne et al., 2005). Therefore, it has been suggested that the loss 
of histone H3K4 methyltransferase activity might be replaced by the acquisition of 
histone H3K79 methyltransferase activity in an MLL fusion protein (Figure 8). This 
is supported by results from a study, were the disruption of the AF9 interaction with 
AF4 with a synthetic peptide leads to a proliferation block of MLL-AF4 transformed 
cells (Srinivasan et al., 2004). 
 
1.11. Models of MLL-fusion mediated leukaemia 
 
Several  in vivo models have been established in order to investigate the 
leukaemogenic potential of MLL-fusion proteins utilizing different strategies. The 
first established in vivo model of MLL leukaemia was the Mll-AF9 ‘knock-in’ mouse 
model (Corral et al., 1996). Homologous recombination was used in order to fuse the 
3’-terminal human AF9 sequence with exon 8 of Mll. Therefore, expression of the 
Mll-AF9 fusion gene was under the control of the endogenous murine Mll promoter 
and mice developed AML after 6 month of age.    53
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Figure 8: Proposed transcriptional regulation by the MLL-fusion 
MLL-fusion oncogenes that lack the C-terminal SET H3K4 methyltransferase 
activity may recruit the H3K79 methyltransferase DOT1L. This mechanism allows 
recruitment of DOT1L to promoters that are normally occupied by MLL and 
promote H3K79 methylation which leads to abnormal activation of genes, such as 
genes in the HoxA cluster (adapted from Krivtsov and Armstrong, 2007; Dou and 
Hess, 2008).   54
The late onset of leukaemia suggested that secondary mutations were 
necessary for development of leukaemia (Corral et al., 1996). However, the ‘knock-
in’ approach did not allow for tissue or cell-specific fusion protein expression but 
expressed the fusion protein in all cells in which the endogenous Mll promoter was 
active. 
 
To overcome this problem, the ‘translocator’ mouse model was developed in 
which chromosomal translocations were generated de novo during development 
(Collins et al., 2000; Forster et al., 2003; Drynan et al., 2005). The ‘translocator’ 
mice were generated by introducing locus of X-over P1 (loxP) recombination sites 
into Mll and Af9 (Collins et al., 2000) or Enl (Forster et al., 2003), and inter-bred 
with Cyclization Recombination (Cre)-expressing mice. The Cre-loxP system 
controls site specific recombination events in genomic DNA. Cre expression in cells 
with loxP sites in their genome causes a reciprocal recombination between the loxP 
sites. The double stranded DNA is cut at both loxP sites by the Cre recombinase and 
the strands are then rejoined with DNA ligase. In one model, the Cre recombinase 
was expressed from knock-in of the Cre cDNA into the haematopoietic regulator 
Lmo2 locus (Forster et al., 2003; Drynan et al., 2005). Lmo2 is generally expressed 
in pluripotent stem cells and multipotent myeloid progenitors. This model gave rise 
to AML when either Mll-Enl or Mll-Af9 translocations were formed in these 
progenitors. 
 
A more frequently used method of generating murine models of MLL-fusion 
leukaemias is the retroviral transduction assay (Figure 9). Bone marrow derived HPC 
were transduced with retroviral MLL-fusion gene expression constructs and cultured 
in semi-solid methylcellulose medium containing myeloid growth factors.   55
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Figure 9: Retroviral transduction assay 
Experimental strategy for transduction of myeloid progenitor cells. Bone marrow-
derived HPC were transduced with retroviral MLL-fusion gene expression constructs 
and cultured in semi-solid methylcellulose medium containing myeloid growth 
factors (SCF, IL3, IL6, GM-CSF). Immortalised myeloid progenitors were serially 
replated and immortalised cell lines were established in liquid medium (RPMI 
containing SCF, IL3, IL6). Retrovirally transduced HPC were either analysed in vitro 
or injected into irradiated mice to assess leukaemia development (adapted from 
Eguchi et al., 2003).   56
HPC form myeloid colonies in methylcellulose. Immortalised myeloid 
progenitors retained their self-renewal and clonogenic potential and were able to 
serially replate in methylcellulose. In contrast, non-immortalised HPC terminally 
differentiated after two rounds of plating (reviewed in Ayton and Cleary, 2001; 
Eguchi et al., 2003; Krivtsov and Armstrong, 2007). Retrovirally transduced HPC 
were either analysed in vitro or injected into irradiated mice to assess leukaemia 
development (Lavau et al., 1997; Slany et al., 1998; Zeisig et al., 2004; Horton et al., 
2005; Horton, Walf-Vorderwülbecke et al., 2009).  
 
The first study using the retroviral transduction assay showed that MLL-ENL 
transduced cells could serially replate in methylcellulose and establish immortalised 
myeloid cell lines in vitro (Lavau et al., 1997). Furthermore, the immortalised cell 
lines induced AML after 3 to 4 months when transferred into syngeneic recipients 
(Lavau et al., 1997). The retroviral transduction assay was also used for studies of 
MLL fusion between ELL, AF10, AFX, FKHRL1, CBP, GAS7 and AF9 partner 
genes (DiMartino et al., 2000; Lavau et al., 2000; DiMartino et al., 2002; So and 
Cleary 2002; So and Cleary 2003; So et al., 2003, Krivtsov et al., 2006). This 
approach was also used to express MLL-ENL and MLL-AF9 in lineage negative  
(lin
-) human cord blood progenitor cells (CB) and induce leukaemia in 
immunodeficient mice (Barabe et al., 2007). Lin
-CB cells expressing MLL-ENL 
initiated B-lymphoid leukaemia in recipient mice, whereas lin
-CB cells expressing 
MLL-AF9 initiated both B-lymphoid and myeloid leukaemia upon transplantation. 
All recipients developed leukaemia with short latencies of less than 19 weeks and 
limiting dilution experiments estimated the frequency of leukaemia initiating cells to 
be less than 1:2000 (Barabe et al., 2007). This model demonstrated that MLL fusion 
oncogenes possess a lympho-myeloid potential to induce leukaemia in primary   57
human HPC, which is influenced by the translocation partner and 
microenvironmental signals (Wei et al., 2008). 
 
1.12. The cell of origin of MLL-translocations 
 
Although all MLL-fusion oncogenes may affect common pathways to induce 
malignant transformation, the different MLL translocations are often associated with 
haematopoietic malignancies of different lineages. The MLL-AF4 translocation 
t(4;11)(q21;q23) is the most common partner gene of MLL and is almost exclusively 
associated with infant ALL (reviewed in Felix and Lange, 1999). The MLL-AF9 
translocation t(9;11)(p22;q23) is predominantly associated with infant AML and 
therapy related AML, while the MLL-ENL translocation t(11;19)(p13;q23) is found 
in both infant AML and ALL (Rubnitz et al., 1996). Further insight into the distinct 
lineage association of these fusions in infant leukaemia, has been produced by 
experiments using the translocator mouse model (Forster et al., 2003, Drynan et al., 
2005). The translocator mouse model allows the targeting of de novo chromosomal 
translocations to specific lineages, based on the pattern of expression of different 
Cre-cassettes. One translocator mouse model, in which chromosomal translocations 
of murine Mll-Enl occur in pluripotent stem cells (Lmo2-Cre), resulted in myeloid 
leukaemia in 100% of the mice (Forster et al., 2003). A different translocator mouse 
model, with Cre under the control of the distal Lck promoter (Lck-Cre); demonstrated 
that translocation of Mll-Enl occurring in T-cells and their progenitors can be 
oncogenic in the lymphoid lineage (Drynan et al., 2005). However, it was observed 
that murine Mll-Af9 translocations induced in similar T-cell populations did not give 
rise to leukaemia, although Mll-Af9 translocations in uncommitted progenitors did 
induce myeloid leukaemias in 100% of the mice (Drynan et al., 2005).    58
These studies in mouse models suggest that although MLL-AF9 is highly 
homologous to MLL-ENL and may function via a common pathway to induce 
leukaemia, the two fusions are not functionally identical. As mentioned above, 
different MLL-rearrangements are often associated with leukaemias of different 
lineages. In order to identify the cell of origin of MLL-fusion induced leukaemia, 
murine models were used to analyse the effect of the MLL-fusion gene on 
haematopoietic cells. Two models, the instructive and the stochastic model, have 
been proposed in order to explain the lineage specificity of different MLL-fusion 
genes. The instructive model proposes that the translocation occurs in HSC, or 
uncommitted progenitors, providing lineage specific developmental signals which 
depend on the particular translocation (reviewed in Daser and Rabbitts, 2004). 
Therefore, MLL-AF9 or MLL-AF4 would provide signals for myeloid or lymphoid 
differentiation, respectively. The stochastic model proposes that MLL-translocations 
occur in committed myeloid or lymphoid progenitors, depending on the MLL-
translocation (reviewed in Daser and Rabbitts, 2004). Therefore, fusion activities 
would only be compatible with leukaemogenesis in the appropriate lineage. 
Translocations occurring in an inappropriate lineage would have no consequence. 
 
In order to analyse whether AML arises only from self-renewing stem cells or 
also from committed myeloid progenitors, HSC, CMP, GMP and MEP were purified 
and separately transduced with a retroviral expression vector encoding MLL-ENL 
and transplanted into recipient mice (Cozzio et al., 2003). Transduction of HSC, 
CMP and GMP, but not MEP, generated myeloid immortalised cell lines and induced 
leukaemia in recipients with similar latencies and the same phenotype. All 
leukaemias exhibited a similar maturation arrest, at a late stage of myelomonocytic 
differentiation, independent of the starting population (Cozzio et al., 2003). These   59
results suggest that the MLL-ENL oncogene does not expand the transduced 
progenitor population but initiates a specific arrest downstream of the GMP 
compartment (Cozzio et al., 2003). Furthermore, it shows that myeloid leukaemias 
with the same immunophenotype can be initiated in HSC as well as committed 
progenitors. 
 
1.13. Leukaemic stem cells 
 
HSC are characterised by their ability to undergo asymmetric cell division 
and generate primitive HSC which indefinitely self-renew as well as generate more 
mature progenitors in order to sustain haematopoiesis (Ho et al., 2005). It has been 
proposed that cancer cells contain rare cancer stem cells which also have the ability 
to indefinitely self-renew and therefore maintain the growth of the cancer (reviewed 
in Bonnet, 2005). In leukaemias these cells are termed leukaemic stem cells (LSC) 
which have either maintained or acquired the ability to self-renew through 
accumulation of genetic mutations (reviewed in Bonnet, 2005). Results from 
xenotransplantation experiments support the theory that AML LSC are transformed 
HSC. It was shown that only AML cells with a CD34
+CD38
- phenotype, similar to 
the HSC phenotype, were able to transplant leukaemia in NOD/SCID mice (reviewed 
in Bonnet, 2005). On the contrary, Cozzio et al. showed that MLL-ENL induced the 
exact same leukaemia in HSC as well as progenitor populations (Cozzio et al., 2003). 
Therefore, it seems possible that AML can arise in both immature HSC and more 
mature progenitor populations possibly depending on the nature of the associated 
oncogene. 
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1.14. Is the MLL-fusion oncogene sufficient to cause leukaemia? 
 
The particularly short latencies of infant and therapy-related leukaemias with 
MLL rearrangements are very unusual for malignant cancer formation, which is 
usually a result of multiple genetic aberrations. Additionally, the high concordance of 
MLL-fusion gene positive leukaemia found in twins suggests that the MLL-fusion 
gene might be sufficient to initiate leukaemia (Greaves et al., 2003). This fact has 
been supported by some of the data coming from animal models such as the Mll-Enl 
translocator mice which developed leukaemia with a rapid onset after 4 months of 
age (Forster et al., 2003). Furthermore, mice that were engrafted with human 
transduced cells also showed short latencies (less than 5 months) to the onset of 
leukaemia (Barabe et al., 2007). On the other hand, leukaemias with MLL-fusion 
gene rearrangements are often found to have acquired additional chromosomal 
abnormalities and gene mutations (reviewed in Eguchi et al., 2003). In addition, 
some of the murine models of MLL leukaemias have demonstrated that leukaemia is 
induced with longer latencies, for example the Mll-Af9 ‘knock-in’ mice (< 9 month) 
(Corral et al., 1996). This longer latency possibly reflects the time necessary for 
secondary genetic events to occur. In general, different murine models of MLL 
leukaemias have shown to induce leukaemia with different latencies. Cytogenetic 
analysis of human leukaemias associated with MLL-ENL translocations identified 
additional genetic abnormalities (Moorman et al., 1998). Whether additional 
abnormalities are required for the onset of leukaemia or are a consequence of MLL-
ENL induced leukaemia is still unclear. However, in infant leukaemias it is possible 
that additional genetic mutations are also caused by the genotoxic agent that caused 
the MLL-rearrangement in utero and long latencies are therefore not required 
(reviewed in Eguchi et al., 2003). Alternatively, MLL-fusion proteins could play a   61
role in promoting genomic instability by de-regulating the expression of MLL target 
genes (So and Cleary, 2002). 
 
 
1.15. Identification of MLL-fusion protein target genes 
 
Several previous studies have compared gene expression profiles of patients 
with 11q23 translocations (MLL leukaemias) to patients with leukaemias that lack 
this genetic lesion (other leukaemias) (Armstrong et al., 2002; Ross et al., 2004, 
Kohlmann et al., 2005). In all studies, gene expression signatures were identified 
which were able to distinguish AML and ALL with 11q23 translocations from other 
ALL and AML subtypes (‘MLL’ vs ‘non-MLL’) (Figure 10). In some studies it was 
observed that although MLL leukaemias were clearly distinct from other leukaemia 
subtypes of the same cell lineage, they cluster primarily according to lineages 
independent of molecular abnormalities (‘MLL AML with other AML’ vs ‘MLL 
ALL with other ALL’) (Ross et al., 2004, Kohlmann et al., 2005). Kohlmann et al. 
then went on to demonstrate that MLL rearranged myeloid and lymphoid leukaemias 
can also be segregated with respect to their lineage but not with respect to their 
partner genes (‘MLL AML’ vs ‘MLL ALL’) (Kohlmann et al., 2005). These results 
suggest common downstream pathways of MLL-fusion mediated transformation but 
do not explain why the presence of specific MLL rearrangements is associated with 
particularly lineages of leukaemia (Kohlmann et al., 2005). However, another gene 
expression study shows that primary acute leukaemias and cell lines with the same 
primary genetic changes segregate based on their genetic rearrangement (Andersson 
et al., 2005). Controversial results like these may be caused by inherent problems 
with comparing different kind of leukaemias with each other.   62
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Figure 10: Top 50-ranked MLL discriminating genes 
The figure illustrates the expression patterns of the top 50-ranked non-lineage 
restricted MLL class discriminating genes revealed by gene expression profiling of 
paediatric AML. All cases with MLL rearrangements were grouped on the left. The 
majority of the MLL class discriminating genes were overexpressed. Among these 
are genes that are expressed in the majority of MLL rearranged cases, such as MEIS1, 
HOXA4, HOXA5, HOXA9, HOXA10 and MYH9 (adapted from Ross et al., 2004).   63
In mice, previous gene expression studies with MLL-AF9 have analysed gene 
expression in leukaemic-GMP (L-GMP), an HPC sub-population (Krivtsov et al., 
2006). L-GMP is described to contain a high frequency of leukaemic stem cells 
(Krivtsov et al., 2006). These studies have yielded important information, such as the 
characterisation of gene expression changes that occur during the transition from 
committed progenitor to LSC and the identification of a small set of direct MLL-AF9 
activated target genes (Krivtsov et al., 2006). However, this study has several 
potential drawbacks. Since LSC enrichment does not mean that LSC are only 
contained in the enriched population, it is unclear how many LSC were lost from the 
analysis because of the L-GMP purification protocol. One of the main problems 
associated with this approach of gene expression profiling is that the transformed 
cells permanently express MLL-AF9, which makes the definition of an appropriate 
control group difficult. In order to allow a comparison and identify differentially 
expressed genes, the gene expression profile of transformed cells was compared to 
the gene expression profile of non-transformed GMP (Krivtsov et al., 2006). 
However, this resulted in an inadequate comparison. It is questionable if every GMP 
is capable of being transformed and therefore if the transformed GMP are different to 
the non-transformed GMP in terms of progenitor composition. Immortalised cells 
may represent an expansion of a small fraction of GMP, not equivalent to the total 
GMP pool. In order to exclude non-specific MLL-AF9 target genes, this study also 
performed an additional gene expression profiling shortly after transduction of HPC 
with MLL-AF9 (Krivtsov et al., 2006). However, flow cytometry sorting and 
retroviral infection of the cells just before global gene expression profiling can cause 
high noise to signal ratio and therefore results in identification of only a small set of 
target genes. 
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Similar difficulties were encountered by Chen et al. using sorted HSC, CLP, 
CMP and GMP populations from pre-leuakemic Mll-AF9 ‘knock-in’ mice and wild-
type mice, to compare the early in vivo effects of MLL-AF9 on gene expression 
levels (Chen et al., 2008). Mll-AF9 ‘knock-in’ mice show myeloproliferation but are 
not leukaemic at this stage (Corral et al., 1996, Chen et al., 2008). Similar to 
Krivtsov et al., the potential caveat of this study is that differentially expressed genes 
were identified based on the comparison between a population of transformed cells 
and a population of wild-type cells which may be completely different in their 
progenitor composition (Chen et al., 2008). Furthermore, this study does not take 
into account that Mll-AF9-induced transformation varies within the different cell 
types, being most efficient in HSC and lowest in GMP. Differentially expressed 
genes were identified by analysing gene expression changes for all four Mll-AF9 cell 
types compared to wild-type or by comparing Mll-AF9 transformation sensitive 
HSC/CLP to Mll-AF9 transformation-resistant CMP/GMP (Chen et al., 2008). It is 
likely that an approach like this will only facilitate reliable identification of primary 
Mll-AF9 target genes with high fold changes, such as Evi1 and HoxA5, similar to the 
well-known MLL and MLL-fusion protein targets HoxA9 and Meis1. Therefore, this 
system does not seem sensitive enough to identify downstream pathways required for 
Mll-AF9 mediated transformation. 
 
MLL-AF9 target genes were also identified in a study, using immortalised 
MLL-AF9 cell lines generated by retroviral transduction of human CD34
+ cord blood 
cells (Wei et al., 2008). As comparison samples, Wei et al. used retrovirally 
immortalised cell lines, expressing one of the CBF fusion genes, AML1-ETO or 
CBFβ-MYH11. In order to further compare the gene expression profile of MLL-AF9 
cells to primary AML samples, samples from two public data sets (Ross et al., 2004,   65
Valk et al., 2004) were combined and analysed for the most differentially expressed 
genes between CBF patient samples and MLL patient samples (Wei et al., 2008). 
Differentially expressed genes in patient and culture samples were then compared 
and it was shown, that the gene expression profile of the MLL-AF9 expressing cell 
lines resembles human AML with 11q23 translocations (Wei et al., 2008). 
 
Zeisig et al. generated conditional MLL-ENL immortalised mouse cell lines 
by using a synthetic hormone-inducible system and performed a global gene 
expression analysis (Zeisig et al., 2004). This system utilizes fusions between a 
mutated synthetic hormone-binding domain of the oestrogen receptor and the MLL-
ENL fusion protein. In the absence of the synthetic hormone precursor tamoxifen, 
the fusion protein is held in an inactive state, presumably due to complex formation 
with HSP90. Addition of tamoxifen causes a conformational change that dissociates 
HSP90, resulting in activation of the fusion protein (Littlewood et al., 1995). One 
caveat of this system was that the maintenance of MLL-ENL immortalised cell lines 
was dependent on addition of tamoxifen to the cell cultures. By excluding 
constitutive cell lines from the analysis, the effect of tamoxifen itself on gene 
expression was not taken into account (Zeisig et al., 2004). Although biologically 
replicates are of critical importance for statistically and biologically valid 
conclusions, differentially expressed genes were identified by comparing RNA, from 
one cell line in triplicate experiments, cultured with and without tamoxifen (Zeisig et 
al., 2004). Therefore, gene expression profiling using this approach resulted in only a 
small set of target genes. 
 
Since leukaemia is a very heterogeneous disease, it is particularly difficult to 
define an appropriate control for global gene expression studies with patient   66
materials. One possibility is to compare different genetic subtypes with each other 
and identify genes that are differentially regulated between the compared subtypes of 
leukaemia. However, none of the leukaemic subgroups can be considered as a 
control group but rather as comparison samples. Furthermore, leukaemic cells from 
patient material often contain multiple genetic aberrations which can cause 
significant skewing of the gene expression profiles. The available data shows that 
there is a need for target gene analysis using a different, biologically and statistically 
more robust approach.   67
PROJECT AIM 
 
The aim of my project was to investigate the transcriptional networks used by 
the MLL-AF9 and MLL-ENL fusion oncogenes to transform haematopoietic 
progenitor cells in vitro and induce leukaemia in vivo. It was envisaged that analysis 
of global gene expression changes in conditionally immortalised MLL-AF9 and 
MLL-ENL cell lines would identify genes which could play a role in the underlying 
transformation process induced by MLL-fusions. By changing MLL-fusion target 
gene expression, for example by knock down of target genes which are induced by 
the MLL-fusions, the importance of a particular target gene for MLL-fusion 
mediated transformation could be examined. Abrogated expression of target genes 
which affected MLL-AF9 and MLL-ENL immortalised cell lines in vitro could 
potentially play an important role in AML development in vivo. Therefore, 
conditional MLL-ENL cell lines were used to induce leukaemia in vivo and the 
dependence of the leukaemia on conditional expression of MLL-ENL was examined. 
This approach allowed the validation of targeting the transcriptional pathways 
controlled by MLL-fusions in order to abrogate leukaemia.   68
CHAPTER II  - MATERIALS AND METHODS 
 
2.1.  Buffers and Solutions 
 
Table 4: Buffers used in this study 
Buffer Components  Supplier 
Red Cell 
Lysis  
17 mM Tris(hydroxymethyl)methylamine   
(TrisHCl) [pH 7.2]  
0.144 M Ammonium Chloride (NH4Cl) 
VWR 
 
VWR 
TE Buffer  10 mM TrisHCl [pH 8.0] 
1 mM Ethylenediaminetetraacetic Acid 
Disodium Salt (EDTA) [pH 8.0] 
 
VWR 
 
TNES  TE Buffer [pH 8.0] 
0.1 M Sodium Chloride (NaCl) 
1% w/v Sodium Dodecyl Sulfate (SDS) 
 
VWR 
Sigma 
Denaturation   1.5 M NaCl 
0.5 M Sodium Hydroxide (NaOH) 
 
VWR 
Neutralisation   1 M TrisHCl [pH 7.7] 
1.5 M NaCl 
 
Denhardt’s 
solution (1x) 
[pH 7.0] 
0.5% w/v Bovine Serum Albumin (BSA) 
0.5% w/v Ficoll 400 
0.5% w/v Polyvinylpyrrolidone 
Sigma 
Sigma 
Sigma 
Pre-
hybridisation 
0.1 g/ml Dextran Sulphate  
4 x SSC (NaCl, Sodium Citrate) [pH 7.0] 
5x Denhardt’s solution 
0.5% w/v SDS 
Sigma 
NationalDiagnostics
2x Reducing 
Sample Buffer 
200 mM Dithiothreitol (DTT) 
2% w/v SDS 
10% v/v Glycerol 
0.1% w/v Bromophenol Blue 
0.125 M TrisHCl [pH 6.8] 
Sigma 
 
Sigma 
Sigma   69
(Table 4 continues) 
 
Buffer Components  Supplier 
Triton X-100 
Lysis Buffer 
150 mM NaCl 
20 mM TrisHCl [pH 7.4] 
1 mM EDTA 
1% v/v Triton X-100 
 
 
 
Sigma 
Upper Buffer  0.5 M TrisHCl [pH 6.8] 
0.4% w/v SDS  
 
Lower Buffer  1.5 M TrisHCl [pH 8.8] 
0.4% w/v SDS 
 
Running 
Buffer (1x) 
0.192 M Glycine 
25 mM TrisHCl [pH 8.3] 
0.1% w/v SDS 
VWR 
Transfer 
Buffer (1x) 
9.5 mM CAPS [pH 11.0]  Sigma 
Western Wash 
Buffer 
1x Phosphate-Buffered Saline (PBS)  
0.1% v/v Tween-20 
Oxoid 
Sigma 
Stripping 
Buffer 
50 mM 2-Mercaptoethanol (2-ME) 
1% w/v SDS 
62.5 mM TrisHCl [pH6.7] 
Sigma 
FACS Wash 
Buffer 
PBS 
0.1% w/v Sodium Azide (NaN3) 
Gibco 
Sigma 
FACS Stain 
Buffer 
PBS 
0.1% w/v NaN3 
1% w/v BSA 
 
 
 
 
The table shows a list of all buffers used in this study. 
 
 
2.2.  Transformation of Bacteria 
 
Electrocompetent cells: 
To prepare electrocompetent cells, cells from the DH10βtrfA and DH10β bacterial 
strain were plated out from the glycerol stock onto LB Agar (1.5g Bacto Agar (BD)   70
per 100 ml LB broth) plates and incubated at 37ºC overnight. On the next day, one 
bacterial colony was picked and inoculated into 5 ml LB Broth (1% w/v Bacto 
Tryptone (BD), 0.5% w/v Bacto Yeast Extract (BD), 1% w/v Sodium Chloride 
(NaCl), [pH 7.0]) at 37ºC overnight with shaking at 240rpm. 5 ml of the overnight 
culture was inoculated in 500 ml of 2xYT (1.6% w/v Bacto Tryptone, 1% w/v Bacto 
Yeast Extract, 0.5% w/v NaCl) at 37ºC overnight with shaking at 240rpm. Cells were 
poured into 10 pre-chilled 50 ml falcon tubes and put on ice for five minutes to cool 
the cells quickly. Cells were centrifuged at 2260g for seven minutes at 4ºC and the 
supernatant was discarded. The pellets were gently resuspended in 4 ml chilled 10% 
glycerol and divided into 10 new 50 ml pre-chilled falcon tubes. 25 ml chilled 10% 
glycerol was added to each tube, centrifuged at 2260g for seven minutes at 4ºC and 
the supernatant was discarded. This step was repeated two times but the cells were 
pooled and divided into 5 new 50 ml chilled falcon tubes after centrifugation. Finally 
the pellets were resuspended in 8 ml chilled 10% glycerol and transferred into one 
pre-chilled 50 ml falcon tube. The cells were centrifuged at 2260g for five minutes at 
4ºC and the supernatant was discarded. The pellet was resuspended in 250µl chilled 
10% glycerol and the OD600nm was measured. The cells were diluted to an OD600nm 
reading of about 0.2. 
 
1 µl DNA was incubated on ice and mixed with 25 µl electrocompetent cells, 
previously thawed on ice. The mixture was transferred to a 1 mm cuvette 
(Eppendorf) and pulsed once with 1.8 V using an electroporator (Micropulse, 
BioRad, bacteria  program: EC1). The mixture was added to 1 ml LB broth and 
incubated for one hour at 37ºC with shaking. The transformed cells were plated onto 
LB Agar plates containing 100 µg/ml Ampicillin (Sigma) and cultured overnight at 
37°C.   71
Chemocompetent cells: 
Subcloning Efficiency DH5αCompetent Cells (Invitrogen) were transformed 
according to the manufacturer’s instructions. After transformation the cells were 
treated as described earlier. 
 
2.3.  Isolation of plasmid DNA 
 
For small amounts of DNA, used for cloning, a single bacterial colony was 
picked and inoculated into 3 ml LB broth containing 100 µg/ml Ampicillin and 
incubated overnight at 37ºC with shaking. Plasmid DNA was isolated from the 
bacterial cultures using High Pure Plasmid Isolation Kit (Roche) according to the 
manufacturer’s instructions. To purify large quantities of plasmid DNA, used for 
transfections, a single bacterial colony was picked and inoculated into 3 ml LB broth 
containing 100 µg/ml Ampicillin for 6 hours at 37ºC with shaking. 250 µl of this 
starter culture was then transferred into 250 ml LB broth containing 100 µg/ml 
Ampicillin and incubated for at least 16 hours at 37ºC with shaking. Plasmid DNA 
was isolated from the bacterial cultures using Genopure Plasmid Maxi Kit (Roche) 
according to the manufacturer’s instructions. The plasmid DNA concentration was 
determined by measuring the absorbance at 260 nm using a spectrophotometer 
(NanoDrop ND-1000, Labtech International). The ratio of absorbance at 260 nm to 
280 nm was used to assess the purity of DNA. A ratio of ~1.8 is accepted as pure for 
DNA. If the ratio is lower, it may indicate the presence of protein, phenol or other 
contaminants that absorb strongly at or near 280 nm (NanoDrop user’s manual). 
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2.4.  Cloning 
 
Polymerase chain reaction (PCR): 
Template specific primers were designed and provided by Sigma. Table 5 shows the 
TRE PCR primers used in this study. 
 
Table 5: TRE PCR primer 
Name Direction Sequence  (5’-3’)  Vector 
TRE 1F NEW  forward  GGATCCTCTCGAGTTTACCACTCC  pRevTRE 
TRE 444R NEW  reverse  GTCGACGTACCGAGCTCGAATTCG pRevTRE 
 
The table shows the TRE PCR primers used in this study. 
 
For the PCR reaction mix, 1 ng insert was mixed with 10x reaction buffer, 
0.25 µl (1 unit) Taq polymerase, 0.2 mM dNTP, 1.5 mM MgCl2, 0.5 pmol forward 
primer, 0.5 pmol reverse primer and H2O up to 50 µl total volume. The PCR was 
performed using the cycle conditions illustrated in Table 6. 
 
Table 6: PCR cycle conditions 
 
Stage 1 
 
Stage 2 (35 cycles) 
 
Stage 3 
 
94ºC    5 minutes  94ºC    30 seconds  72ºC    10 minutes 
  50ºC    1 minute  Hold: 10ºC    16 hours 
  72ºC    1 minute   
 
The table shows the PCR cycle conditions. 
 
 
   73
Restriction enzyme digests: 
Restriction enzymes (Promega) were used to cleave double stranded DNA. The 
digests were set up according to the manufacturer’s instructions, with two- to ten-
fold excess of enzyme over DNA and under 10% of the final volume. The digest was 
incubated for two hours at 37ºC, mixed with Orange G (Sigma) loading buffer and 
analysed on a 0.7% - 1.2% w/v (depending on the size of the fragments) Agarose gel 
(Agarose (Invitrogen), 1xTAE buffer (National diagnostics), 0.5% Ethidium 
Bromide (Sigma)).  
 
Ligations: 
A variety of insert to vector ratios (10:1, 3:1, 1:1 and 0:1) was set up for each 
ligation. The following equation was used to calculate the required amount of insert 
for a 3:1 ligation:  
nginsert required = [(50ngvector x kbinsert)/kbvector] x 3 
 
For the ligation reaction 0.3 µl (1 unit) T4 DNA ligase (Promega) was mixed with 1 
µl 10x T4 ligase buffer (Promega), calculated amount of insert, 50 ng vector and 
made up to 10 µl total volume with H2O. The reaction was left at room temperature 
for three hours for a sticky end ligation or overnight at 4ºC for a blunt end ligation. 
 
Gel Extraction: 
QIAquick Gel Extration Kit (Qiagen) was used to extract and purify DNA from 
Agarose gels according to the manufacturer’s instructions. The concentration of 
purified DNA was determined using the NanoDrop ND-1000. 
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2.5.  Retroviral constructs 
 
Diagrams of all retroviral constructs used in this study are shown in Figure 11 and 
Figure 12. 
 
pCR2.1-TREintermediate: 
To generate the full length MLL-ENL conditional expression vector (pMSCV-neo-
TRE-fMLLENL), the cDNA of the tetracycline-responsive promotor element (TRE) 
was amplified by PCR using pRevTRE vector (Clontech) as a template. A 0.5 kb 
fragment encoding the TRE was amplified using a forward primer incorporating a 
Sal1 and BamH1 site: 5’-CGACTTGTCGACGGATCCTCTCGAGTTTACCACTC 
CCTATC-3’ and a reverse primer incorporating a Sal1 site: 5’-CGTTACGTCGACC 
CGGGTACCGAGCTCGAATTC-3’ (added restriction sites are underlined). A poly 
A overhang was added to the 0.5 kb TRE fragment using Taq polymerase (Promega) 
to sub-clone into the pCR2.1 vector (Clontech). The resulting vector, pCR2.1TRE, 
was then digested with BamH1 and re-ligated to remove the first Sal1 restriction site 
for further cloning purposes (pCR2.1TREintermediate). 
 
pCR2.1-TRE-fMLLENL: 
pMSCV-neo-mod-fMLLENL was digested with Xho1 and the overhang was filled in 
with Klenow (Roche) to generate a blunt end. The vector was then digested with Sal1 
to release the 6.1 kb fragment encoding a flag epitope upstream of the full-length 
MLLENL (fMLLENL) sequence. To be able to distinguish between the 6.5 kb vector 
fragment and the 6.1 kb fMLLENL fragment the vector was also digested with Cla1. 
The pCR2.1TREintermediate vector was digested with Not1 and the overhang was 
filled in with Klenow to generate a blunt end.   75
MYC MLL ENL 5’LTR PGK NEOr 3’LTR Ψ TRE
pMSCV-neo-TRE-mMLLENL:
BamH1 BamH1
FLAG MLL ENL 5’LTR PGK NEOr 3’LTR Ψ
pMSCV-neo-mod-fMLLENL:
Sal1 Xho1 Cla1
pRevTRE:
HYGr TRE 3’LTR 5’LTR Ψ
KANr AMPr pUC ori Plac F1 ori
BamH1
pCR2.1:
lacZα
KANr AMPr pUC ori F1 ori TRE
pCR2.1-TRE:
BamH1
Sal1, BamH1
Sal1 Not1
Plac lacZα
KANr F1 ori TRE
pCR2.1-TRE-fMLLENL:
MLL ENL FLAG
BamH1 BamH1
Plac lacZα
KANr AMPr pUC ori F1 ori
pCR2.1-TREintermediate:
TRE
BamH1 Sal1 Not1
Plac lacZα
 
 
Figure 11: Retroviral constructs used in this study 
LTR, long terminal repeat; Ψ, viral packaging signal; PKG, murine phosphoglycerate 
kinase promoter; NEOr, neomycin resistance gene; Plac, LacZ promotor; LacZα, 
LacZ gene fragment. Restriction enzyme sites shown in red were used for sub-
cloning the full length MLL-ENL and MLL-AF9 conditional expression vector. Final 
vectors used in this study are highlighted in grey.   76
PGK NEOr 3’LTR 5’LTR Ψ
pMSCV-neo:
BamH1 Sal1
FLAG MLL AF9 5’LTR PGK NEOr 3’LTR Ψ
pMSCV-neo-mod-fMLLAF9:
BamH1 Xho1
pMSCV-neo-TRE-fMLLENL:
FLAG MLL ENL 5’LTR PGK NEOr 3’LTR Ψ TRE
BamH1 BamH1
FLAG MLL AF9 5’LTR PGK NEOr 3’LTR Ψ TRE
pMSCV-neo-TRE-fMLLAF9:
BamH1 BamH1
PGK NEOr 3’LTR 5’LTR Ψ
pMSCV-neo-endMLLAF9:
MLL AF9
BamH1 Xho1
MYC MLL AF9 PGK NEOr 3’LTR 5’LTR Ψ
pMSCV-neo-mod-mMLLAF9:
hCD2 tailless 5’LTR 5’miR30 3’LTR Ψ
pMSCV-hCD2tailless-miR30:
EcoR1 Xho1
3’miR30
shRNA
IRES-EGFP 3’LTR tTA2s
pMSCV-tTA2s-IRES-EGFP:
5’LTR Ψ
 
 
 
 
Figure 12: Retroviral constructs used in this study (continued) 
LTR, long terminal repeat; Ψ, viral packaging signal; PGK, murine phosphoglycerate 
kinase promoter; NEOr, neomycin resistance gene. Restriction enzyme sites shown 
in red were used for cloning. Final vectors used in this study are highlighted in grey.   77
The resulting vector was then digested with Sal1 to generate a sticky end. The 6.1 kb 
fMLLENL fragment was then sub-cloned directionally into the 
pCR2.1TREintermediate vector. 
 
pMSCV-neo-TRE-fMLLENL: 
pCR2.1TRE-fMLLENL was digested with BamH1 to release the 4.3 kb TRE-fMLL 
fragment. This fragment was inserted into pMSCV-neo-TRE-mMLLENL which had 
previously been digested with BamH1, to generate pMSCV-neo-TRE-fMLLENL. 
 
pMSCV-neo-endMLLAF9: 
To generate the full length MLL-AF9 conditional expression vector (pMSCV-neo-
TRE-fMLLAF9) pMSCV-neo-mod-fMLLAF9 vector was digested with BamH1 and 
Xho1 to release a 0.65 kb fragment encoding the 3’ part of the MLL-AF9 fusion 
gene sequence. The pMSCV-neo vector was digested with BamH1 and Sal1 (Sal1 
site can ligate with the Xho1 site) and the 0.65 kb fragment was then sub-cloned 
directionally into pMSCV-neo vector, downstream of the neomycin resistant gene to 
generate pMSCV-neo-endMLLAF9. 
 
pMSCV-neo-TRE-fMLLAF9: 
pMSCV-neo-TRE-fMLLENL vector was digested with BamH1 to release the 4.3 kb 
TRE-fMLL fragment. This fragment was sub-cloned into the pMSCV-neo-
endMLLAF9 intermediate vector, which had been digested with BamH1, upstream 
of the 3’ part of the MLL-AF9 fusion gene. The cloning sites were sequenced to 
check that no rearrangements had occurred while sub-cloning the conditional MLL-
ENL and MLL-AF9 vector.  
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2.6.  Culture of LinXE ecotropic retrovirus packaging cell line and NIH-3T3 
fibroblast cells 
 
The LinXE ecotropic retrovirus packaging cell line and NIH-3T3 fibroblast 
cells were cultured in a 10 cm culture dish (NUNC) in 10 ml Dulbecco’s Modified 
Eagle’s medium (DMEM, Gibco) supplemented with 10% heat-inactivated foetal 
calf serum (FCS, Sigma-Aldrich), 100 U/ml Penicillin (Gibco), 100 μg/ml 
Streptomycin (Gibco) and 2 mM L-glutamine (Gibco) (DMEM complete medium). 
LinXE cells were maintained in the presence of 7.5 μg/ml Hygromycin B 
(InvivoGen). To replate the cells, old medium was discarded, the plate was washed 
in 5 ml  Phosphate-Buffered Saline (PBS, Gibco) and the cells were incubated with 2 
ml 1xTrypsin/EDTA (Gibco) for 5 minutes. 2 ml of trypsinised cells were then added 
to 8 ml PBS mixed with 2 ml DMEM complete medium and centrifuged at 300g for 
5 minutes at room temperature (Hettich Zentrifugen Rotina 46 R). The cell pellets 
were resuspended in 5 ml DMEM complete medium and counted. The cells were 
replated at 1:25 for 3 to 4 days. 
 
2.7.  Transfection of LinXE cells 
 
Three days before transfection LinXE cells were seeded at a density of 5x10
5 
per 10 cm plate without Hygromycin B selection. For transfection 8 μg retroviral 
plasmid DNA mixed with 800 μl serum free medium Optimem (Gibco) was added 
drop-wise to 40 μl Lipofectamine (Invitrogen) mixed with 760 μl Optimem and 
incubated at room temperature for 15 to 45 minutes. LinXE cells were washed once 
in 8 ml Optimem. 6.4 ml Optimem was added to the transfection mix and incubated 
with the LinXE cells for five hours at 37°C. After five hours 8 ml DMEM complete   79
medium containing 20% FCS was added and incubated overnight at 37°C. One day 
after transfection, media on transfection plates was replaced with 8 to 10 ml fresh 
DMEM complete medium containing 10% FCS. 
 
2.8.  Determination of the viral titre 
 
The viral titre of pMSCV-neo-TRE-fMLLAF9 was determined by titration on 
NIH-3T3 cells (Appendix Figure 74). Transfection of LinXE cells was carried out as 
described earlier. NIH-3T3 fibroblast cells were seeded at 5x10
4 per well of a 6-well 
plate (NUNC) in 2 ml DMEM complete media. Two days after transfection virus 
supernatant was harvested and diluted with DMEM complete medium 1:10, 1:1000 
and 1:100000 containing 5 μg/ml polybrene (Sigma-Aldrich). Medium of the 
cultured NIH-3T3 fibroblast cells was replaced with 2 ml of virus dilution and 
incubated overnight at 37°C. On the following day cells were split 1:20 into 10 cm 
plates and incubated over night at 37°C. The medium was replaced twice by 10 ml of 
fresh DMEM complete medium containing 1 mg/ml G418 (Invitrogen) and 
incubated for five days at 37°C. After this, the cells were washed with 5 ml PBS and 
stained with 5 ml methylene blue (0.1 g methylene blue (Sigma)/70 ml Methanol 
(MeOH)). The stain was incubated for 5 minutes on the plates, washed upside down 
in water 5 times and dried. The viral titre was calculated using the following formula: 
 
viral titre (infectious particles/ml) = (number of colonies x dilution factor)/2 
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2.9.  Determination of number of viable cells 
 
Trypan Blue (Sigma) exclusion was used to determine the number of viable 
cells present in a cell suspension. The cell suspension was mixed with Trypan Blue 
(1:1) dye and then visually examined to determine whether cells had taken up or 
excluded dye and counted. Viable cells had a clear cytoplasm whereas nonviable 
cells had a blue cytoplasm. 
 
2.10. Isolation of adult murine HPC from bone marrow 
 
Mice were maintained in the animal facilities of the Western Laboratories 
(UCL Biological Services Unit) and experiments were performed according to 
institutional guidelines and Home Office regulations. Bone marrow was extracted 
from the femur and tibia and a single cell suspension was made. Red cells were lysed 
for 5 minutes with Red Cell Lysis buffer. Haematopoietic progenitor cells (HPC) 
were sorted by magnetic activated cell sorting (MACS) using the Lineage Cell 
Depletion Kit (Miltenyi Biotec). Lineage positive cells were labelled using 10 μl per 
1x10
7 cells of a biotin-conjugated monoclonal antibody cocktail (CD5, B220, 
CD11b, anti-GR-1, 7-4 and Ter-119). Then the cells were magnetically labelled 
using 20 μl per 1x10
7 cells of an anti-biotin monoclonal antibody conjugated to 
MicroBeads. The magnetically labelled lineage positive cells were depleted by using 
a MACS LS or LD column in the magnetic field of the MACS separator. Lineage 
negative cells were seeded at a density of 1x10
6/ml. HPC were cultured overnight in 
DMEM complete medium supplemented with 50 μM 2-mercaptoethanol (2-ME, 
Sigma), 100 ng/ml SCF, 10 ng/ml IL-3 and 10 ng/ml IL-6 (all from Peprotech). 
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2.11. Transduction of HPC 
 
Retroviral supernatants were produced as described earlier, using the 
ecotropic retrovirus packaging cell line LinXE. Isolated HPC were cultured for 24 
hours in DMEM complete medium supplemented with 50 μM 2-ME, 100 ng/ml 
SCF, 10 ng/ml IL-3 and 10 ng/ml IL-6. For unconcentrated virus, retroviral 
supernatants were filtered through a 0.45 M filter (Sartorius) and used for 
infections. For concentration of virus, retroviral supernatants were centrifuged in a 
15 ml falcon tube (NUNC) at 470g for 5 minutes to remove cellular debris. All 
supernatant but 1 ml was removed to a new 15 ml falcon tube and centrifuged again. 
1 ml retroviral supernatant each was aliquoted into 1.5 ml tubes and centrifuged in a 
microcentrifuge (Eppendorf Centrifuge 5415R) at 15700g for 1 hour at 4°C. The 
virus pellet was resuspended in one tenth of the original volume in DMEM complete 
medium. Infections were performed in a 96 well flat bottomed plate (TPP) by 
spinoculation. 1x10
4 cells were plated per well in 100 l of virus supernatant 
supplemented with 50 μM 2-ME, 100 ng/ml SCF, 10 ng/ml IL-3 and 10 ng/ml IL-6 
and 5 g/ml polybrene. In total 6x10
4 cells were infected per virus. The plates were 
centrifuged at 680g for 45 minutes at 20°C. Infections were either performed on two 
consecutive days or alternatively 100 l fresh DMEM complete medium, 
supplemented with growth factors was added to the infections on the second day. 
 
2.12. Myeloid methylcellulose colony forming assays 
 
On the third day of infection, the cells were pooled and 3.3x10
4 cells were 
aliquoted in 3.3 ml methylcellulose medium containing SCF, IL-6 and IL-3 
(MethoCult GF M3434, Stem Cell Technologies Inc), supplemented with 10 ng/ml   82
GM-CSF (Peprotech). The vials were shaken vigorously to mix growth factors and 
cells. Bubbles were allowed to settle for 5 minutes. 1.1 ml of M3434 and cell mix 
was dispensed into each of two 35 mm culture dishes (Stem Cell Technologies Inc.) 
using 2.5 ml syringes (BD) and blunt ended needles (Stem Cell Technologies Inc.). 
In some cases cells were selected with 1mg/ml G418 (Gibco) in the first round of 
methylcellulose plating. After 6 to 10 days colonies were counted. To harvest the 
cells, 1 ml MEMalpha (Gibco) was added to each plate, pipetted up and down to 
disperse the methylcellulose and transferred into 10 ml MEMalpha. The cells were 
centrifuged at 300g for 5 minutes at room temperature and resuspended in 1 ml 
MEMalpha to count. 3.3x10
4 cells per 3.3 ml M3434 were replated into subsequent 
rounds without selection. In some cases 2 μg/ml Doxycycline (BDH) was added to 
subsequent rounds. Colonies were defined as clusters of more than 50 cells. To 
visualise colonies, cultures were stained with 1mg/ml p-iodonitrotetrazolium (INT, 
Sigma-Aldrich) in PBS. 
 
2.13. Generation and maintenance of cell lines in liquid culture 
 
After the third round of plating in M3434, cells were harvested, pooled and 
plated at a density of 1x10
5/ml in RPMI-1640 (Gibco) with 10% FCS, 100 U/ml 
Penicillin, 100 μg/ml Streptomycin, 2 mM L-glutamine and 50 μM 2-ME (RPMI 
complete medium) supplemented with 100 ng/ml SCF, 10 ng/ml IL-3 and 10 ng/ml 
IL-6. Cell lines were counted and replated every two to three days at a density 
between 5x10
3 to 1x10
5 per ml,
 depending on the proliferation rate of the cell line. 
The following calculation was used, to determine the rate of accumulation of the cell 
lines (Table 7). 
   83
Table 7: Determination of cell line proliferation rate 
days in 
culture 
fold increase  fold accumulation 
n -  1 
n+x [cell  #  (n+x)] / [cell # plated(n)] [fold  accumulation(n) x fold increase(n+x)] 
 
Determination of cell line proliferation rate, where x represents number of days after day n. Fold 
accumulation was plotted on a log10 scale. 
 
2.14. Isolation of genomic DNA from eukaryotic cells 
 
Typically 5 to 10x10
6 cells were centrifuged at 300g for 5 minutes, washed in 
PBS and resuspended in 400 μl TNES containing 0.5 mg/ml proteinase K (Roche). 
The mixture was incubated overnight a 37°C. The next day 0.5 ml 
phenol(25):chloroform(24):isoamylalcohol(1) solution (Sigma) was added and mixed 
by shaking vigorously for 1 minute. The mixture was centrifuged at 15700g for 5 
minutes to separate the phases and the supernatant was mixed with 1 ml ethanol 
containing 3M NaOAc (Sigma) (25:1 mixture). After inverting the tubes several 
times the DNA was precipitated at room temperature and centrifuged for 10 minutes 
at 300g, then 1 ml 70% ethanol was added to the DNA pellet and centrifuged again 
for 2 minutes at 300g. The supernatant was taken off and the DNA pellet was air-
dried for approximately 10 to 15 minutes. The DNA was redissolved in 100 μl TE 
buffer and left at 4°C overnight prior to freezing at -20°C. 
 
2.15. Southern blot analysis 
 
DNA isolated from MLL-ENL immortalised cell lines was digested overnight 
at 37°C with BamH1 to generate end fragments (30 μl DNA, 10 μl 10x buffer E, 4 μl   84
BamH1, 4 μl BSA, 5 μl RNAse in a total volume of 100 μl). DNA extracted from 
murine spleen or bone marrow was also digested and used as the negative control. 
For the positive control DNA from murine spleen or bone marrow was ‘spiked’ with 
1 ng pMSCV-neo-TRE-fMLLENL plasmid DNA and digested. After that 10 μg of 
digested DNA was electrophoresed on a 0.8% w/v agarose gel overnight at 40V. 
Meanwhile pRev-TREneo was digested with BamH1 and HindIII and the fragments 
were gel purified to obtain the neo-fragment (0.8 kb), used as the hybridisation 
probe. Next the gel was washed three times for 20 minutes with shaking in 
denaturation buffer to denature the DNA. The gel was washed two times with H2O 
prior to incubation with neutralisation buffer for 30 minutes with shaking. Thereafter, 
the gel was washed twice with 10x SSC buffer (National Diagnostics) and the 
nitrocellulose membrane Hybond-N+ (GE Healthcare) as well as Wattman paper 
(Fisher Scientific) were wet in 10x SSC buffer. The nitrocellulose membrane was 
placed on top of the gel, covered with 3 layers of Wattman paper and stacks of paper 
towels. Overnight, pressure was applied evenly to the gel, to transfer the DNA from 
the gel to the membrane by capillary forces. Next, the membrane was baked at 80°C 
for 2 hours to fix the DNA permanently to the membrane. The membrane was then 
briefly washed with 2x SSC and blocked with 100 ml pre-warmed pre-hybridisation 
buffer containing preheated (2 minutes, 100°C) 100 μl salmon testes DNA (Sigma) 
for 2 hours at 65°C shaking. To label the hybridisation probe, 100 ng probe in a total 
volume of 45 μl was denatured at 94°C for 3 minutes and placed on ice for 5 
minutes. The probe was then used to resuspend the Ready-To-Go DNA Labeling 
Beads (-dCTP) (GE Healthcare), 5 μl of [α-
 32P]dCTP was added and incubated for 
one hour at 37°C. To purify the labelled probe, the ProbeQuant G-50 Micro Columns 
Purification Kit (GE Healthcare) was used according to the manufacturer’s 
instructions. The labelled and purified probe was denatured at 94°C for 10 minutes,   85
added to the prehybridsation mix and incubated overnight at 65°C with rotation. 
After hybridisation, excess probe was washed off the membrane with 2x SSC buffer 
containing 0.1% SDS for one hour at 55°C. The pattern of hybridisation was 
visualized using a Typhoon phosphoimager (Amersham Biosciences) as well as on 
X-ray film by autoradiography. 
 
2.16. Preparation of protein extracts for Western blot analysis 
 
Cells were harvested and centrifuged at 300g for 5 minutes at 4°C. Cell 
pellets were lysed using 60 μl 2 x reducing sample buffer per 1x10
6 cells. The lysate 
was incubated at 100°C for five minutes and vortexed for 10 seconds. Then the 
lysate was centrifuged at 15700g for 1 minute at 4°C in a microcentrifuge. The 
supernatant containing the protein extract was recovered and frozen at –20°C. To 
denature proteins before loading, samples were incubated at 100°C for five minutes 
and kept on ice until loading. 
 
2.17. MLL-AF9 Western blot analysis 
 
Table 8: Components of a 4% stacking gel 
Solutions  Stacking Gel (4%) 
30% Acrylamide/Bis Solution (29:1) (BioRad)  0.8 ml 
Upper Buffer  1.6 ml 
H2O 3.8  ml 
Temed (BioRad)  6.25 µl 
10% w/v Amonium Persulfate (APS, BioRad)  31.3 µl 
 
The table shows the components of a 4% stacking gel used for Western blot analysis.   86
Table 9: Components of resolving gels 
Resolving Gel  Solutions 
5% 10%  12.5% 
30% Acrylamide/Bis Solution (29:1) (BioRad)  5 ml  10 ml  12.5 ml 
Lower Buffer  7.5 ml  7.5 ml  7.5 ml 
H2O  17.5 ml  12.5 ml  10 ml 
Temed (BioRad)  20 µl  20 µl  20 µl 
10% w/v Amonium Persulfate (APS, BioRad)  100 µl  100 µl  100 µl 
 
The table shows the components of 5%, 10% and 12.5% resolving gels used for Western blot analysis. 
 
Hoeffer equipment (GE Healthcare) was used for all Western blot analysis. 
Protein samples were stacked in a 4% SDS-polyacrylamide gel (Table 8) and 
resolved on a 5% SDS- polyacrylamide gel (Table 9) at 65V overnight at room 
temperature. SDS- polyacrylamide gel electrophoresis (SDS-PAGE) was performed 
in 1x running buffer. After that, samples were first transferred to a 
polyvinylidenefluoride (PVDF) membrane (Millipore) for 6 hours at 500 mA at 4ºC 
in 1 x CAPS and then membranes were blocked in PBS with 5% non-fat milk and 
0.1% Tween-20 (Sigma) (PBS-T) overnight at 4°C. The membranes were then either 
incubated with anti-MLL
N/HRX [clone N4.4] monoclonal antibody (mAb) (Upstate) 
for 4 hours or with an anti-HSP90α/β antibody (Cell Signaling Technology) for 1 
hour at room temperature. Excess antibody was removed by washing membranes six 
times with PBS-T for 10 minutes each. Proteins were detected using sheep anti-
mouse secondary antibody conjugated to horseradish peroxidase (HRP, GE 
Healthcare) or anti-rabbit antibody conjugated to HRP (GE Healthcare) and a 
chemiluminescent reagent (ECL, Amersham Biosciences) according to the 
manufacturer’s instructions. To estimate the size of proteins, the High-Range   87
Rainbow Molecular Weight Marker (Amersham Biosciences) was used. In order to 
re-probe membranes with different antibodies, membranes were stripped of bound 
antibodies. Membranes were incubated at 50ºC for 30 minutes with agitation in 
stripping buffer. The membranes were then washed twice with PBS-T for 15 minutes 
and blocked again in PBS-T with 5% non-fat milk. Hypofilms ECL (Amersham) 
were exposed to membranes for various exposure times and then developed using a 
Xograph CompactX4 developer. Exposed films were scanned using a Calibrated 
Densitometer (GS-800, BioRad) and bands were quantitated using QuantityOne 
software (BioRad). The relative protein expression was calculated dividing the 
values of the protein of interest by the expression values of the protein loading 
control. Protein expression values from treated samples were normalised to untreated 
samples. Table 10 lists all antibodies used in this study and their corresponding HRP 
conjugated secondary antibodies, which were used for detection. 
 
2.18. RNA isolation 
 
Total RNA was isolated from the cells using either the RNeasy Mini Kit 
(Qiagen) according to manufacturer’s instructions or TRIzol reagent (Invitrogen). 
For the TRIzol reagent extraction method, a maximum of 1x10
7 cells were 
centrifuged in a 15 ml falcon tube at 300g for 5 minutes. Tubes were flicked to 
dislodge pellets and the cells were lysed in 1 ml TRIzol reagent (Invitrogen) using 
repetitive pipetting. The lysate was transferred to a 1.5 ml tube and incubated at 
room temperature for 5 minutes. 200 µl chloroform (VWR) was added to the lysate, 
shaken vigorously for 15 seconds, incubated for 2–15 minutes at room temperature 
and centrifuged at 12000g for 15 minutes at 4ºC.   88
Table 10: Antibodies used in this study 
Antibody (clone)  Supplier  Dilution  Secondary Ab 
Actin (I-19)  Santa Cruz Biotechnology  1:500  α-goat (1:6000) 
AF4 antiserum  provided by Prof KE Davies  1:1000  α-rabbit (1:10000) 
Active-Ctnnb(8E7) Upstate  Millipore  1:2000  α-mouse (1:2000) 
Total-Ctnnb (E-5)  Santa Cruz Biotechnology  1:500  α-mouse (1:2000) 
c-Myb (H-141)  Santa Cruz Biotechnology  1:500  α-rabbit (1:10000) 
HSP 90α/β (F-8)  Santa Cruz Biotechnology  1:10000  α-mouse (1:10000) 
MLL
N/HRX(N4.4) Upstate  Millipore  1:400  α-mouse (1:2000) 
Pontin52 (N-15)  Santa Cruz Biotechnology  1:500  α-goat (1:3000) 
SIAH-1 (N-15)  Santa Cruz Biotechnology  1:500  α-goat (1:3000) 
SIAH-2 (N-14)  Santa Cruz Biotechnology  1:500  α-goat (1:3000) 
β-Tubulin (D-10)  Santa Cruz Biotechnology  1:500  α-mouse (1:2000) 
 
The table lists all antibodies used for Western blot analysis in this study. 
 
After centrifugation the upper aqueous phase containing the RNA was 
transferred to a fresh tube, mixed with 500 µl isopropanol, incubated at room 
temperature for 10 minutes and centrifuged at 12000g for 10 minutes at 4ºC. The 
pellet was washed in 1 ml 70% ethanol (EtOH) and centrifuged for 5 minutes at 
5100g at 4ºC. The supernatant was discarded and the pellet was air dried. To 
redissolve the pellet carefully, 30 µl filtered H2O was added and incubated at 55ºC 
for 5 minutes. The concentration of isolated RNA was determined using a 
spectrophotometer (NanoDrop ND-1000). The ratio of absorbance at 260 nm and 
280 nm is used to assess the purity of RNA. A ratio of ~2.0 is accepted as pure for 
RNA. If the ratio is lower, it may indicate the presence of protein, phenol or other 
contaminants that absorb strongly at or near 280 nm (NanoDrop user’s manual).   89
RNA quality of samples used for the Affymetrix Gene Chip Arrays was determined 
using the Agilent 2100 Bioanalyzer (Agilent RNA 6000 Nano Kit) according to 
manufacturer’s instructions. An indication for good RNA quality is a ratio of 18S to 
28S ribosomal RNA between 1.6 and 2.0. Furthermore the entire electrophoretic 
trace of the RNA sample including the presence or absence of degradation products 
is calculated in a RNA Integrity Number (RIN). The RIN tool automatically assigns 
an integrity number to the RNA sample, with 1 representing poor quality and 10 
representing good quality (Agilent 2100 Bioanalyzer 2100 Expert User’s Guide). 
 
2.19. cDNA preparation 
 
RNA was converted into cDNA using a cDNA synthesis kit from Invitrogen 
according to the manufacturer’s instructions. Samples were treated with DNase 
(Invitrogen) prior to reverse transcription. Moloney Murine Leukemia Virus Reverse 
Transcriptase (M-MLV RT, Invitrogen) was used to synthesize a complementary 
DNA strand. 
 
2.20. Real-time quantitative PCR 
 
A specific primer and probe set spanning the MLL-AF9 breakpoint region 
was designed and optimised to measure relative expression levels of MLL-AF9 in 
the cells by real-time quantitative PCR (qPCR). Primer and probe were designed 
using the PrimerExpress software v2.0 (Applied Biosystems). MLL-AF9 was 
amplified from cDNA using a forward primer 5’-CAAGTATCCCTGTAAAACAAA 
AACCA-3’ (which binds to MLL) and a reverse primer 5’-CATTCACCATTCTTTA 
TTTGCTTATCTG-3’ (which binds to AF9) and a probe 5’-TGCTTTGCTTTATTG   90
GACTTTTCACTTCAAGAATCTTT-3’ (which spans the MLL-AF9 breakpoint) 
(Appendix, Figure 75). Various forward primer, reverse primer and probe 
concentrations were tested, to determine the optimal primer and probe concentration 
for measuring the MLL-AF9 transcript expression (Appendix, Figure 76). The 
optimal combination of 900 nM forward primer and 900 nM reverse primer 
concentration produced the lowest cycle threshold (CT) value and the highest 
reaction (Rn) value (Appendix, Figure 76 A). The optimal probe concentration was 
150 nM since this was the lowest concentration which did not affect the CT value 
(Appendix, Figure 76 B). MLL-AF9 and 18S (endogenous control) qPCR reactions 
have to be equally efficient, in order to analyse the MLL-AF9 qPCR data using  the 
2
-ΔΔCT relative quantitation method (Livak and Schmittgen, 2001). A standard curve 
was generated to determine the qPCR efficiency at low and high cDNA 
concentrations (0.39 ng to 50 ng), prepared from total RNA isolated from cMA3 
(Appendix, Figure 77). MLL-AF9 reactions were set up with 900 nM forward 
primer, 900 nM reverse primer, 150 nM probe and 1 x TaqMan universal mastermix 
(Applied Biosystems). 18S reactions were set up with 1 x 18S primer and probe set 
(optimised by the manufacturer, Applied Biosystems) and 1x TaqMan mastermix. 
MLL-AF9 and 18S qPCR are reproducible at low and high cDNA concentrations 
with 0.9943 and 0.97 correlation coefficients of the MLL-AF9 and 18S standard 
curve, respectively. The efficiency of each reaction was calculated using the formula: 
PCR efficiency = (10
(1/-s))-1 (Ginzinger et al., 2002), where s is the gradient of the 
standard curve and a slope of 3.3 equals 100% PCR efficiancy. The efficiency of 
MLL-AF9 reaction was 99% and of 18S was 100%. Therefore the 2
-ΔΔCT relative 
quantitation method can be used to determine the relative expression level of MLL-
AF9. Expression of other genes was measured using inventoried qPCR primer-probe 
assays (Table 11).   91
 
Table 11: Inventoried Applied Biosystems primer-probe assays 
 
Gene Name 
 
Applied Biosystem Assay Number 
18S Hs99999901_s1 
c-myb Mm00501741_m1 
c-myc Mm00487804_m1 
Ctnnb1 Mm00483039_m1 
Frat1 Mm00484502_s1 
Gapdh Mm99999915_g1 
HoxA9 Mm00439364_m1 
Hprt Mm00446968_m1 
Mef2c Mm01340842_m1 
Meis1 Mm00487664_m1 
Msi2h Mm00475180_m1 
Siah1a Mm00845411_s1 
Siah2 Mm00486114_m1 
Mouse ACTB (20x)  4352933E 
 
The table shows a list of all Applied Biosystem qPCR assays used in this study. 
 
2.21. Cytospin analysis 
 
3x10
4 cells were washed in PBS, centrifuged at 300g for 5 minutes and cell 
pellets resuspended in 100µl PBS. The cell suspension was added dropwise to a 
cytospin funnel and centrifuged onto a slide at 35g for 5 minutes at low deceleration 
using a cytospin 3 machine (Shandon). The slides were then fixed and stained with 
Wright-Giemsa stain using a Hematek (Bayer Health Care) automated staining 
machine in the Haematology Department at Great Ormond Street Hospital, London. 
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2.22. Flow cytometry 
 
2 ml of wash buffer was added to the cells (maximal 1x10
6 per stain). Cells 
were centrifuged at 300g for 5 minutes at 4°C and resuspended in 100 µl stain buffer 
containing unlabelled anti-Fcγ III/II receptor mAb supernatant (2.4G2) for 10 to 30 
minutes on ice, in the dark. Cells were washed with 2 ml wash buffer and centrifuged 
at 300g for 5 min at 4ºC. After that, the cells were stained in a total volume of 100 µl 
stain buffer containing the required dilution of the appropriate antibody for 30 
minutes on ice in the dark. In some cases, cells were washed and either a 
streptavidin-conjugated antibody or 7AAD was added and incubated for 15 minutes 
on ice, in the dark. The cells were washed again with 2 ml wash buffer, centrifuged 
at 300g for 5 minutes at 4ºC and resuspended in 300 µl wash buffer. Biotin 
conjugated antibodies and antibodies conjugated to either phycoerythrin (PE), 
allophycocyanin (APC) or peridinin-chlorophyll protein complex (Per-CP) 
fluorochromes were used in this study (Table 12) (eBioscience and BD). Flow 
cytometry was performed using the Cyan ADP analyser and Summit 4.3 software 
(Beckman Coulter). 
 
2.23. Cell Proliferation assay 
 
The viability of cells after culture with different cytokine combinations (SCF, 
IL-3, IL-6 or GM-CSF) was measured using the CellTiter 96 AQueous One Solution 
Cell Proliferation Assay kit according to manufacturer’s instructions (Promega). 
Depending on the proliferation rate of the cell line, triplicates of 1x10
3 or 1x10
4 cells 
were seeded per well. Cells were seeded in a 96 well flat bottomed plate in a total 
volume of 100 µl per well containing different combinations of growth factors.    93
Table 12: Antibodies used for flow cytometry 
Antibody   Clone  Isotype  Working dilution 
c-kit
PE (eBiosience)  2B8  IgG2b, κ 1:200 
Gr-1
PE (eBiosience)  RB6-8C5  IgG2b, κ 1:200 
Gr-1
APC (eBiosience)  RB6-8C5  IgG2b, κ 1:200 
Mac-1
PE (eBiosience)  M1/70  IgG2b, κ 1:200 
F4/80
PE (eBiosience)  BM8  IgG2a, κ 1:200 
CD45.2
PE (eBiosience)  104  IgG2a, κ 1:200 
CD45.2
BIO (eBiosience)  104  IgG2a, κ 1:100 
hCD2
PE (eBiosience)  RPA-2.10  IgG1, κ 1:25 
IgG2a, κ
 PE (eBiosience)  MOPC-173  N/A  1:200 
IgG2b, κ
 PE (eBiosience)  A-1  N/A  1:200 
IgG1, κ
 PE (eBiosience)  MOPC-21  N/A  1:200 
Streptavidin
Per-CP (BD)  N/A  N/A  1:250 
 
The table shows all eBioscience or BD antibodies used for flow cytometry in this study. 
 
Cells were cultured for three days and than stained with the CellTiter 96 
AQueous One Solution Reagent for 4 hours in the incubator. Absorbance was recorded 
at 490 nm using a 96 well plate reader (Model 680, BioRad). To yield correct 
absorbance values the average was calculated for triplicates and the average 490 nm 
absorbance from wells containing medium alone was subtracted from all other 
absorbance values. 
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2.24. Leukaemogenesis assay 
 
Leukaemogenesis assays were performed by Dr. Owen Williams as described 
in the Appendix: “Acute myeloid leukemia induced by MLL-ENL is cured by 
oncogene ablation despite acquisition of complex genetic abnormalities”, Methods.  
 
2.25. Giemsa banding 
 
10 mg/ml Colecemid (KaryoMAX) was added to the cell cultures for at least 
1 hour. The cells were then treated with 75 mM potassium chloride (KCl, VWR), 
centrifuged at 300g for 5 minutes at 4°C and fixed using a methanol and acetic acid 
mixture (3:1). Fixed cells were dropped onto a glass slide and visualised by Giemsa 
banding (analysis of slides was then performed by Steve Chatters, Paediatric 
Malignancies Cytogenetics Unit, Institute of Child Health and Great Ormond Street 
Hospital). 
 
2.26. Array-based comparative genomic hybridisation (aCGH) 
 
Array-based CGH analysis of genomic DNA isolated from immortalised and 
leukaemic cells, was performed by Miltenyi Biotec using 4 x 44K Agilent Mouse 
Genome CGH Microarrays (Agilent Technologies).  
 
2.27. Affymetrix Microarrays 
 
Total RNA was extracted, using TRIzol reagent, from three conditional 
(MA1, MA3, MA4) and one constitutive (cMA3) MLL-AF9 immortalised cell lines   95
and also from three conditional (ME4, ME5, ME7) and one constitutive (cME3) 
MLL-ENL immortalised cell lines, each of them cultured without or with 2μg/ml 
Doxycycline for 48 hours. The concentration and quality of isolated RNA was 
determined using the NanoDrop ND-1000. Since the quality of RNA is essential for 
the success of microarray analysis, the RNA quality was verified by ensuring the 
A260 to A280  ratio was between 1.8 and 2.0 as well as using the Agilent 2100 
Bioanalyzer. 
 
All subsequent steps were performed by Kerra Pearce and Nipurna Jina (ICH 
Microarray Center, UCL Genomics) using Affymetrix reagents according to the 
manufacturer’s instructions. In brief, 5 µg RNA was reverse transcribed to cDNA 
using a poly-dT primer linked to a T7 promoter sequence. This was followed by 
second strand cDNA synthesis using DNA polymerase I. Double-stranded cDNA 
was then purified and used for synthesis of biotin-labelled complementary RNA 
(cRNA) using T7 RNA polymerase and biotinylated ribonucleotide analogue mix. 
The biotinylated cRNA was then fragmented to between 35 bp and 200 bp and 
hybridised to GeneChip Mouse Genome 430.2 arrays (Affymetrix). After 
hybridisation the arrays were washed and stained with Streptavidin Phycoerythrin 
(SAPE). The signal was then amplified by addition of biotynilated anti-Streptavidin 
antibody and subsequent staining with SAPE. The arrays were washed and scanned 
at 570 nm and levels of fluorescence converted to numeric data as a measure of gene 
expression (Expression Manual, Affymetrix).  
 
GeneChip microarrays consist of small DNA fragments (probe), chemically 
synthesized at specific locations on a coated quartz surface. A transcript, represented 
as a probe set, is made up of a perfect match (PM) and mismatch (MM) probe pair.   96
Eleven pairs (probe set) are selected from the 3’ end of each gene and are used to 
measure the level of transcription. The mismatch probe contains a single mismatch 
located directly in the middle of the 25-base probe sequence. While the perfect match 
probe provides measurable fluorescence when the sample binds to it, the paired 
mismatch probe is used to detect and eliminate any false or contaminating 
fluorescence within that measurement. The mismatch probe serves as an internal 
control for its perfect match partner because it hybridizes to non-specific sequences 
about as effectively as its counterpart (Affymetrix Technical Support, 2001). The 
hybridisation intensity data from the GeneChip expression probe arrays was analysed 
with Affymetrix Microarray Suite version 5.0 (MAS 5.0). The Detection algorithm 
implemented in MAS 5.0 used the probe pair intensities to generate a Detection p-
value and assign a present, marginal or absent call. The Detection p-value for a probe 
set was calculated in two steps. The first step calculates the probe pair ability to 
detect its transcript (Discrimination score R) for all 11 probe pairs of each probe set. 
This is described by the transcript specific intensity difference between PM and MM 
relative to its overall hybridisation intensity (R = (PM-MM)/(PM+MM)). The second 
step compared each Discrimination score to a defined threshold τ (0.015 by default). 
Discrimination scores higher than τ indicate present transcripts and Discrimination 
scores lower than τ indicate absent transcripts. All Discrimination score to τ 
comparisons are summarised as a Detection p-value. The higher the Discrimination 
scores are above τ, the smaller the p-value and the more likely the transcript is 
present. Cut-offs were defined to define the Detection Calls present (Detection p-
value < 0.04), marginal (0.04 < Detection p-value < 0.07) and absent (Detection p-
value > 0.07) calls (Statistical Algorithms Reference Guide, Affymetrix). 
 
   97
2.28. Short hairpin RNA cloning and knockdown 
 
Short hairpin RNA (shRNA) was expressed as sequences embedded in the 
miR30 microRNA sequence (Stegmeier et al., 2005). For each gene of interest three 
hairpin oligonucleotides were designed against the sense strand of the target gene, 
using either the katahdin prediction software (http://katahdin.cshl.org:9331/siRNA/R 
NAi.cgi?type=shRNA) or sequences published on the RNAi codex web site 
(http://codex.cshl.edu). All hairpin oligos used in this study are listed in the 
Appendix, Table 21. shRNA were cloned into pMSCV-hCD2tailless-miR30 (Figure 
13) according to published protocol (Paddison et al., Nature Methods, Vol.1 No 2, 
163-167, Nov 2004). In brief, the target gene-specific oligonucleotides were 
designed to incorporate part of the miR30 microRNA (miRNA) sense and antisense 
sequences (sense: 5’-TGCTGTTGACAGTGAGCG-3’, antisense: 5’-
TCCGAGGCAGTAGGCA-3’). The template oligonucleotide was then amplified by 
PCR reaction, incorporating EcoRI and XhoI restriction enzyme sites (miRNA 
forward: 5’-GATGGCTGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCG-
3’, miRNA reverse: 5’-GTCTAGAGGAATTCCGAGGCAGTAGGCA-3’) and 
cloned into pMSCV-hCD2tailless-miR30 using EcoRI and XhoI. In this vector 
expression system human CD2 (hCD2) tailless (lacking part of the intracellular 
domains) cDNA is fused to the miR30 sequence. Therefore hCD2 is expressed from 
the same mRNA that gives rise to the cloned shRNA. The cloned shRNA construct 
was then transformed using Subcloning Efficiency DH5αCompetent Cells 
(Invitrogen) and sequenced using GATC Biotech sequencing services (www.gatc-
biotech.com).   98
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Figure 13: Retroviral construct used for shRNA gene knockdown 
A) Restriction enzyme sides used for cloning the shRNA into pMSCV-hCD2tailless-
miR30 are shown in red. B) Schematic representation of secondary structure fold of 
the miR30 based shRNA (adapted from Stegmeier et al., 2005). The mature miR30 
miRNA region was replaced with the relevant gene of interest-specific shRNA (N = 
any nucleotide).   99
LinXE ecotropic retrovirus packaging cells were transfected with the pMSCV-
hCD2tailless-miR30 shRNA vector as described earlier and MLL-AF9 and MLL-
ENL immortalised cell lines were infected once with retroviral supernatants, also as 
described earlier. On the following day 100 µl of fresh RPMI complete medium 
supplemented with 100 ng/ml SCF, 10 ng/ml IL-3 and 10 ng/ml IL-6 was added to 
the cells. The cells were replated and analysed on the flow cytometer every two to 
three days for expression of hCD2 as an indicator for the infection efficiency, after 
48 hours, and after that as an indicator for the proportion of transduced cells in the 
culture. Cells were also analysed on the flow cytometer for expression of Gr-1 as an 
indicator for the state of differentiation. Cells were sorted by magnetic activated cell 
sorting for isolation of RNA. Cells were labelled using 100 μl MACS buffer per 
1x10
7 cells and hCD2-PE-conjugated antibody (1:25). The mixture was incubated for 
10 minutes in the dark at 4°C. Then the cells were magnetically labelled using 20 μl 
per 1x10
7 cells of an anti-PE monoclonal antibody conjugated to MicroBeads. A 
MACS MS column was used to retain the magnetically labelled hCD2 positive cells 
in the magnetic field of the MACS separator. 
 
2.29. Tet-off system 
 
Tetracycline controlled transcriptional activation is a stable method of 
expression, where transcription is turned on (Tet-on) or off (Tet-off) in the presence 
of the antibiotic Tetracycline or one of its derivatives, e.g. Doxycycline (Gossen and 
Bujard, 1992). In this study, MLL-AF9 or MLL-ENL expression is driven by the 
tetracycline-responsive promoter element (TRE). In the cotransduced cells, this 
expression depends on tetracycline-controlled transactivator protein (tTA2
s, Urlinger 
et al., 2000) binding. In the absence of Doxycycline, tTA2
s binds to the TRE and   100
allows transcription of the MLL-fusion cDNA (Figure 14). When Doxycycline is 
added to the system, it binds to tTA2
s causing a conformational change. Therefore 
tTA2
s is no longer able to bind to the TRE and can not activate transcription of 
MLL-AF9 cDNA.   101
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Figure 14: Tet-off expression system 
In this system, MLL-AF9 expression is driven by the tetracycline-responsive 
promoter element (TRE). In the cotransduced cells this expression depends on 
tetracycline-controlled transactivator protein (tTA2s) binding. In the absence of 
Doxycycline (DOX), tTA2s protein binds to TRE and activates transcription of the 
MLL-AF9 cDNA. Upon addition of Doxycycline the antibiotic binds to the tTA2s 
protein causing a conformational change. As a result the tTA2s protein is blocked 
from binding to TRE and activation of transcription of MLL-AF9 cDNA is inhibited 
(adapted from Gossen and Bujard, 1992).   102
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CHAPTER III  - Generation and characterisation of immortalised 
cell lines 
 
In order to generate conditional MLL-AF9 immortalised cells, retroviral 
delivery of the Tet-off expression system was used to conditionally express the 
MLL-AF9 fusion oncogene in primary haematopoietic progenitor cells. Serial 
replating of transduced HPC caused an outgrowth of immortalised cells with 
constitutive or conditional expression of the MLL-AF9 fusion oncogene. 
Immortalised cells were subsequently plated into liquid culture to generate cell lines. 
In total, eight independent cell lines with conditional MLL-AF9 expression and three 
independent cell lines with constitutive MLL-AF9 expression were generated. Five 
of the conditional and one of the constitutive immortalised cell lines were further 
characterised to determine the tTA dependent MLL-AF9 expression, morphology, 
immunophenotype and cytokine requirements of the cells. Furthermore, the response 
of immortalised cell lines with conditional MLL-AF9 expression to Doxycycline, 
was studied and compared to that of cells with constitutive MLL-AF9 expression. 
 
3.1.  Generating immortalised HPC with conditional full-length MLL-AF9 
expression in methylcellulose 
 
MLL fusion proteins interact with menin through multiple domains within the 
N-terminus, including a high-affinity N-terminal conserved binding motif (RXRFP) 
mapped to amino acids six to ten. It was shown that this high-affinity menin 
interaction domain is required for induction and maintenance of myeloid progenitor 
immortalisation by the MLL-fusion proteins, MLL-ENL, MLL-GAS7 and MLL-
AF10 (Yokoyama et al., 2005).   104
 
In previous studies in our laboratory, a myc-tagged conditional MLL-ENL 
expression vector, missing the high-affinity menin binding motif, has been 
successfully used to immortalise HPC (Horton et al., 2005). The pMSCV-neo-mod-
mMLLAF9 (mycMLL-AF9) vector with constitutive expression of MLL-AF9 also 
contains a sequence encoding a myc epitope instead of the first 27 amino acids of 
MLL (Figure 15 A). Therefore, this MLL-AF9 expression vector does not contain 
the region encoding the high-affinity menin binding motif (amino acids six to ten). 
Myeloid progenitors were transduced with the constitutive mycMLL-AF9 vector, to 
test if this construct could immortalise HPC. However, myeloid progenitors 
transduced with mycMLLAF9 exhausted their clonogenic activity after the second 
round of plating in methylcellulose culture, as did cells transduced with the empty 
pMSCV-neo vector (Figure 15 B). Therefore, the mycMLL-AF9 vector was not 
capable of immortalising HPC. In order to overcome this problem, an alternative 
vector, the pMSCV-neo-mod-fMLLAF9 (flagMLL-AF9) vector, was made. This 
vector drives constitutive expression of full length MLL-AF9 (Figure 16 A). HPC 
transduced with flagMLLAF9 formed large compact colonies in methylcellulose 
cultures, through at least three rounds of plating and gave rise to immortalised cell 
lines (Figure 16 B and C). This data suggested that the full-length MLL-AF9 protein, 
containing the high-affinity menin binding motif, is required for immortalisation of 
HPC. 
 
For all further experiments, new conditional expression vectors with full 
length MLL-AF9 and MLL-ENL expression were generated (for cloning details see 
Materials and Methods, section 2.5).    105
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Figure 15: Constitutive expression of MLL-AF9 lacking the menin high-affinity 
binding motif does not immortalise HPC 
HPC were transduced with the constitutive truncated MLL-AF9 expression construct 
or the empty neo vector as a control. 24 hours after transduction the cells were plated 
in methylcellulose culture with G418 selection. After 7 days the numbers of colonies 
were counted and 1x104 cells were plated without G418 selection into subsequent 
rounds. A) Schematic diagram of the constitutive truncated MLL expression 
construct: mycMLL-AF9. B) The graph shows the number of colonies after each 
round of plating. Black bars: empty vector, neo; grey bars: mycMLL-AF9. Error bars 
represent standard deviations of duplicate plates. Similar results were observed in 
four independent experiments.   106
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Figure 16: Constitutive expression of full length MLL-AF9 immortalises HPC 
A) Schematic diagram of the constitutive full-length MLL expression construct: 
flagMLL-AF9. B) HPC were transduced with the constitutive full-length MLL 
expression construct (flagMLL-AF9, grey) or the empty neo vector as a control (neo, 
black). 24 hours after transduction the cells were plated in methylcellulose culture 
with G418 selection. After 7 days the number of colonies were counted and 1x104 
cells were plated without G418 selection into subsequent rounds. The graph shows 
the number of colonies after each round of plating. Error bars represent standard 
deviations of duplicate plates. C) p-iodonitrotetrazolium stains of the third round 
methylcellulose cultures. Similar results were observed in seven independent 
experiments.   107
Retroviral delivery of the Tet-off expression system was used to conditionally 
express the MLL-AF9 or MLL-ENL oncogene, as done in previous experiments in 
our laboratory with the MLL-ENL oncogene (Horton et al., 2005). In this system, 
MLL-AF9 or MLL-ENL expression is driven by the tetracycline-responsive 
promoter element (TRE). In the cotransduced cells, this expression depends on 
tetracycline-controlled transactivator protein (tTA) binding. Addition of Doxycycline 
to the system causes inhibition of the MLL-fusion cDNA transcription (Figure 14).  
 
24 hours after purification, lineage negative HPC were cotransduced with 
unconcentrated pMSCV-neo-TRE-fMLLAF9 and ten times concentrated pMSCV-
tTA2
s-IRES-EGFP retroviral supernatants. As a control, cells were transduced with 
unconcentrated pMSCV-neo-TRE-fMLLAF9 retroviral supernatant alone. In all 
experiments, cells cotransduced with pMSCV-neo-TRE-fMLLAF9 and pMSCV-
tTA2
s-IRES-EGFP formed large compact colonies throughout five rounds of plating 
in methylcellulose cultures. Cells transduced with pMSCV-neo-TRE-fMLLAF9 
alone exhausted their clonogenic activity after the second round of plating (Figure 
17). 
 
In order to examine the effect of Doxycycline on conditionally immortalised 
(pMSCV-neo-TRE-fMLLAF9 and pMSCV-tTA2
s-IRES-EGFP) cells, 2 μg/ml 
Doxycycline was added to the methylcellulose cultures in round four. In the absence 
of Doxycycline, the cells formed large compact colonies, which were composed of 
immature cells with a myeloblastic phenotype (Figure 18 A). The presence of 
Doxycycline caused a significant reduction in the number of colonies formed by cells 
conditionally immortalised with MLL-AF9 (Figure 18 B).    108
 
A)
B)
n
u
m
b
e
r
s
 
o
f
 
c
o
l
o
n
i
e
s
 
p
e
r
 
1
0
4
c
e
l
l
s
round of plating
1st 2nd 3rd 5rd 4th
0
1000
800
600
400
200
1400
1200
+ tTA
TRE-fMLL-AF9
-t T A
TRE-fMLL-AF9
+ tTA -t T A
 
 
 
Figure 17: Conditional expression of MLL-AF9 immortalises HPC 
HPC were co-transduced with the conditional MLL-AF9 expression construct 
(pMSCV-neo-TRE-fMLLAF9, unconcentrated virus) and the inducer tTA (pMSCV-
tTA2s-IRES-EGFP, 10 x concentrated virus). As a control HPC were transduced 
with pMSCV-neo-TRE-fMLLAF9 alone. A) The graph shows the number of 
colonies after each round of plating. pMSCV-neo-TRE-fMLLAF9 + tTA (grey) and 
pMSCV-neo-TRE-fMLLAF9 alone (black). B) p-iodonitrotetrazolium stains of the 
third round methylcellulose cultures. Similar results were observed in eight 
independent experiments.   109
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Figure 18: Effect of Doxycycline on MLL-AF9 immortalised cells 
A) p-iodonitrotetrazolium stains of methylcellulose cultures, morphology of colonies 
(original magnification x 40) and morphology of cells (cytospin preparation followed 
by Wright’s staining, original magnification x 400) in the fourth round 
methylcellulose cultures in the presence or absence of 2µg/ml Doxycycline for 5 
days. B) The graph shows the number of colonies of immortalised HPC with 
conditional expression of MLL-AF9 cultured in the presence or absence of 2μg/ml 
Doxycycline for 5 days. Similar results were observed in five independent 
experiments.   110
The colonies that did form were composed of small clusters of cells 
displaying macrophage cytological features (Figure 18 A). This data suggested that 
HPC with conditional expression of MLL-AF9 were successfully immortalised in 
methylcellulose culture. 
 
3.2.  Generation and characterisation of immortalised myeloid cell lines with 
conditional or constitutive MLL-AF9 expression 
 
Cell lines were established by plating the immortalised HPC in liquid culture 
after three to five rounds of replating in methylcellulose cultures. In total, eight 
conditional and three constitutive cell lines were maintained in RPMI medium 
supplemented with 100 ng/ml SCF, 10 ng/ml IL-3 and 10 ng/ml IL-6. Due to their 
similar rate of proliferation the conditional cell lines MA1, MA2, MA3, MA4, MA6 
and the constitutive cell line cMA3 were picked for further characterisation (Figure 
19). All cell lines stably proliferated in vitro and could be maintained indefinitely in 
liquid culture. The conditional cell lines MA5, MA7 and MA8 could also be 
maintained indefinitely in liquid culture but showed a slower proliferation rate. 
 
Having generated immortalised myeloid cell lines with constitutive and 
conditional MLL-AF9 expression, it was necessary to firstly confirm the MLL-AF9 
protein expression in the cell lines and secondly test that this expression was 
conditional, by addition of 2µg/ml Doxycycline to the cultures. The conditional cell 
line MA1 and the constitutive cell line cMA3 were maintained in the presence and 
absence of Doxycycline for 48 hours and then harvested and cell pellets lysed for 
Western blot analysis (Figure 20).    111
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Figure 19: Generation of MLL-AF9 immortalized cell lines in liquid culture 
The graph shows the fold accumulation in cell number, displayed as log10, of the 
conditional cell lines MA1 (yellow triangles), MA2 (red squares), MA3 (dark blue 
diamonds), MA4 (light blue triangles), MA5 (brown circles), MA6 (dark green 
diamonds), MA7 (orange squares), MA8 (light green diamonds) and of the 
constitutive cell line cMA3 (black circles). Similar results were observed in four 
independent experiments.   112
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Figure 20: Detection of MLL-AF9 protein expression 
The figure shows Western blot analysis of protein extracts from immortalized 
conditional (MA1) and constitutive (cMA3) cells. Cells were maintained for 48 
hours with or without Doxycycline and then lysed using 2xDTT sample buffer. 
Protein lysates from LinXE cells transfected with the constitutive retroviral MLL-
AF9 construct were used as a positive control (lane 1). As a negative control, protein 
lysates from untransfected LinXE cells (lane 2) and lysates from E2A-HLF 
immortalised myeloid cells (lane 3) were used. MA1 – DOX (lane 4), MA1 + DOX 
(lane 5), cMA3 –DOX (lane 6) and cMA3 + DOX (lane 7). Anti-MLLN/HRX (clone 
N4.4) antibody was used to detect the endogenous N-terminal MLL fragment and the 
MLL-AF9 fusion protein. An anti-HSP90α/β antibody was used to control for 
protein loading. Proteins were resolved on a 5% resolving gel. Similar results were 
observed in four independent experiments.   113
Protein extract made from LinXE cells transfected with the constitutive 
retroviral MLL-AF9 vector, was used as a positive control. Untransfected LinXE 
cells and an E2A-HLF immortalised mouse myeloid cell line were used as negative 
controls (the E2A-HLF immortalised mouse myeloid cell line was kindly provided 
by Dr. Ramya Ramunjachar of the MHCB Unit). The anti-MLL
N/HRX (clone N4.4) 
antibody was used to detect MLL-AF9. The anti-MLL-N4.4 monoclonal antibody 
was raised against amino acid residues 161-356 of human MLL, and therefore 
recognises the N-terminal proteolytic fragment of MLL (~320 kDa), of both human 
and mouse. 
 
MLL-AF9 was not detected in the untransfected LinXE cells (lane 2) and the 
E2A-HLF myeloid cell line (lane 3) (Figure 20). As expected, a 170 kDa band 
corresponding to full-length MLL-AF9 was detected in MA1 (lane 4) and cMA3 
(lane 6) cells cultured without Doxycycline as well as in the MLL-AF9 transfected 
LinXE cells (lane 1). However, it was not detected in the conditional MA1 cells 
maintained in the presence of Doxycycline (lane 5). There was a small effect on 
MLL-AF9 protein expression by Doxycycline in the constitutive cells cMA3 (lane 
7). An anti-HSP90α/β antibody was used to control for protein loading. The cell lines 
were then treated with Doxycycline for different periods of time, to further examine 
the effect of Doxycycline on MLL-AF9 protein expression. Conditionally 
immortalised MA1 cells and constitutively immortalised cMA3 cells were 
maintained in the absence and the presence of Doxycycline for two, four, eight and 
16 hours, and cell pellets were then lysed for Western blot analysis. A significant 
down-regulation of MLL-AF9 protein expression was detected in conditional MA1 
cells cultured in the presence of Doxycycline for 16 hours (Figure 21 A).    114
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Figure 21: Detection of MLL-AF9 protein expression following a time course of 
Doxycycline treatment 
The figure shows Western blot analysis of protein extracts from immortalized 
conditional MA1 (panel A) and constitutive cMA3 (panel B) cells. Cells were 
maintained for 0 hours (lane 1), 2 hours (lane 2), 4 hours (lane 3), 8 hours (lane 4) 
and 16 hours (lane 5) with Doxycycline and then lysed. Anti-MLLN/HRX, clone 
N4.4 antibody was used to detect endogenous N-terminal MLL fragment and MLL-
AF9 fusion protein. anti-HSP90α/β antibody was used as the protein loading control. 
Proteins were resolved on a 5% resolving gel. Similar results were observed in two 
independent experiments.   115
Addition of Doxycycline to the cultures of the constitutive cMA3 cells 
slightly reduced MLL-AF9 protein expression (Figure 21 B). 
 
The effect of Doxycycline on MLL-AF9 mRNA expression was examined by 
qPCR. A specific primer and probe set spanning the MLL-AF9 breakpoint region 
was designed and optimised to measure the relative expression levels of MLL-AF9 
(Figure 22). Total RNA was isolated from all cell lines maintained with or without 
Doxycycline for 48 hours and used for qPCR analysis. MLL-AF9 expression was 
much lower in the conditional cell lines MA2 and MA6, compared to the other 
analysed cell lines. In the presence of Doxycycline, MLL-AF9 expression was down-
regulated in all five conditional cell lines. As expected, treatment with Doxycycline 
did not have an effect on MLL-AF9 mRNA expression in the cMA3 cells. However, 
MLL-AF9 appeared to be down-regulated to a greater degree at the protein than 
mRNA level. This is most likely due to the way the pMSCV-neo-TRE-fMLLAF9 
vector is designed. In this vector, MLL-AF9 expression is driven independently of the 
LTR by the tTA dependent TRE promoter. However, the qPCR assay will detect 
both the LTR driven mRNA, from which neomycin phosphotransferase but not 
MLL-AF9 is translated, and the independent, TRE driven MLL-AF9 mRNA, from 
which MLL-AF9 is translated. 
 
In order to characterise the phenotype and morphology of the immortalised 
MLL-AF9 cells before and after turning off the expression of MLL-AF9, viable cell 
counts, flow cytometric analysis of cell surface markers and Wright-Giemsa stains of 
cytospin preparations, were performed. Cells were cultured in 2μg/ml Doxycycline 
for seven days and viable cells were counted using Trypan Blue exclusion after two, 
four and seven days (Figure 23).    116
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Figure 22: Relative MLL-AF9 mRNA expression in the presence or absence of 
Doxycycline 
The graph shows the relative level of  MLL-AF9 mRNA expression in immortalised 
MA1, MA2, MA3, MA4, MA6 and cMA3 cells after treatment (grey bars or 
indicated with arrow) or not (black bars) for 48 hours with 2µg/ml Doxycycline. 
Columns represent the mean of triplicate measurements, error bars represent the 
standard deviations. Similar results were observed in three independent experiments.   117
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Figure 23: Effect of Doxycycline on cell accumulation 
The graph shows the growth curves of immortalised cells MA1 (triangles), MA2 
(squares), MA3 (diamonds), MA4 (circles), MA6 (stars) and cMA3 (open triangles) 
after treatment with 2 μg/ml Doxycycline. Viable cells were counted using Trypan 
Blue exclusion after 2, 4 and 7 days. The graph shows the log10 of the accumulation 
in cell numbers of cells treated with 2µg/ml Doxycycline (red) or untreated cells 
(black). Similar results were observed in three independent experiments.   118
After two days, the number of cells counted in cultures with or without 
Doxycycline was similar. By day four, the proliferation rate of cells in the presence 
of Doxycycline decreased and a decrease in cell numbers was observed. By day 
seven, all conditional cells cultured in the presence of Doxycycline died. MA4 cells 
had already terminally differentiated by day four. As expected, culture in the 
presence of Doxycycline did not have an effect on the proliferation capacity of cells 
with constitutive expression of MLL-AF9. Four days after addition of Doxycycline, 
the cells were analysed for the expression of the myeloid cell surface antigens Gr-1 
and Mac-1, as well as the HPC surface marker c-kit, by flow cytometry (Figure 24). 
All cells maintained without Doxycycline had a characteristic immature myeloid 
phenotype, being c-kit
+Gr-1
+Mac-1
hi. Analysis by Wright-Giemsa stained cytospin 
preparations of these cells showed that the cells displayed immature myeloblastic 
morphology (Figure 25). Following four days in the presence of Doxycycline, most 
of the conditionally immortalised cells had terminally differentiated into neutrophils, 
as identified by their lobular shaped nuclei (Figure 25). Furthermore, a significant 
increase in Gr-1 expression and a decrease in c-kit expression were observed in all 
conditional cell lines (Figure 24). This c-kit
-Gr-1
hiMac-1
hi phenotype is associated 
with a more differentiated myeloid phenotype. The conditional cell line MA4 
differentiated more rapidly into neutrophils than the others and was therefore 
analysed after three days. As expected the constitutively immortalised cells did not 
differentiate in the presence of Doxycycline. They maintained the myeloblastic 
morphology and immature c-kit
+Gr-1
+Mac-1
hi phenotype (Figure 24 and Figure 25). 
 
To determine the cytokine requirements of the cell lines, cell proliferation 
assays were carried out. Data for the representative conditional MA1 and constitutive 
cMA3 cell lines are shown in Figure 26.   119
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Figure 24: MLL-AF9 immortalized cell lines differentiate into mature cells after 
loss of MLL-AF9 expression 
The graph shows flow cytometric analysis of cell surface antigen expression of 
immortalized cell lines after treatment with 2µg/ml Doxycycline for 96 hours (red 
line) compared to untreated cells (black line) and to the appropriate isotype control of 
untreated cells (filled grey area). Expression of the isotype control did not change in 
treated cells. MA4 was analysed after 72 hours with Doxycycline. Similar results 
were observed in three independent experiments.   120
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Figure 25: MLL-AF9 immortalized cell lines differentiate into mature cells after 
loss of MLL-AF9 expression in liquid culture 
The figure shows the morphology of immortalised cells after treatment with 2µg/ml 
Doxycycline (48 hours and 96 hours) or not (48 hours), assessed by cytospin 
preparation and Wright-Giemsa staining (original magnification x 400). Only 
conditional cells differentiated into neutrophils after treatment with Doxycycline. 
Similar results were observed in three independent experiments.   121
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Figure 26: Cell proliferation assay to test the growth factor requirements for 
cell viability 
Cells were seeded at 1x104 cells per well and maintained for 3 days in a 96-well plate 
with various combinations of cytokines (SCF, IL-6, IL-3 or GM-CSF). The optical 
density, which is proportional to the number of viable cells, was measured at an 
absorbance of 490 nm. The graph shows the viability of MA1 (black) and cMA3 
(grey) cells cultured in different cytokine combinations. Bars represent means of 
triplicate values and error bars their standard deviations. Similar results were 
observed in three independent experiments.   122
The cells were able to survive and proliferate at a similar rate in IL-3 alone, 
GM-CSF alone, IL-3 in combination with IL-6, IL-3 in combination with SCF or IL-
3 in combination with IL-6 and SCF. A previous study in our laboratory (Dr. Sarah 
Horton of the MHCB Unit) had shown that the optimal cytokine combination for 
long term maintenance of MLL-ENL immortalised HPC is SCF, IL-3 and IL-6. 
Therefore, for long term maintenance, the MLL-AF9 immortalised cells were also 
cultured in the combination of SCF, IL-3 and IL-6 cytokines.   123
3.3.  Discussion – Chapter III 
 
It has been shown in several previous in vitro and in vivo studies that MLL-
AF9 and MLL-ENL fusion proteins play an important role in leukaemogenesis 
(Corral et al., 1997; Dobson et al., 1999; Forster et al., 2003; Zeisig et al., 2004; 
Horton et al., 2005; Drynan et al., 2005; Krivtsov et al., 2006; Horton, Walf-
Vorderwülbecke et al., 2009). In order to study the oncogenic activity of MLL-
fusions, we have generated MLL-AF9 and MLL-ENL conditionally immortalised 
cell lines in an in vitro immortalisation assay.  
 
In vitro myeloblastic immortalisation with conditional oncogene expression 
in primary HPC has been previously studied with the E2a-Pbx1 fusion gene (Sykes et 
al., 2001). In this study, the oestrogen binding domain of the oestrogen receptor was 
fused to E2a-Pbx1 (E2a-ER-Pbx1) and fusion protein expression was dependent on 
addition of β-oestradiol to the transduced cells. This model was used to generate 
conditionally immortalised cell lines. Upon oestrogen withdrawal immortalised cells 
were found to differentiate into granulocytes and monocytes (Sykes et al., 2001). 
This model was used to identify changes in gene transcription controlled by the E2a-
Pbx1 oncogene (Sykes et al., 2001). Two previous studies have also used a 
Tamoxifen-regulated, a synthetic oestrogen derivate, expression system (ER system) 
to generate conditionally immortalised MLL-ENL cell lines (Ayton and Cleary, 
2003; Zeisig et al., 2004). Due to size restraints for retroviral packaged DNA, one of 
these studies used a truncated ENL cDNA encoding only the last 129 amino acids of 
ENL to generate conditionally MLL-ENL immortalised cell lines (Zeisig et al., 
2004). The tamoxifen expression system is comparable to the Tet-on expression 
system where the introduction of Doxycycline to the system initiates the transcription   124
of the gene of interest. The Tamoxifen expression system is frequently used to study 
immediate downstream transcriptional and signalling activities of oncogenes, 
because of the rapid response kinetics. However, the Tet expression systems, which 
depend on transcription and subsequent translation of a target gene either in the 
presence (Tet-on) or absence (Tet-off) of Doxycycline, are not as fast acting as the 
Tamoxifen expression system, which stabilizes the already expressed target protein 
upon hormone administration. However, the On-systems (Tet-on and Tamoxifen 
expression system) suffer from the potential drawback that Doxycycline or 
Tamoxifen have to be continuously present for proliferation of the cells. This 
presents particular problems in studying the capacity of the conditional cell lines to 
generate leukaemia in vivo, where in order to express the fusion oncogene, the drug 
would have to be constantly administered to the animals. While these two 
Tamoxifen-regulated studies were published (Ayton and Cleary, 2003; Zeisig et al., 
2004), a different approach was used in a previous study in our laboratory in order to 
generate conditionally immortalised MLL-ENL cell lines using the Tet-off 
expression system (Horton et al., 2005). The advantage of using the Tet-off 
expression system was that MLL-ENL immortalised cells can be maintained without 
addition of Doxycycline to the cultures. Although there was a small effect on MLL-
AF9 protein expression by Doxycycline in the constitutive cells, this is presumably 
an effect of Doxycycline on the cell cycle but not a direct effect on the MLL-AF9 
protein expression. Furthermore, it facilitates the identification of changes in gene 
expression required for maintenance of the immortalised phenotype. 
 
The previous study in our laboratory used the conditional MLL-ENL 
expression vector to generate immortalised cell lines, which terminally differentiated 
upon addition of Doxycycline. However, as mentioned earlier, this vector contained   125
a sequence encoding a myc epitope instead of the first 27 amino acids of MLL 
(Horton  et al., 2005). Wild-type MLL associates with many proteins in a 
macromolecular complex through its C-terminal methylase domain (Yokoyama et 
al., 2004). It was shown that menin, a member of this macromolecular complex, 
interacts with the N-terminus of MLL. Menin and LEDGF are the only known 
member of the complex that are not associated with the C-terminus and therefore 
remain associated with the disrupted MLL-fusion proteins (Hughes et al., 2004; 
Yokoyama et al., 2005; Yokoyama and Cleary, 2008). It has been shown in various 
studies that menin interaction with MLL is required for the fusion proteins MLL-
ENL, MLL-AF9, MLL-GAS7 and MLL-AF10 to induce and maintain oncogenic 
transformation of myeloid progenitors (Yokoyama et al., 2005; Caslini et al., 2007). 
Furthermore, a high-affinity N-terminal conserved binding motif (RXRFP) has been 
identified, which spans amino acids six to ten (Yokoyama et al., 2005). 
 
The conditional MLL-ENL vector used in previous studies in our laboratory, 
does not contain the high-affinity binding motif (amino acids six to ten of MLL) but 
was successfully used to immortalise HPC (Horton et al., 2005). Therefore, a similar 
myc-tagged vector containing the MLL-AF9 fusion cDNA was initially used in the 
present study. However, this truncated MLL-AF9 vector failed to immortalise HPC. 
In contrast, a full-length MLL-AF9 construct, encoding the intact MLL portion of the 
MLL-AF9 fusion gene, successfully immortalised HPC, resulting in replatable 
methylcellulose assays and long-term maintenance in liquid culture. Our data is 
consistent with a previous study using the MLL-AF9 fusion oncogene, suggesting 
that the high-affinity menin interaction domain is required for transformation 
(Caslini et al., 2007). Therefore, MLL-AF9 full-length expression constructs were 
used to generate conditionally and constitutively immortalised MLL-AF9 cell lines.   126
Since known target genes of MLL-ENL, such as myeloid ecotropic viral integration 
site 1 (Meis1) (Zeisig et al., 2004), were not identified in the previous MLL-ENL 
Affymetrix study in our laboratory, we also decided to clone new full-length MLL-
ENL expression constructs. The expression constructs were encoding the intact MLL 
portion of the MLL-ENL fusion gene, to generate new conditionally and 
constitutively immortalised MLL-ENL cell lines and screen again for MLL-ENL 
target genes (cell line ME4 was generated by myself, all other MLL-ENL cell lines 
were generated and characterised in our laboratory by Dr. Sarah Horton). Since 
MLL-AF9 and MLL-ENL are structurally very similar to each other but have 
different leukaemic activities in patients and animal models (Forster et al., 2003; 
Drynan et al., 2005), we were interested in comparing the transcriptional targets of 
these two MLL-fusion oncogenes. We hypothesised that both fusion oncogenes 
activate the same core pathways for transformation but also affect different 
transcriptional targets that are specific for MLL-ENL or MLL-AF9 transforming 
activity. This analysis would allow us to focus on the core pathways used by MLL-
fusions to induce leukaemia. 
 
By using retroviral delivery of the Tet-off expression system to conditionally 
express the MLL-AF9 or MLL-ENL oncogenes, immortalised cells were maintained 
in liquid culture without a requirement for continuous drug treatment. RNA isolated 
from conditionally MLL-AF9 and MLL-ENL immortalised cells expressing the 
fusion oncogene was compared to RNA isolated from cells upon loss of the 
oncogene. By characterising the immortalised cells before and after loss of the MLL-
fusion expression we were able to choose a suitable time point for the gene 
expression study. A suitable time point for such analyses would be one at which the 
cells displayed the most marked change in oncogene expression and the expression   127
of known target genes but at the same time showed a minimal phenotypic change 
associated with differentiation. A significant down-regulation of MLL-AF9 protein 
expression was observed in conditional MA1 cells cultured with Doxycycline for 16 
hours and no MLL-AF9 protein expression was detected in cells cultured with 
Doxycycline for 48 hours. However, MLL-ENL protein expression could not be 
detected by Western blot analysis. It is possible that levels of MLL-ENL protein 
expression are very low but nevertheless physiologically significant in order to 
immortalise HPC. Previous work in our laboratory has shown that down-regulation 
of known MLL-ENL target genes, such as homeobox A7 (HoxA7) and homeobox A9 
(HoxA9), was more significant 48 hours after addition of Doxycycline to the cultures, 
compared to 24 hours after addition of Doxycycline (PhD Thesis Dr. Sarah Horton, 
London University). Furthermore, Wright-Giemsa staining of cytospin preparations 
of the cells showed that 48 hours after addition of Doxycycline most of the 
conditional cells still had a myeloblastic morphology. Hence, 48 hours incubation 
with Doxycycline was chosen as the time point for global gene expression analysis. 
This time point appears optimal in order to detect changes to transcript levels of 
target genes upon loss of the MLL-fusion expression and minimise differentiation 
related changes in gene expression. However, in order to completely exclude 
differentially expressed genes regulated by differentiation, MLL-fusion-independent 
differentiation can be induced by addition of the granulocyte colony-stimulating 
factor (G-CSF). Addition of G-CSF to the cultures of MLL-ENL immortalised cells 
was shown to induce terminal differentiation into neutrophils without abrogating 
MLL-ENL expression or resulting in decreased HoxA7 and HoxA9 expression 
(Horton et al., 2005). Future comparisons of differentially expressed genes identified 
by G-CSF induced differentiation with differentially expressed genes identified upon   128
loss of MLL-fusion expression may facilitate the exclusion of genes that change as a 
result of differentiation.   129
CHAPTER IV  - Gene Expression Profiling 
 
Gene expression profiling facilitates simultaneous mRNA measurements on 
an entire genome, providing a global picture of the relative amount of mRNA 
expressed in cells under different conditions. Using the Tet-off conditional system, a 
stable assay with immortalised HPC was generated, expressing the MLL-AF9 fusion 
protein. Treatment of the conditional cells with Doxycycline caused a decrease in 
MLL-AF9 mRNA and protein expression, and resulted in terminal differentiation of 
the cells. In parallel to the generation of MLL-AF9 immortalised cell lines, MLL-
ENL immortalised cell lines were also generated and characterised in the same way. 
MLL-AF9 and MLL-ENL fusion proteins are structurally very similar to each other 
but show differences in the presentation of leukaemia. Unlike MLL-AF9, which is 
predominantly found in infant AML and t-AML, MLL-ENL is commonly found in 
infant acute leukaemias of both the myeloid and lymphoid lineages (Ayton and 
Cleary, 2001; Daser and Rabbitts, 2004). However, because of their structural 
similarity, it is likely that both MLL-translocations would have the underlying 
oncogenic transformation mechanism in common. By analysing MLL-AF9 and 
MLL-ENL immortalised cells together, we aimed to define critical target genes 
involved in the immortalisation pathways of MLL-fusion oncogenes.  
 
4.1.  Identification of an appropriate time point for global gene expression 
analysis 
 
In order to avoid measuring too many differentiation related gene expression 
changes, it was important to pick an early time point which would identify 
expression level changes of direct target genes of the MLL-fusion oncogenes, MLL-  130
AF9 and MLL-ENL. The results from the characterisation of the immortalised cell 
lines (Chapter III), and results from a previous study using MLL-ENL immortalised 
cells (Horton et al., 2005), were considered for choosing a suitable time point for the 
global gene expression analysis. MLL-ENL immortalised cell lines generated for the 
previous study were missing the high-affinity N-terminal conserved binding motif 
for menin. However, it was shown that expression of the primary MLL-ENL 
transcriptional target genes HoxA7 and HoxA9 were still regulated by these N-
terminal truncated constructs. Analysis showed that HoxA7 and HoxA9 gene 
expression levels were significantly decreased after 24 hours (p < 0.07, two-tailed 
students t-test) but not as significant as the decrease observed after 48 hours culture 
with Doxycycline (p < 1.4 x 10
-5, two-tailed students t-test; data not shown). This 
was considered in order to pick a suitable time point for the present study. Changes 
in MLL-fusion protein expression were also considered but we were not able to 
detect MLL-ENL protein expression. However, detection of MLL-AF9 protein 
expression was possible and is shown in Chapter III. MLL-AF9 protein expression 
was significantly decreased after 16 hours incubation with Doxycycline (Figure 21) 
and completely lost by 48 hours (Figure 20). In order to allow time for changes to the 
transcript levels of primary MLL-fusion targets after loss of the MLL-fusion protein 
expression, 48 hours treatment with Doxycycline was considered an appropriate time 
point for the study of global gene expression. 
 
4.2.  Selection of cell lines for global gene expression analysis 
 
It was important to validate that known MLL-AF9 and MLL-ENL 
transcriptional target genes were down-regulated upon loss of the MLL-fusion 
expression in conditionally immortalised cells, but not in the constitutive cells.   131
HoxA9 and Meis1 have both been identified as primary target genes of MLL, MLL-
AF9 and MLL-ENL (Yu et al., 1998; Kumar et al., 2004). Previous work from our 
laboratory has shown that HoxA9 is highly expressed in MLL-ENL immortalised 
myeloid cell lines and that expression of HoxA4-A11 genes is directly maintained by 
MLL-ENL (Horton et al., 2005). The expression levels of HoxA9 and Meis1 in 
MLL-AF9 immortalised cells, and the expression levels of HoxA9 and MLL-ENL in 
MLL-ENL immortalised cells, were measured by qPCR. Total RNA was extracted 
from all cell lines cultured with or without 2μg/ml Doxycycline for 48 hours and 
used for qPCR analysis.  
 
As expected, a significant down-regulation of HoxA9 expression was 
observed in the conditionally immortalised MLL-AF9 cell lines MA1 (p < 0.0002, 
two-tailed students t-test), MA2 (p < 0.0042, two-tailed students t-test), MA3 (p < 
0.0024, two-tailed students t-test) and MA4 (p < 8.33 x 10
-5, two-tailed students t-
test) cultured with Doxycycline (Figure 27 A). HoxA9 expression was significantly, 
but less markedly, down-regulated in MA6 (p < 0.0047, two-tailed students t-test) 
compared to the other conditional cell lines, after loss of MLL-AF9 expression. 
Meis1 was expressed at similar levels in MA1, MA3, MA4 and cMA-3 cultured 
without Doxycycline (Figure 27 B). However, there was less expression of Meis1 in 
MA6 and almost no detectable Meis1 expression in MA2. A significant down-
regulation of Meis1 expression was observed in the conditionally immortalised cell 
lines MA1 (p < 1.67 x 10
-5, two-tailed students t-test), MA3 (p < 0.0028, two-tailed 
students t-test), MA4 (p < 0.0014, two-tailed students t-test) and MA6 (p < 0.0029, 
two-tailed students t-test) cultured with Doxycycline.    132
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Figure 27: Expression of the MLL target genes HoxA9 and Meis1 
The graph shows the relative mRNA expression of HoxA9 and Meis1 in 
immortalised MA1, MA2, MA3, MA4, MA6 and cMA3 cells after treatment (grey 
bars or indicated with grey arrow) or not (black bars or indicated with black arrow) 
for 48 hours with 2µg/ml Doxycycline. Columns represent the mean of triplicate 
measurements, error bars represent the standard deviations.   133
As expected, there was no significant down-regulation of HoxA9 (p < 0.5, 
two-tailed students t-test) and Meis1 (p < 0.9, two-tailed students t-test) expression in 
the constitutively immortalised cells cMA3. For the gene expression profiling, at 
least three individual cell lines were required. This allows to group the samples as 
replicates, to remove differences and facilitate comparison analysis between 
Doxycycline treated and untreated samples. As a result of the HoxA9 and Meis1 
expression analysis, the conditionally immortalised MLL-AF9 cell lines MA1, MA3 
and MA4 were phenotypically most similar to each other and picked for gene 
expression profiling. 
 
In all the conditionally immortalised MLL-ENL cell lines analysed, MLL-
ENL expression was completely lost after 48 hours of Doxycycline treatment (Figure 
28 A, experiment performed by Dr. Sarah Horton, MHCB Unit, ICH). The cell line 
ME6 had a higher level of MLL-ENL expression when compared to the other cell 
lines. A significant down-regulation of HoxA9 expression was observed in all 
conditionally MLL-ENL cell lines (ME3 p < 0.0019, ME4 p < 0.0002, ME5 p < 
0.0011, ME6 p < 0.0276, ME7 p < 0.0048 all two-tailed students t-test) cultured with 
Doxycycline (Figure 28 B experiment performed by Dr. Sarah Horton, MHCB Unit, 
ICH). The cell lines ME3 and ME6 had a slightly less marked down-regulation of 
HoxA9 expression when compared to the other conditional cell lines. As expected, 
there was no significant down-regulation of MLL-ENL (cME3 p < 0.14, two-tailed 
students t-test) and HoxA9 (cME3 p < 0.046, two-tailed students t-test) expression in 
the constitutively immortalised cells cME3. The conditionally immortalised cell lines 
ME4, ME5 and ME7 were picked for the gene expression profiling. These cell lines 
had similar expression levels of MLL-ENL and HoxA9, as well as similar levels of 
down-regulation of these genes in the presence of Doxycycline.    134
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Figure 28: Expression of MLL-ENL and of the MLL target gene HoxA9 
The graph shows the relative mRNA expression of MLL-ENL and HoxA9 in 
immortalised ME3, ME4, ME5, ME6, ME7 and cME3 cells after treatment (grey 
bars or indicated with grey arrow) or not (black bars) for 48 hours with 2µg/ml 
Doxycycline. Columns represent the mean of triplicate measurements, error bars 
represent the standard deviations. 
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HoxA9 and Meis1 expression levels were not changed in the constitutively 
immortalised cell lines cMA3 and cME3. This result indicated that these cell lines 
were suitable controls. By comparing gene expression changes in conditionally 
immortalised cell lines with changes in the constitutively immortalised cell lines it is 
possible to exclude genes which were affected by the Doxycycline treatment. Hence, 
a significant gene expression change in the constitutive as well as the conditional 
cells after treatment with Doxycycline would most likely have resulted from an 
effect of Doxycycline, unrelated to MLL-AF9 or MLL-ENL expression. Consequently 
it was possible to exclude these false positive genes from the list of target genes. 
 
4.3.  Global gene expression analysis 
 
Total RNA was extracted, using TRIzol reagent, from three conditional 
(MA1, MA3, MA4) and one constitutive (cMA3) MLL-AF9 immortalised cell lines 
and also from three conditional (ME4, ME5, ME7) and one constitutive (cME3) 
MLL-ENL immortalised cell lines, each of them cultured without or with 2μg/ml 
Doxycycline for 48 hours. The concentration and quality of isolated RNA was 
determined using the NanoDrop ND-1000 (Table 13), as well as using the Agilent 
2100 Bioanalyzer (data not shown). Since the quality of RNA is essential for the 
success of microarray analysis, the RNA quality was verified by ensuring the A260 to 
A280 ratio was between 1.8 and 2.0. 
 
In total 16 GeneChip Mouse Genome 430.2 arrays (Affymetrix) were hybridised and 
scanned (performed by K. Pearce and N. Jina, ICH Microarry Center, UCL 
Genomics). The data was analysed using two different methods and GeneSpring 
7.3.1 software (Agilent).   136
Table 13: Concentration and quality of isolated RNA 
Cell line  ng/µl (1:10 dilution)  A260/A280 
cME3 -DOX  84.77  1.87 
cME3 +DOX  161.07  1.83 
ME4 –DOX  254.93  1.89 
ME4 +DOX  246.78  1.85 
ME5 –DOX  158.79  1.84 
ME5 +DOX  154.94  1.83 
ME7 -DOX  274.13  1.87 
ME7 +DOX  224.38  1.85 
cMA3 –DOX  159.2  1.88 
cMA3 +DOX  204.11  1.91 
MA1 –DOX  226.69  1.84 
MA1 +DOX  149.06  1.82 
MA3 –DOX  99.10  1.87 
MA3 +DOX  34.42  1.99 
MA4 –DOX  198.58  1.90 
MA4 +DOX  38.06  1.89 
 
The table shows the RNA concentration and quality of treated and untreated cell lines used in the 
microarray study. 
 
For the first method of identifying differentially expressed target genes, 
MLL-AF9 immortalised cell lines and MLL-ENL immortalised cell lines were 
divided into two groups according to their MLL-fusion and analysed separately 
(Analysis I, Figure 29). The six arrays, hybridised with the conditional cell lines, 
were normalised to each other by firstly normalising each probe set intensity of an 
array to the median of all probe set intensities of that array (per chip normalisation). 
Secondly, each probe set intensity of an array was normalised by the median of its 
probe set intensities in all arrays (per gene normalisation). To allow pair-wise 
comparisons between cell lines treated with and without Doxycycline, the three 
conditional cell lines were grouped as replicates.    137
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Figure 29: Analysis I 
The figure shows a diagram of the Analysis I strategy. Genes which showed a 
significant change in gene expression in the constitutive cells after treatment with 
Doxycycline were filtered out.   138
The data were filtered by selecting for a probe set detection p-value smaller 
than 0.07, detected in at least two out of eight samples. This included the two arrays 
hybridised with the constitutively immortalised cells, with or without Doxycycline 
(Figure 30). Application of this filter reduced the number of detected genes to 25,618 
in the MLL-AF9 group and to 25,307 genes in the MLL-ENL group. The data were 
filtered further by selecting for genes whose expression level changed more than 2-
fold, with a defined p-value cut-off of less or equal than 0.05, upon treatment with 
Doxycycline. Application of this filter reduced the number of detected target genes to 
2,486 in the MLL-AF9 group and 2,120 in the MLL-ENL group. In order to exclude 
genes which were affected by the Doxycycline treatment per se, all genes whose 
expression level changed more than 2-fold in the constitutively immortalised cells, 
upon treatment with Doxycycline, were excluded. In the MLL-AF9 group 131 genes 
could be excluded from the final target gene list. In the MLL-ENL group 127 genes 
could be excluded from the final target gene list. 
 
The final MLL-AF9 target gene list included 2,335 differentially expressed 
genes of which 1,204 genes were up-regulated and 1,151 genes were down-regulated 
upon loss of MLL-AF9 expression. The final MLL-ENL target gene list included 
1,993 differentially expressed genes of which 795 genes were up-regulated and 1,198 
genes were down-regulated upon loss of MLL-ENL expression. In order to 
distinguish between common MLL-fusion target genes and unique MLL-ENL or 
unique MLL-AF9 target genes, the two lists of target genes were compared. The 
comparison showed that MLL-AF9 and MLL-ENL immortalised cells had 1,082 
differentially expressed target genes in common (569 up-regulated, 513 down-
regulated).    139
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Figure 30: Generation of gene lists using the Analysis I strategy 
MLL-AF9 immortalised cell lines and MLL-ENL immortalised cell lines were 
divided into two groups according to the MLL-fusion and analysed separately.   140
1,273 target genes were unique for MLL-AF9 (581 up-regulated, 692 down-
regulated) and 911 target genes were unique for MLL-ENL (628 up-regulated, 283 
down-regulated). Since MLL-AF9 and MLL-ENL immortalised cells had a high 
number of target genes in common and only three replicates per sample were used 
for the statistical analysis, a different method of analysing the data was applied. 
 
For the second method, all MLL-AF9 and MLL-ENL immortalised cell lines 
were analysed together (Analysis II, Figure 31). Each probe set intensity of one array 
was normalised to the median of all probe set intensities of that array (per chip 
normalisation). Specified samples were than paired (Table 14) and normalised to one 
another. The probe set intensity for each gene in the experimental sample (with 
Doxycycline) was divided by the median of that genes probe set intensity in the 
corresponding control sample (without Doxycycline treatment) (per gene 
normalisation). 
 
Table 14: Normalisation to control 
Control samples (-DOX)  Experimental samples ( + DOX) 
cMA3- cMA3+ 
MA4- MA4+ 
MA3- MA3+ 
MA1- MA1+ 
cME3- cME3+ 
ME7- ME7+ 
ME5- ME5+ 
ME4- ME4+ 
 
The table shows all pairs of control samples (-DOX) and experimental samples (+DOX) normalised to 
each other. 
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Figure 31: Analysis II strategy 
The figure shows a diagram of the Analysis II strategy. Genes which showed a 
significant gene expression change in the constitutive cells after treatment with 
Doxycycline were filtered out.   142
The data were filtered by selecting for a probe set detection p-value smaller 
than 0.07, detected in at least two out of 16 samples. This included the two arrays 
hybridised with the constitutively immortalised cells, with or without Doxycycline 
(Figure 32). The number of detected genes was reduced to 29,100 after application of 
this filter. To allow pair-wise comparisons between treated and untreated cell lines, 
the six conditional cell lines with Doxycycline and the six conditional cell lines 
without Doxycycline were grouped as replicates. This step allowed filtering the data 
further by selecting for genes whose expression level changed more than 2-fold, with 
a defined p-value cut-off of less or equal to 0.05, upon treatment with Doxycycline. 
The p-value cut-off of 0.05 allows a 5% chance of error. That means that 5% of all 
tested genes could be genes that are found to be statistically different between 
conditions but are not in reality (false positives). The incidence of false positives is 
proportional to the number of tests performed and the p-value cut-off. In a 
microarray experiment, a t-test is performed on each gene separately. The very high 
number of genes on an array makes it likely that differential expression of some 
genes represent false positives. To control for the false positive discovery rate, the 
Benjamini-Hochberg method, a multiple testing correction procedure, was applied. 
Multiple testing correction adjusts the individual p-value for each gene to keep the 
overall false positive rate to less than or equal to the specified p-value cut-off 
(GeneSpring Analysis Guide, Multiple Testing Corrections). 
 
Application of these filters reduced the number of 29,100 detected genes to 
3,177 differentially changed target genes. In order to exclude genes which were 
affected by the Doxycycline treatment, all genes whose expression level changed 
more than 2-fold in the constitutively immortalised cells, upon treatment with 
Doxycycline, were excluded.    143
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Figure 32: Generation of gene list using the Analysis II strategy 
MLL-AF9 and MLL-ENL immortalised cell lines were analysed together. To control 
for the false positive discovery rate, the Benjamini-Hochberg (BH) method, a 
multiple testing correction procedure, was applied.   144
The final target gene list included 2,934 differentially expressed genes of 
which 1,552 genes were up-regulated and 1,447 genes were down-regulated upon 
loss of MLL-fusion oncogene expression. 
 
Both gene expression analyses methods resulted in target gene lists with more 
than 1,000 entries. Analysis I showed that nearly half of the genes regulated by 
MLL-AF9, and more than half of the genes regulated by MLL-ENL, were the same. 
When the different analysis methods were compared to each other, only two genes of 
the common MLL-fusion target gene list generated by Analysis I were not contained 
in the target gene list generated by Analysis II (Table 15). 
 
Table 15: Comparison of gene lists 
Analysis I  Analysis II  number of concordant 
genes 
common MLL-fusion: 1082 genes    1080 genes 
unique MLL-ENL: 911 genes  2934 genes  608 genes 
unique MLL-AF9: 1273 genes    607 genes 
 
The table shows the comparisons of the three gene lists generated by Analysis I with the target gene 
list generated by Analysis II. 
 
Replication of the biological samples is essential for drawing conclusions 
from the experiment. The six replicates of conditional untreated and treated samples 
in the Analysis II allowed application of more robust statistics than the minimum 
required three replicates of untreated and treated samples in the translocation specific 
analysis. Therefore Analysis II was generally considered more reliable. Furthermore, 
because of the significant overlap of genes regulated by MLL-ENL and MLL-AF9, 
the 2,934 genes generated by Analysis II were more closely inspected in order to 
identify common transcriptional target genes of MLL-fusion oncogenes.   145
4.4.  Selection of target genes 
 
Large numbers of genes were found to be changed, with a more or less equal 
number of up-regulated genes (1,552 genes) or down-regulated genes (1,447 genes). 
The genes HoxA5,  HoxA7,  HoxA9,  HoxA11 and Meis1 were among the list of 
differentially expressed target genes and have been previously reported to be 
expressed in MLL-ENL and MLL-AF9 immortalised cell lines (Horton et al., 2005; 
Zeisig et al., 2004, Krivtsov et al., 2006). Detection of the differential expression of 
these genes was considered as an internal positive control for the gene expression 
profiling. In a first attempt to group genes and find patterns among the regulated 
genes, gene ontology analysis was used to categorise the regulated genes (data not 
shown). However, this categorisation was not very helpful in terms of identification 
of MLL-fusion regulated pathways, given that genes were categorised into an 
unmanageable large number of possible pathways. 
 
Genes were also sorted by rank and association with transcriptional 
regulation, cancer, leukaemia or MLL-fusions found in the literature. Table 22 in the 
Appendix, lists 41 genes which were picked by rank and publication from the list of 
genes that were up-regulated in the presence of MLL-fusions. Interestingly, 
inspection of the list revealed that 12 of the 41 picked genes were found to be 
associated with the wingless (Wnt) signalling pathway (Table 16).   146
Table 16: Genes involved in Wnt signalling pathway and found in the list of 
target genes 
Gene Symbol  Accession Number  Fold Change 
Ascl2  1422396_s_at 10.93 
Sox4  1419156_at 8.23 
Frat2  1455220_at 6.627 
Six4  1425767_a_at 5.831 
Six1  1427277_at 3.968 
Pontin  1416585_at 3.916 
c-Myc  1424942_a_at 3.724 
Reptin  1422482_at 3.614 
c-Myb  1423430_at 3.462 
Frat1  1449814_at 3.047 
Tcf4  1424089_a_at 3.04 
Fzd7  1450044_at 2.46 
 
The table lists genes, picked from the list of target genes, which are involved in the Wnt signalling 
pathway. The genes are sorted by fold change. 
 
Following up this link, the Wnt signalling pathway derived from the Kyoto 
Encyclopaedia of Genes and Genome (KEGG) database was compared with the 
complete list of target genes, using GeneSpring 7.3.1 software, in order to detect 
further Wnt signalling associated target genes. The KEGG pathway database 
contains molecular interaction and reaction networks for metabolism and various 
cellular processes which are manually entered from published material. The genes, 
Fzd7, Frat1, Frat2, Cacybp/SIP, Pontin and c-Myc were found to be involved in the 
Wnt signalling network and up-regulated by MLL-fusions (Figure 33). The genes, 
Siah-1 and CyclinD, were found to be down-regulated. Since the KEGG pathway 
entries are not validated relations, further inspection of the Wnt signalling pathway 
using Ingenuity Pathway Analysis (IPA) software, was performed. 
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Figure 33: KEGG pathway analysis of the Wnt signalling pathway 
The figure shows an overlay of the KEGG database derived Wnt signalling pathway with the MLL-fusion analysis target gene list. The level of gene 
up-regulation is indicated by increasing red intensity, the level of gene down-regulation is indicated by increasing green intensity. White boxes 
represent unchanged genes of the pathway. 
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The IPA software assembles genes with known relationships and can be used 
to compare pathways with experiments that generate gene lists. Using the IPA 
derived Wnt signalling pathway, the genes Fzd7, Frat/GBP, SOX, c-Myc and TCF4 
were found to be involved in the Wnt signalling network and up-regulated by MLL-
fusions and the gene PP2A was found to be down-regulated (Figure 34). 
Discrepancies between the lists of genes associated with the Wnt signalling pathway 
result from the fact that the two different pathway analyses tools do not have the 
same entries of genes associated with Wnt signalling in their databases. Therefore it 
is helpful for the gene expression analysis to compare the results from different 
pathway analyses tools. Since a previous study demonstrated that c-Myc was 
required for MLL-ENL mediated transformation (Schreiner et al., 2001), a Myc-
network analysis was performed overlaying IPA derived Network 7 with the 2,934 
differentially expressed target genes. Interestingly, almost all genes which have 
known relationships with Myc are entries of the MLL-fusion target gene list (Figure 
35). Analysis with IPA software also revealed the most common identified canonical 
pathways when overlaid with the complete list of target genes (Table 17).  
 
Table 17: Five most common canonical pathways identified by IPA software 
Canonical Pathway  Number of genes 
up-regulated 
Number of genes 
down-regulated 
Neuregulin Signalling  5  5 
Ceramide Signalling  2  7 
Protein Ubiquitination Pathway  9  5 
14-3-3-mediated Signalling  7  1 
Dopamine Receptor Signalling  4  4 
 
The table lists the five most common canonical pathways containing genes from the list of 
differentially expressed target genes. The number of up-or down-regulated genes is given.   149
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Figure 34: Ingenuity Pathway Analysis of the Wnt signaling pathway 
The figure shows an overlay of the Wnt signaling pathway with the 2,934 
differentially expressed genes derived from the Analysis II target gene list. Genes 
highlighted in red are up-regulated, genes highlighted in green are down-regulated. 
The level of fold change is indicated by increasing intensity of colouring. White 
boxes represent unchanged genes of the pathway.   150
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Figure 35: Ingenuity Pathway Analysis neighbourhood explorer of myc 
The figure shows an overlay of the myc network (network 7) with the 2,934 
differentially expressed genes derived from the Analysis II target gene list. Genes 
highlighted in red are up-regulated, genes highlighted in green are down-regulated. 
The level of fold change is indicated by increasing intensity of colouring. White 
boxes represent unchanged genes of the pathway.   151
To further identify genes that are affected by MLL-rearranged leukaemia, 
published data sets obtained from patient samples were compared to the genes 
identified in this study. Several of the genes identified in the present study are 
differentially expressed in patients with 11q23 rearrangements. Kohlmann et al. 
report the genes FRAT1 and ZFHX1B to be common t(11q23)/MLL up-regulated 
target genes and Andersson et al. report MSI2,  MYB and SOX4 among the 
differentially expressed genes when comparing AML cell lines with ALL cell lines 
(Kohlmann  et al., 2005; Andersson et al., 2005). The mouse homologues Frat1, 
Zfhx1b, Msi2, c-Myb and Sox4 were also found to be up-regulated by the MLL-
fusions in the present study. Furthermore, the genes Evi2a, Ltf, Lcn2, Cybb, Sh3bp5, 
Plaur and Tnfaip2 were found to be down-regulated and their human orthologs have 
also been reported previously to be down-regulated in MLL-rearrangement 
leukaemia (Rozovskaia et al., 2003; Yagi et al., 2003; Ross et al., 2004; Andersson 
et al. 2005).   152
4.5.  Discussion – Chapter IV 
 
In this study of global gene expression profiling of MLL-ENL and MLL-AF9 
immortalised cell lines, we were able to confirm the presence of the most prevalent 
genes that have previously been identified in association with MLL-fusion mediated 
transformation. Two of the well characterised transcriptional target genes of MLL-
fusion oncogenes are HoxA9 and Meis1 (Yu et al., 1998; Kumar et al., 2004; Zeisig 
et al., 2004; Horton et al., 2005). Analysis of the differential expression of these 
genes by qPCR, prior to global gene expression profiling, was used to select 
appropriate cell lines for the present gene expression study. In addition, the genes 
HoxA5, HoxA7, HoxA9, HoxA10 as well as HoxA11 were found to be differentially 
expressed. These genes have been previously reported to be expressed in MLL-ENL 
immortalised cell lines (Ayton and Cleary, 2003; So et al., 2003) and have also been 
identified as part of a HoxA code expressed in MLL-ENL immortalised cell lines by 
our laboratory (Horton et al., 2005). 
 
The gene Mef2c, which has been identified as part of a subset of 11 genes 
immediately activated by MLL-AF9 expression (Krivtsov et al., 2006), was also 
among the differentially expressed genes in the present study. These different 
previous gene expression analyses allowed the identification of MLL-fusion target 
genes with the most marked expression changes, such as genes of the HoxA cluster, 
Meis1 and Mef2c, and underlined the importance of Hox gene regulation by MLL-
fusion oncogenes (Ayton and Cleary, 2003; So et al., 2003; Zeisig et al., 2004; 
Horton et al., 2005; Krivtsov et al., 2006; Chen et al., 2008). Many of these studies 
have restricted their further analyses to just a few hundred target genes, either 
because they only identified a small set of target genes (Zeisig et al., 2004; Krivtsov   153
et al., 2006; Chen et al., 2008) or only the top 100 most differentially expressed 
genes were considered (Ross et al., 2004; Wei et al., 2008). However, the 
experimental designs and the applied comparison methods are most likely not 
sensitive enough for identification of other not so markedly regulated underlying 
MLL-fusion mediated pathways and networks. 
 
There are two different previous studies of conditional MLL-ENL expression 
in primary HPC. Our laboratory has previously optimised the Tet-off system and 
successfully used it in a study of conditional MLL-ENL expression in primary 
haematopoietic progenitor cells, for global gene expression profiling and to identify 
the Hox gene expression profile (Horton et al., 2005; PhD Thesis, Sarah J. Horton, 
London University). Although the vector encoded an N-terminally truncated MLL-
ENL construct, HPC were successfully immortalised and global Hox gene expression 
profiling revealed that these cells expressed a specific HoxA code, similar to the 
HoxA genes expressed in our study (Horton et al., 2005). Later it was demonstrated 
that the MLL N-terminus contains a high-affinity conserved binding motif, which is 
required for interaction with the MLL co-factor menin (Yokoyama et al., 2004). It 
was shown that HoxA9 and Meis1 are among the major effectors of menin in 
haematopoiesis (Chen et al., 2006) This might be a potential explanation why for 
example the MLL-fusion target gene Meis1 (Zeisig et al., 2004; Krivtsov et al., 
2006) was not expressed (Horton et al., 2005). Furthermore, it suggests that most 
likely other previously unidentified MLL-ENL target genes may not be identified by 
this truncated MLL-ENL vector. By generating a new full-length MLL-ENL cDNA 
conditional expression vector for the present study, we were able to confirm Meis1 as 
a target gene. 
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The other conditional MLL-ENL model generated immortalised cell lines by 
using a synthetic hormone-inducible system (Zeisig et al., 2004). Using this system, 
the maintenance of MLL-ENL immortalised cell lines was dependent on addition of 
tamoxifen to the cell cultures. This is a potential disadvantage, since the effect of 
tamoxifen itself on gene expression was not taken into account. It makes it unclear if 
differential expression of identified target genes was directly caused by MLL-ENL 
meditated transformation. Furthermore, biologically replicates are of critical 
importance for statistically and biologically valid conclusions. However, this study 
analysed one cell line in triplicates, therefore only the technical replicates were 
considered in the experimental design, whereas biological replicates were not 
included. Therefore, gene expression profiling using this approach resulted in a small 
set of target genes.  In our study, we were able to overcome these problems by 
including immortalised cell lines with constitutive expression of the MLL-fusion as 
an internal control. This enabled us to eliminate differentially expressed genes, which 
change was caused by an effect of Doxycycline, unrelated to the loss of MLL-fusion 
expression. Furthermore, three different cell lines per fusion gene were used as 
biological replicates to identify differentially expressed genes. 
 
Another gene expression study analysed MLL-AF9 target genes. Gene 
expression changes that occur during the transition from committed progenitor to 
LSC were characterised and a small set of 11 target genes directly activated by MLL-
AF9 expression was identified (Krivtsov et al., 2006). A potential caveat of this 
study is that only  a  very  small  HPC  sub-population of  cells, the  leukaemic-GMP 
(L-GMP), was used to perform the global gene expression studies and it is unclear 
how many LSC are lost from the analysis because of the L-GMP purification 
protocol. Furthermore, in order to distinguish between gene expression changes   155
directly caused by MLL-AF9 and gene expression changes caused by the 
transformation process in general, an additional gene expression profiling shortly 
after infection of HPC with MLL-AF9 was performed. However, flow cytometry 
sorting and retroviral infection of the cells just before global gene expression 
profiling can cause a low signal to noise ratio and therefore results in a small set of 
11 directly activated target genes. In contrast, the advantage of our study is that by 
using the Tet-off system the MLL-fusion genes are conditionally expressed and 
immortalised cells are maintained in the absence of Doxycycline. Thus, this system 
minimises manipulation of the cells which may affect gene expression itself. 
Furthermore, comparison of the 11 direct target genes with those identified in the 
present study revealed that eight of the 11 immediately activated genes, Meis1, 
HoxA9, HoxA10, HoxA5, Mef2c, Mylk, Stau2 and Itf2 (also known as Tcf4) were also 
identified in our study. The genes Peli1, Runx2 and Laptm4b could not be identified 
as targets but instead the family members Peli2 and Runx1 were found to be 
differentially expressed.  
 
One main problem of gene expression studies is the choice of a control 
population of cells for a gene expression analysis. The phenotype of the immortalised 
target population of cells can only be categorised into HSC and the various different 
progenitor populations. This is due to the lack of enough characterised cell surface 
marker, specific for the different sub-stages of haematopoietic cell maturation. 
Krivtsov et al. describe the target population of cells as a GMP-like population of 
leukaemic cells that is most likely a subset of GMP (Krivtsov et al., 2006). Given 
that this is the fact, the defined progenitor population of GMP is still a heterogeneous 
population of progenitor cells with a heterogeneous gene expression pattern. 
Therefore, the population of GMP do not provide an appropriate group of cells for   156
this kind of gene expression studies. Another study uses a different approach and 
compares MLL-AF9 immortalised human CD34
+ cord blood cells with retrovirally 
immortalised cell lines, expressing one of the CBF fusion genes AML1-ETO or CBF-
MYH11 (Wei et al., 2008). These comparisons will most likely only allow for 
identification of MLL-fusion target genes that have the most marked expression 
changes.  
 
In our study, lineage depleted HPC, comprising a heterogeneous population 
of cells, including HSC and various progenitor populations, were transduced with 
MLL-fusion oncogenes under myeloid conditions. This resulted in an immortalised 
population of cells displaying phenotypic characteristics of differentiation arrest at a 
late state of myelomonocytic differentiation downstream of the GMP (c-kit
+Gr-
1
+Mac-1
hi phenotype, Figure 24). A major advantage of using the Tet-off system is 
that upon loss of the MLL-fusion, the cells terminally differentiate and the phenotype 
of the population simultaneously shifts to c-kit
-Gr-1
hiMac-1
hi, associated with a more 
differentiated myeloid phenotype. Since it is not possible to precisely define the 
phenotype of the target population of cells, it is better to analyse the loss of the 
oncogene in transformed cells. Comparing the gene expression profile of cells 
expressing the MLL-fusion with cells after loss of the MLL-fusion allows identifying 
pathways that are directly affected by MLL-fusion mediated transformation. 
 
By not restricting the analysis to the top most differentially expressed genes 
but rather including all of the differentially expressed genes, we were able to identify 
several genes associated with the Wnt signalling pathway. Besides the crucial role of 
Wnt signalling in embryonic development and regeneration of tissue in adult 
organisms, several studies have implicated a role of Wnt signalling in   157
haematopoiesis. It was shown in studies with human CD34
+ cells and WNT-
expressing co-cultures, that WNT signals can provide proliferative signals for 
immature HPC and HSC (Austin et al., 1997; Van Den Berg et al., 1998). Wnt 
signalling was also described in association with self-renewal of murine HSC (Reya 
et al., 2003; Willert et al., 2003). This is of interest, since self-renewal is an 
important feature of leukaemic stem cells, Wnt signalling might also play a role in 
leukaemia. Furthermore, among the direct transcriptional target genes of Wnt 
signalling are c-Myc and c-Myb (reviewed in Barker and Clevers 2006; Klaus and 
Birchmeier 2008). Both of these genes were among the differentially expressed 
genes of the present study and have been reported to be important in driving cancer 
formation. c-Myb is found to be overexpressed in many leukaemias and is required 
for normal HSC development (Mucenski et al., 1991; Emambokus et al., 2003). c-
Myc is a central regulator of proliferation, differentiation, cell survival and neoplastic 
transformation and is found mutated or overexpressed in most human cancers, 
including myeloid leukaemia (reviewed in Levens, 2003). Therefore, it is not 
surprising that c-Myc and c-Myb were found to be up-regulated by MLL-fusion 
oncogenes in the present study. However, it has previously been reported that MLL-
ENL requires c-Myc expression to establish a differentiation arrest of a 
myelomonocytic progenitor population (Schreiner et al., 2001). Furthermore, the IPA 
pathway analysis tool was used to identify networks in which these genes might be 
implicated and which could potentially be regulated by the MLL-fusion genes. 
Strikingly, almost all genes which have known relationships with c-Myc were found 
to be differentially expressed. This high number of involved genes suggests that the 
c-Myc network may be targeted by MLL-fusion mediated transformation. Further 
analysis of immortalised cells after loss of c-Myb or c-Myc expression is required, in 
order to investigate the role of these genes as primary transcriptional targets of MLL-  158
fusion mediated transformation. In addition, MLL-fusion target genes, such as 
HoxA9 and Meis1, are also found to be MLL target genes. In a study to identify 
human genomic binding sites of MLL1, Guenther et al. reported c-Myc, Sox4, Pontin 
and Reptin among the target genes of MLL1 (Guenther et al., 2005). In total 236 of 
our identified target genes are also identified as target genes of human MLL1.  
 
The human orthologs of the genes Frat1, Msi2, and Sox4, identified in this 
study, are also differentially expressed in patients with 11q23 translocations. The 
murine Msi2 shares 75% amino acid identity with its paralogue Msi1 and has been 
suggested to share its role in the maintenance and proliferation of neuronal stem cells 
(Sakakibara  et al., 2001). There is little evidence of a role in haematopoietic 
malignancies besides its association with 11q23 translocations. However, one study 
reported a novel in-frame MSI2-HOXA9 fusion transcript which was found to be 
involved in the disease progression of CML (Barbouti et al., 2003). Frat1 and Frat2 
are positive regulators of Wnt signalling. By binding to GSK3, Frat prevents the 
phosphorylation of Ctnnb1 and allows the activation of downstream target genes by 
Ctnnb1/TCF complexes (reviewed in van Amerongen, 2005). There is evidence for 
involvement of Frat1 in tumour progression of T-cell lymphomas and it was found to 
be overexpressed in t(11q23)/MLL leukaemias (Jonkers et al., 1997, Kohlmann et 
al., 2005). Since we also found Frat1 to be up-regulated in transformed cells, maybe 
it plays a role in MLL-mediated transformation. Further analysis of these genes is 
required to elucidate their role in the underlying mechanism of oncogenic 
transformation induced by MLL-fusion proteins. 
 
In general, gene expression profiling provides a global impression of the 
relative amount of mRNA expressed in cells under different conditions and allowed   159
us to identify genes regulated by MLL-AF9 and MLL-ENL. While global gene 
expression profiling lacks the quantitative accuracy of qPCR, it facilitates high-
throughput identification of target genes that show statistically significant changes 
under different conditions, by analysing all genes of a cell simultaneously. A caveat 
of these experiments is that changes in RNA expression are not always reflected at 
the level of protein expression. Expression profiling cannot account for post-
translational modifications of proteins or mechanisms regulating protein stability. 
Therefore, protein expression and functional analysis of target genes is necessary to 
confirm and validate gene expression analysis results.   160
CHAPTER V  - Target Gene Validation 
 
In order to validate the results from the Affymetrix global gene expression 
analysis, protein expression of target genes needs to be validated by Western blot 
analysis. In addition, target genes can also be functionally validated by knocking 
down up-regulated target genes or by over expressing down-regulated target genes. 
Expression of non-physiologically high amounts of a down-regulated target gene can 
produce non-specific effects, making the validation of down-regulated genes more 
complicated. Hence, we decided to initially choose the faster approach of knocking 
down up-regulated target genes in the MLL-AF9 and MLL-ENL immortalised cells, 
using shRNA. This method was used as an initial screen to select for critical target 
genes for further analysis. Following this initial screen, levels of knock-down and 
expression changes of the selected genes of interest, with and without Doxycycline 
treatment, were validated by qPCR and Western blot analysis. Both conditionally and 
constitutively immortalised cell lines were used for validation. Conditionally 
immortalised cells had to be used in order to analyse the effect of Doxycycline. Since 
we did not want to reduce the analysis to one type of immortalised cells, we also 
used constitutive cells for validation when possible. Additionally, using constitutive 
cell lines also validated the results of the Affymetrix screen, which was done with the 
conditionally immortalised cells. 
 
5.1.  Screening for critical target genes by knock-down 
 
A selection of thirteen genes were picked for knock-down from the list of up-
regulated target genes which were selected by rank and publication for further 
analysis, as described in Chapter IV (Appendix, Table 22). Although β-Catenin   161
(Ctnnb1) was not among the target genes identified by the Affymetrix gene 
expression analysis, it was also included for analysis because of its pivotal role in the 
Wnt signalling pathway. Furthermore, Meis1 was included for analysis since it has 
been shown to be necessary for induction and maintenance of MLL-fusion induced 
transformation (Wong et al., 2007). In order to knock down a target gene, hairpin 
oligonucleotides were designed against the sense strand of the target gene of interest 
(Appendix, Table 21). Constitutive MLL-AF9 and MLL-ENL immortalised cell lines 
were then retrovirally transduced with a vector that expresses hCD2 from the same 
mRNA giving rise to the cloned shRNA (Stegmeier et al., 2005). As an indication of 
the effect of the knock-down on immortalised cells, enrichment or loss of hCD2 
expression from the culture was monitored by flow cytometry (Table 18). Knock-
down of the two genes, c-Myb and Msi2, had a marked effect on the transduced cells, 
whereas knock-down of Frat1 and c-Myc had only a slight effect. In contrast, knock-
down of the other selected target genes did not have any effect on the immortalised 
cells. 
 
Constitutively immortalised cME3 cells were retrovirally transduced with one 
of three different shRNA knocking down c-Myb expression (22B, 23A and 24D) or 
with a non-silencing verified negative control shRNA (CO, Open Biosystems 
RHS1707). The effect of c-Myb knock-down on the percentage of hCD2 expressing 
cells in the cultures was measured by flow cytometry, two, seven and 14 days after 
transduction (Figure 36 A). A significant reduction of hCD2 expressing cells was 
observed seven days after transduction. Then, 14 days after transduction, hCD2 
expressing cells had almost completely disappeared from the cultures. As expected, 
cells transduced with the control shRNA were not lost from the culture, shown by the 
relatively constant percentage of hCD2 expression in the control culture.    162
Table 18: Tested shRNA and their effect on hCD2 expressing cells 
Gene Name  shRNA number  Loss of hCD2
+ expressing cells 
1  - 
2  - 
Meis1  
3  - 
4  - 
5  - 
Zfhx1b 
6  - 
7  - 
8  - 
P2ry2 
9  - 
10  - 
11  - 
Hpgd 
12  - 
13  -/+ 
14  -/+ 
Frat1 
15  -/+ 
16  - 
17  - 
Frat2 
18  - 
19  - 
20  - 
Fzd7 
21  - 
22  + 
23  + 
c-Myb 
24  + 
25  + 
26  + 
Msi2 
27  + 
28  - 
29  - 
Sox4 
30  - 
31  - 
32  - 
Gata2 
33  - 
34  - 
35  - 
Ctnnb1 
36  - 
37  -/+  c-Myc 
38  -/+ 
 
The table lists the 13 target genes and their corresponding shRNA identification number that were 
tested in this study. shRNA that had a significant effect on the percentage of hCD2 expressing cells 
are marked with +. Effects that were not clear are marked with -/+ and no effects are marked with -. 
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Figure 36: Analysis of c-Myb knock down using shRNA 
A) The figure shows the percentage of hCD2
+ cME3 cells 2, 7 and 14 days after 
retroviral transduction with the c-Myb specific shRNA 22B (black squares), 23A 
(black triangles), 24D (black diamonds) and with control shRNA (open squares). 
Similar results were observed in three independent experiments. B) The graph shows 
the relative expression of c-Myb mRNA in hCD2
+ cells, 48 hours after infection with 
either one of the c-Myb specific shRNA (22B, 23A, 24D) or the non-silencing 
negative control shRNA (CO). Similar results were observed in two independent 
experiments. Columns represent the mean of triplicate measurements, error bars 
represent the standard deviations.   164
In order to measure the level of c-Myb knock-down, transduced cells were 
sorted for hCD2 expression by MACS, 48 hours after transduction, and total RNA 
was isolated from the purified hCD2
+ cells and used for qPCR analysis (Figure 36 
B). Expression of c-Myb mRNA was reduced in all three analysed knock-downs 
(22B: p < 0.0016, 23A: p < 0.0001, 24D: p < 0.29; two-tailed students t-test). shRNA 
22B showed the most marked reduction in c-Myb expression and shRNA 24D 
showed the weakest reduction. Interestingly, the level of mRNA knock-down did not 
correlate with the effect of the construct on the reduction of hCD2 expressing cells in 
culture. 
 
The same experiment was performed using three different shRNA to knock 
down Msi2 (25B, 26A and 27B) and hCD2 expression was measured two, seven, 14 
and 21 days after retroviral transduction (Figure 37 A). Compared to the non-
silencing control shRNA, all three Msi2-specific shRNA transduced cells showed a 
reduction in the percentage of hCD2 expression 14 days after retroviral transduction. 
Msi2 mRNA expression in sorted hCD2 cells was significantly reduced in all three 
knock downs (25B: p < 0.0003, 26A: p < 0.0005, 27B: p < 0.0002, two-tailed 
students t-test) (Figure 37 B). Knock-down of the two genes, Frat1 and c-Myc, did 
not have a consistent effect on the hCD2 expressing cells. A reduction of hCD2 
expression in culture was observed only in cells transduced with the Frat1 specific 
shRNA 14A and 15B, and the c-Myc specific shRNA 37B (Figure 38). The data for 
Frat1 and c-Myc need to be further validated by analysing the level of knock-down 
of each shRNA by qPCR. If necessary, the level of gene knock-down could be 
improved by designing new shRNA or co-transducing the cells with multiple 
shRNA, targeting the same gene.    165
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Figure 37: Analysis of Msi2 knock down using shRNA 
A) The figure shows the percentage of hCD2
+ cME3 cells 2, 7, 14 and 21 days after 
transduction with the Msi2 specific shRNA 25B (black squares), 26A (black 
triangles), 27B (black diamonds) and with control shRNA (open squares). Similar 
results were observed in two independent experiments. B) The graph shows the 
relative expression of Msi2 mRNA of hCD2
+ cells 48 hours after infection with 
either one of the Msi2 specific shRNAs (25B, 26A, 27B) or the non-silencing 
negative control shRNA (CO). Columns represent the mean of triplicate 
measurements, error bars represent the standard deviations.   166
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Figure 38: Analysis of Frat1 and c-myc knock down using shRNA 
The figure shows the percentage of hCD2
+ cME3 cells 2, 5 and 7 days after 
transduction with the Frat1 specific shRNA 13A (black squares), 14A (black 
triangles), 15B (black diamonds) and with control shRNA (open squares) (A). 
Similar results were observed in three independent experiments. B) Percentage of 
hCD2
+ cME3 cells 2, 5, 7 and 14 days after transduction with the c-Myc specific 
shRNA 37B (black squares), 38C (black triangles) and with control shRNA (open 
squares).    167
If optimising Frat1 and c-Myc knock-down reveals these genes to be 
important for MLL-fusion mediated immortalisation, they will be included in further 
analyses in future work. 
 
5.2.  Validation of mRNA and protein expression of selected target genes upon 
loss of MLL-fusion expression 
 
The target genes HoxA9, c-Myb, c-Myc, Frat1, Msi2, Pontin and Reptin were 
up-regulated in the presence of the MLL-fusions and were selected for further 
validation. Although Pontin and Reptin were not part of the previous knock-down 
analysis, they were found in the list of up-regulated target genes and are involved in 
Wnt signalling (Chapter IV, Table 16) by interacting with β-Catenin as well as c-
Myc. In order to validate the gene expression changes that were observed by the 
Affymetrix screen, expression levels of the target genes were validated by qPCR 
analysis. For validation, total RNA independent of the preparation used for the 
Affymetrix analysis was isolated from the conditional cell lines MA1 and ME4, 
maintained with or without Doxycycline for 48 hours. As expected, target gene 
expression was down-regulated upon loss of MLL-fusion expression in all cases 
(Figure 39). In addition, we were able to validate c-Myb and Pontin protein 
expression by Western blot analysis with antibodies we had available (Figure 40). 
Conditionally immortalised MA1 and ME4 cells were maintained in the absence and 
presence of Doxycycline for 48 hours and cell pellets were lysed for Western blot 
analysis. A significant down-regulation of c-Myb and Pontin protein expression was 
confirmed in MA1 and ME4 cells upon loss of MLL-fusion protein expression.    168
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Figure 39: Validation of mRNA expression of target genes 
The graphs show the relative expression of HoxA9,  c-Myb,  c-Myc,  Frat1,  Msi2, 
Pontin and Reptin, 48 hours after treatment with Doxycycline in MA1 (A) and ME4 
(B). Each target gene is individually normalised to its expression level in untreated 
cells, shown as dotted line. Columns represent the mean of triplicate measurements, 
error bars represent the standard deviations.   169
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Figure 40: Validation of c-Myb and Pontin protein expression 
The figure shows Western blot analysis of protein extracts from immortalized 
conditional MA1 and ME4 cells without Doxycycline (lane 1 and lane 3) or 48 hours 
with Doxycycline treatment (lane 2 and lane 4). Anti-c-Myb antibody was used to 
detect c-Myb (75 kDa) and anti-αTubulin (55 kDa) antibody was used as the protein 
loading control (10% resolving gel). Anti-Pontin52 antibody was used to detect 
Pontin (52 kDa) and anti-HSP90α/β (90 kDa) antibody was used as the protein 
loading control (12.5% resolving gel). Films were scanned and bands quantitated 
(see Materials and Methods). The relative protein expression, normalised to 
untreated cells, is given in numbers underneath.   170
In future experiments, c-Myc,  Frat1,  Msi2 and Reptin protein expression 
protein expression will also be analysed and validated before further analysis of their 
role in MLL-fusion mediated transformation. 
 
5.3.  Validation of the role of Siah1a in MLL-mediated transformation 
 
Although  β-Catenin itself, the central regulator of Wnt signalling, was 
expressed in MLL-ENL and MLL-AF9 immortalised cells, its expression was not 
differentially regulated by the MLL-fusions. However, several of the Wnt signalling 
associated genes were detected as differentially expressed target genes. Therefore, 
we decided to reassess the expression levels of β-Catenin in Doxycycline treated 
conditional MA1 and ME4 cells by qPCR and Western blot analysis. In contrast to 
the results from the Affymetrix analysis, β-Catenin mRNA expression was down-
regulated upon loss of MLL-fusion expression in both cell lines (Figure 41 A). Total 
β-Catenin protein expression was detected using an antibody that recognises both the 
inactive, phosphorylated and the active, dephosphorylated β-Catenin protein. Total 
cell lysates were prepared and examined by Western blot analysis. A significant 
down-regulation of total β-Catenin protein expression was detected in MA1 and 
ME4 cells cultured in the presence of Doxycycline for 48 hours (Figure 41 B). 
 
Cytoplasmic levels of β-Catenin are usually regulated by phosphorylation 
through a destruction complex, consisting of APC, GSK3β and Axin, leading to 
ubiquitination and proteasomal degradation. β-Catenin can also be ubiquitinated and 
proteasomal degraded via an alternative Siah1a dependent pathway. The E3 ubiquitin 
ligase Siah1a was among the differentially expressed target genes and found to be 
down-regulated in the presence of MLL-fusion oncogenes.    171
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Figure 41: Validation of mRNA expression and protein expression of Ctnnb1 
A) The graph shows the relative expression of Ctnnb1 mRNA without (black) and 48 
hours after treatment with Doxycycline (grey) in conditional immortalised MA1 
(p<0.012) and ME4 (p<0.003) cells. Columns represent the mean of triplicate 
measurements, error bars represent the standard deviations. B) The figure shows 
Western blot analysis of protein extracts from immortalized conditional MA1 and 
ME4 cells without Doxycycline (lane 1 and lane 3) or 48 hours with Doxycycline 
treatment (lane 2 and lane 4). Anti-Ctnnb1 antibody was used to detect total Ctnnb1 
(90 kDa) and anti-αTubulin (55 kDa) antibody was used as the protein loading 
control (10% resolving gel). Films were scanned and bands quantitated. The relative 
protein expression, normalised to untreated cells, is given in numbers underneath.    172
We decided to study Siah1a in greater detail because Siah1a targets not only 
β-Catenin for proteasomal degradation, but also AF4, a central component of the 
MLL-fusion complex, and c-Myb, an essential downstream mediator of MLL-fusion 
activity (Bursen et al., 2004; Mueller et al., 2007). qPCR analysis confirmed that in 
the absence of MLL-AF9 or MLL-ENL fusion gene expression, the relative level of 
Siah1a mRNA expression was up-regulated compared to cells expressing the MLL-
fusion (Figure 42 A). In contrast to Siah1a mRNA expression, protein expression of 
Siah1a in MA1 and ME4 cells was down-regulated upon loss of MLL-fusion 
expression (Figure 42 B). However, this contrary observation could possibly be 
explained by the capacity of Siah1a to auto-ubiquitinate itself (Lorick et al., 1999). 
In that case, increased expression of Siah1a may lead to increased auto-
ubiquitination and consequently degradation, resulting in lower levels of the protein. 
Siah1a and Siah2 have previously been identified as AF4 binding proteins and 
Siah1a has been shown to promote proteasomal degradation of wild-type AF4 and 
the reciprocal MLL-fusion protein AF4-MLL (Bursen et al., 2004). However, AF4 
was not detected as a differentially regulated target gene of MLL-ENL or MLL-AF9 
immortalised cells, which was validated by qPCR analysis (Figure 43 A). AF4 
expression was found to be up-regulated upon loss of MLL-AF9 in MA1 cells but 
was not significantly regulated in ME4 cells. In order to measure AF4 protein levels, 
MA1 and ME4 cells were cultured for 48 hours with and without Doxycycline and 
total cell lysates were prepared and examined by Western blot analysis. Since AF4 
has been described to be a Siah1a target, increased Siah1a activity in the absence of 
the MLL-fusion proteins would correlate with down-regulation of AF4 protein 
expression. Upon loss of MLL-fusion expression a significant down-regulation of 
AF4 protein expression was detected in both cell lines (Figure 43 B).    173
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Figure 42: Validation of mRNA expression and protein expression of Siah1a 
A) The graph shows the relative expression of Siah1a mRNA without (black) and 48 
hours after treatment with Doxycycline (grey) in conditionally immortalised MA1 
and ME4 cells. Columns represent the mean of triplicate measurements, error bars 
represent the standard deviations. B) The figure shows Western blot analysis of 
protein extracts from immortalized conditional MA1 and ME4 cells without 
Doxycycline (lane 1 and lane 3) or 48 hours with Doxycycline treatment (lane 2 and 
lane 4). Anti-Siah1 (N15) antibody was used to detect Siah1a (32 kDa) and anti-
HSP90α/β (90 kDa) antibody was used as the protein loading control (12.5% 
resolving gel). Films were scanned and bands quantitated. The relative protein 
expression, normalised to untreated cells, is given in numbers underneath.    174
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Figure 43: Validation of mRNA expression and protein expression of AF4 
A) The graph shows the relative expression of AF4 mRNA without (black) and 48 
hours after treatment with Doxycycline (grey) in conditional immortalised MA1 and 
ME4 cells. Columns represent the mean of triplicate measurements, error bars 
represent the standard deviations. B) The figure shows Western blot analysis of 
protein extracts from immortalized conditional MA1 and ME4 cells without 
Doxycycline (lane 1 and lane 3) or 48 hours with Doxycycline treatment (lane 2 and 
lane 4). Rabbit anti-mouse AF4 antiserum (kind gift of E. Bitoun and K. Davies) was 
used to detect AF4 (193 kDa) and anti-Clatherin (190 kDa) antibody was used as the 
protein loading control (5% resolving gel). Films were scanned and bands 
quantitated. The relative protein expression, normalised to untreated cells, is given in 
numbers underneath.    175
Further experiments are required in order to assess MLL-fusion mediated 
regulation of Siah1a and link increased Siah1a activity in the absence of MLL-
fusions to degradation of its described targets, such as AF4, β-Catenin and c-Myb. 
 
5.4.  Validation of the effect of Hexachlorophene on Siah1a in MLL-fusion 
transformed cells 
 
In a cell based small-molecule screen, the antimicrobial compound 
Hexachlorophene (Hexa) was identified as an inhibitor of Wnt signalling (Park et al., 
2006). It was proposed that Hexachlorophene induces proteasomal degradation of β-
Catenin in a Siah1a-dependent manner (Park et al., 2006). In order to examine the 
role of Siah1a and Wnt signalling in MLL-fusion mediated transformation, 
Hexachlorophene was used to study induction of Siah1a function without abrogating 
the expression of MLL-AF9 or MLL-ENL. Previous studies demonstrated that 
Hexachlorophene inhibits the growth of human colon cancer cells in a concentration-
dependent manner (Park et al., 2006). The effect of different Hexachlorophene 
concentrations on the viability of conditionally immortalised MA1 and ME4 cells 
was therefore examined. Cells were cultured in the presence of 5μM, 10μM or 20μM 
Hexachlorophene or treated with the vehicle Methanol alone. The number of viable 
cells was determined on the day of plating (day 0) and 2 days and 3 days after 
treatment, by Trypan Blue exclusion (Figure 44). Similar to the results in human 
colon cancer cells, a strong concentration-dependent effect of Hexachlorophene on 
the viability of the MLL-fusion immortalised cell line was observed. 
   176
0µM
MA1
ME4
-1
0
1
2
3
123
5µM 10µM
Days in culture
F
o
l
d
 
a
c
c
u
m
u
l
a
t
i
o
n
 
[
l
o
g
1
0
]
123 0
0
Days in culture
F
o
l
d
 
a
c
c
u
m
u
l
a
t
i
o
n
 
[
l
o
g
1
0
]
-1
0
1
2
3
 
 
 
Figure 44: Concentration dependent effect of Hexachlorophene on viability of 
conditional MA1 and ME4 cells 
The graph shows the number of viable cells 2 and 3 days after treatment with 
increasing concentrations of Hexachlorophene (0µM/yellow, 5µM/red, 10µM/green). 
There were no viable cells by day two with 20µM Hexachlorphene treatment.   177
In order to examine whether the effect of Hexachlorophene was a result of 
differentiation, the expression of the cell surface markers c-Kit and Gr-1 was 
measured by flow cytometry in the constitutively immortalised cME3 cells. Cells 
were cultured in the presence of 0.5μM, 1.25μM, 2.5μM, 5μM and 10μM or 
Methanol alone (0μM) for 24 hours and 5 days. Only treatment with 2.5μM, 5μM 
and 10μM Hexachlorophene caused up-regulation of the differentiation marker Gr-1 
(Figure 45). The progenitor marker c-Kit was down-regulated in cells exposed to 
1.25μM, 2.5μM, 5μM and 10μM Hexachlorophene for 5 days. Higher concentrations 
of Hexachlorophene were correlated with an earlier increase and decrease in 
expression of Gr-1 and c-Kit, respectively. These results suggest that MLL-fusion 
oncogene immortalised cells differentiate in response to Hexachlorophene treatment 
and that the rate of differentiation depends on the concentration of the drug. 
However, further experiments are necessary in order to verify whether or not MLL-
fusion immortalised cells also directly undergo apoptosis in response to treatment 
with Hexachlorophene. 
 
Since it was suggested that Hexachlorophene induces β-Catenin degradation through 
a Siah1a mediated mechanism (Park et al., 2006), we decided to analyse the 
expression of Siah1a protein, following addition of Hexachlorophene to cME3 cells. 
Cells were cultured in the presence of 20μM Hexachlorophene, or Methanol alone, 
for 8 hours. Cell pellets were lysed and examined by Western blot analysis. As 
shown in Figure 46, Hexachlorophene did not induce Siah1a protein expression. 
However, the observed reduction of Siah1a protein expression upon treatment with 
Hexachlorophene is similar to the down-regulation of Siah1a protein expression 
observed upon treatment with Doxycycline (Figure 42).    178
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Figure 45: Differentiation analysis of cME3 cells treated with Hexachlorophene 
The figure shows the expression levels of Gr-1 and c-Kit in cME3 cells treated with 
increasing concentrations of Hexachlorophene (0µM yellow, 0.5µM orange, 1.25µM 
red, 2.5µM blue, 5µM green and 10µM brown) for 1 day and 5 days.    179
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Figure 46: Effect of Hexachlorophene treatment on Siah1a protein expression 
The figure shows Western blot analysis of protein extracts from immortalized 
constitutive cME3 cells cultured without (lane 1) or with 20µM Hexachlorophene 
(lane 2) for 8 hours. Cell pellets were lysed using 2xDTT sample buffer lysis 
method. (Anti-Siah1 (N15) antibody was used to detect Siah1a (32 kDa) and anti-β-
Actin (45 kDa) antibody was used as the protein loading control (12.5% resolving 
gel). Films were scanned and bands quantitated. The relative protein expression, 
normalised to untreated cells, is given in numbers underneath.    180
Similarly to Doxycycline treatment, this result could possibly be explained by 
the regulation of elevated levels of Siah1a through auto-ubiquitination and 
proteasomal degradation. Although detectable Siah1a protein levels are decreased, its 
level of activity may be increased. 
 
We next examined whether protein expression of Siah1a targets was affected 
by Hexachlorophene treatment. Protein expression of AF4 and c-Myb, degradation 
targets of Siah1a, was analysed. cME3 cells cultured in the presence of 20μM 
Hexachlorophene, or Methanol alone, for 8 hours were lysed and examined by 
Western blot analysis. In the presence of Hexachlorophene the protein expression of 
AF4 and c-Myb was significantly down-regulated (Figure 47). This result suggests 
that changes in AF4 and c-Myb protein expression correlate with Hexachlorophene 
induced increase of Siah1a activity, independent of the MLL-fusion proteins. 
However, the mechanism of Hexachlorophene induced Siah1a stimulation remains 
unclear at present. Park and colleagues have shown that Hexachlorophene induces 
Siah1a activity and degrades β-Catenin (Park et al., 2006). By analysing the mRNA 
expression of c-Myc, a transcriptional target of c-Myb as well as the Wnt signalling 
pathway, the Hexachlorophene induced effect of c-Myb down-regulation was further 
examined. In order to compare c-Myc expression in cells treated with 
Hexachlorophene to that in cells treated with Doxycycline, conditional MA1 cells 
were maintained for 48 hours with 5μM Hexachlorophene or Methanol alone, or with 
Doxycycline. mRNA expression of c-Myc was significantly down-regulated with 
both treatments (Figure 48). 
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Figure 47: Effect of Hexachlorophene treatment on c-Myb and AF4 protein 
expression 
The figure shows Western blot analysis of protein extracts from immortalized 
constitutive cME3 cells cultured without (lane 1) or with 20µM Hexachlorophene 
(lane 2) for 8 hours. Cell pellets were lysed using the 2xDTT sample buffer lysis 
method. Anti-cMyb antibody was used to detect c-Myb (75 kDa, 10% resolving gel) 
(A), AF4 antiserum to detect AF4 (193 kDa, 10% resolving gel) (B) and anti-β-Actin 
(45 kDa) antibody was used as the protein loading control. The relative protein 
expression, normalised to untreated cells, is given in numbers underneath.    182
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Figure 48: The effect of Hexachlorophene and Doxycycline on c-Myc and HoxA9 
mRNA expression 
The figure shows the relative expression of c-Myc and HoxA9 mRNA without 
(black), 48 hours after treatment with 5 μM Hexachlorophene (grey) and 48 hours 
after treatment with Doxycycline (white) in conditional immortalised MA1 cells. 
Columns represent the mean of triplicate measurements, error bars represent the 
standard deviations.    183
AF4 has been described as a critical member in a complex with MLL and 
several other MLL fusion partners, such as AF9/ENL and AF10, to recruit DOT1L 
and coordinate transcriptional elongation (Mueller et al., 2007). Therefore, we 
decided to examine the mRNA expression of HoxA9, a known transcriptional target 
of this MLL-fusion complex (Figure 48). Since AF4 has been shown to be a Siah1a 
target for proteasomal degradation we reasoned that transcription of MLL-fusion 
target genes may be down-regulated upon induced activity of Siah1a. A significant 
down-regulation of HoxA9 mRNA expression was observed with both treatments. 
These results suggest that target genes, identified by the global gene expression 
analysis upon loss of MLL-fusion expression, are also differentially regulated upon 
treatment with Hexachlorophene, presumably through induction of Siah1a activity. If 
it can be proven that Hexachlorophene induces Siah1a activity and has a similar 
effect to Doxycycline treatment, this would suggest that repression of Siah1a 
expression may be important for MLL-mediated transformation. Further experiments 
are necessary in order to prove the direct induction of Siah1a activity by 
Hexachlorophene and in order to show which of the Siah1a regulated targets are 
important for MLL-mediated transformation.   184
5.5.  Discussion – Chapter V 
 
Knock-down of the up-regulated target genes c-Myb, Msi2, c-Myc and Frat1 
had an effect on the proliferation of MLL-fusion immortalised cells. Interaction of 
these target genes with other genes or regulatory pathways was verified by using 
pathway analysis software. Using this approach, it was possible to identify c-Myb, c-
Myc, Ctnnb1, Siah1a, AF4, Pontin and Reptin as MLL-fusion target genes which 
may be involved in a common biological process and represent more than chance 
associations. 
 
In our study, several of the differentially regulated target genes have been 
found to be associated with the Wnt signalling pathway. The central mediator of the 
Wnt signalling pathway is β-Catenin. Wnt ligand binding-induced accumulation of 
unphosphorylated cytoplasmic β-Catenin results in translocalisation of β-Catenin into 
the nucleus, where it acts as a transcriptional co-activator. The translocation products 
AML1-ETO, PML-RARα and PLZF-RARα, all found in AML, have been shown to 
activate the Wnt signalling pathway in haematopoietic cells (Müller-Tidow et al., 
2004). Interestingly, it has been shown that the C-terminal activation domain of β-
Catenin associates with the TRRAP and MLL1 SET-1-type chromatin-modifying 
complexes in vitro and that β-Catenin promotes histone H3K4 trimethylation at the 
c-Myc gene in vivo (Sierra et al., 2006). Previous work has also shown that β-Catenin 
interacts with the TRRAP histone acetyltransferase complex subunits, Pontin and 
Reptin (Bauer et al., 1998; Bauer et al., 2000). Both genes Pontin and Reptin were 
found to be up-regulated in MLL-fusion expressing cells, in our study. Furthermore, 
Pontin protein expression was also shown to be up-regulated in MLL-fusion 
transformed cells. However, the roles of Pontin and Reptin in MLL-fusion mediated   185
transformation need to be further elucidated. This will be done by gene specific 
knock-down using shRNA or by introducing a mutant form of the Pontin protein that 
has been shown previously to block the expression of β-Catenin target genes (Feng et 
al., 2003). 
 
Levels of cytoplasmic β-Catenin are regulated by CK1 and GSK3β mediated 
phosphorylation, leading to βTRCP mediated ubiquitination and subsequently 
proteasomal degradation (reviewed in Staal and Clevers 2005; Klaus and Birchmeier 
2008). A GSK3β and βTRCP independent pathway of β-Catenin degradation has 
been found to be mediated by APC and Siah1a (Liu et al. 2001). Siah1a is an E3-
ubiquitin ligase that interacts with the C-terminus of APC and induces ubiquitination 
and proteasomal degradation of β-Catenin (Liu et al., 2001). Human SIAH1 protein 
has been shown to contain an N-terminal RING domain, that is required for its 
proteasomal degradation function, and C-terminal sequences, required for 
oligomerisation and binding to target proteins (Hu et al., 1997). It has been shown 
that Siah1 targets itself via RING dependent auto-ubiquitination for proteasomal 
degradation (Lorick et al., 1999). In our study, Siah1a was one of the target genes 
down-regulated by the MLL-fusions in immortalised cells and was highlighted from 
the list of down-regulated target genes using pathway analysis tools. Furthermore, 
literature searches revealed that Siah1a is also a negative regulator of AF4, a critical 
member of the MLL-fusion complex, and c-Myb (Mueller et al., 2007). It was 
possible to confirm a significant increase in Siah1a mRNA expression upon loss of 
MLL-fusion expression. However, Siah1a protein expression did not correlate with 
mRNA but decreased upon loss of MLL-fusion expression. This observed decrease 
may be a result of an increase in Siah1a activity and a consequent increased auto-
ubiquitination and degradation. In order to examine increased Siah1a activity, we   186
examined protein expression levels of β-Catenin, c-Myb and AF4, all previously 
identified as targets of Siah1a mediated proteasomal degradation (Tanikawa et al., 
2000; Liu et al., 2001; Bursen et al., 2004). It is possible that genes such as β-
Catenin and AF4 were initially not identified as differentially expressed by the 
Affymetrix screen because significant changes in gene expression had to be detected 
in all six independent cell lines. However, we could show that β-Catenin and AF4 
protein expression was significantly decreased in MA1 and ME4 cells, upon loss of 
the MLL-fusion expression. Furthermore, protein expression of c-Myb was also 
shown to be decreased. These data suggest that target genes are regulated at the level 
of transcription by the MLL-fusion oncogene and at the level of protein by MLL-
fusion induced Siah1a repression. 
 
Although deregulation of c-Myb is found in many cancers and leukaemias 
(reviewed in Ganter and Lipsick, 1999), this gene was recently described to be an 
essential transcriptional target of HoxA9 and Meis1 overexpression and by extension 
in MLL-ENL mediated transformation (Hess et al., 2006). On the other hand, as 
mentioned earlier, c-Myb protein has also been described to be a p53-dependent 
degradation target of Siah1a (Tanikawa et al., 2000). In our study, we demonstrated 
that c-Myb is up-regulated in MLL-ENL and MLL-AF9 immortalised cells and 
confirmed increased levels of mRNA and protein expression in the presence of 
fusion gene expression. However, the mechanism of MLL-fusion mediated c-Myb 
regulation remains unclear at present. Further analysis is necessary to elucidate 
whether regulation of c-Myb is solely at the level of transcription or also mediated by 
post-transcriptional regulation. Future experiments will include treating the cells with 
the peptide aldehyde MG132, a potent inhibitor of proteasome function, to analyse 
levels of ubiquitinated c-Myb. By comparing levels of ubiquitinated c-Myb in cells   187
expressing the MLL-fusion and cells upon loss of the MLL-fusion, we will be able to 
determine if c-Myb protein expression is changed due to ubiquitination and therefore 
proteasomal degradation. If we can identify an increase in ubiquitination and 
degradation of c-Myb upon loss of MLL-fusion expression, we can also treat the 
cells with Cycloheximide to block protein synthesis and analyse proteasomal 
degradation in the presence and absence of the MLL-fusion oncogenes. 
 
Both MLL and its fusion partners, Af4, Af9, Af10 and Enl have been shown 
to play a direct role in transcriptional elongation (Bitoun et al., 2007). Af4 has been 
described to recruit Af9 or Enl, Af10, Dot1 and pTEFb in a complex and positively 
regulate transcriptional elongation by RNA polymerase II. This leads to histone 
methylation (H3K79) resulting in increased and deregulated target gene expression 
(Bitoun et al., 2007). The interaction domains of Af4, Af9/Enl and Af10 with Dot1 
are retained in MLL-fusion proteins, suggesting that the fusion proteins mistarget 
Dot1 and pTEFb to transcriptional targets (Bitoun et al., 2007). The observed 
decrease of Siah1a protein expression and increase of AF4 protein expression in 
MLL-fusion expressing cells possibly suggests that Siah1a degradation targets might 
be protected by the MLL-fusion oncogenes. Therefore, the transcriptional elongation 
complex, recruited by Af4, remains active in the presence of MLL-fusion oncogenes. 
Further experiments are necessary, in order to analyse if AF4 is critical in MLL-
fusion mediated transformation. By performing an AF4 specific knock-down we 
could possibly acquire more information about the role of AF4. 
 
In order to elucidate the role of Siah1a down-regulation in MLL-ENL and 
MLL-AF9 immortalised cells, we decided to use the antimicrobial compound 
Hexachlorophene. Hexachlorophene has been suggested to inhibit Wnt signalling   188
through Siah1a-mediated proteasomal degradation of β-Catenin, although the 
mechanism of Siah1a stimulation is unknown at present (Park et al., 2006; Min et al., 
2009). Our preliminary results suggested that upon addition of Hexachlorophene, 
MLL-fusion immortalised cells differentiated in a dose dependent manner. 
Furthermore, we observed that addition of Hexachlorophene caused a decrease in 
AF4 and c-Myb protein expression, both shown to be targets of Siah1a proteasomal 
degradation (Tanikawa et al., 2000; Bursen et al., 2004). This observation suggests a 
correlation between Hexachlorophene-mediated stimulation of Siah1a activity and 
decrease in protein expression of Siah1a degradation targets. Interestingly, the 
correlation between increased activity of Siah1a and down-regulation of Siah1a 
degradation targets is also observed following loss of MLL-fusion expression. 
Further experiments are necessary in order to confirm that Hexachlorophene induces 
Siah1a activity and to analyse if Siah1a is responsible for proteasomal degradation of 
AF4, c-Myb and β-Catenin. 
 
The data presented in this chapter suggest that the target genes c-Myb, c-Myc 
and Siah1a together with Ctnnb1 and AF4 may be involved in a common biological 
process, induced by MLL-mediated transformation. These genes encode proteins that 
function together in different complexes. It is unclear at present if all the described 
protein complexes are required to interact or if they represent independent pathways 
that are regulated by MLL-fusion oncogenes. Since the use of Hexachlorophene in 
rats has been found to have toxic side effects such as cerebral swelling and brain 
damage, Hexachlorophene can not be used in vivo. However, inducing Siah1a 
activity by similar drugs may represent a novel therapeutic approach.   189
CHAPTER VI  - Conditional MLL-ENL in vivo model 
 
Global gene expression analysis was used to identify a number of potential 
transcriptional target genes of the MLL-AF9 and MLL-ENL fusion oncogenes. To 
examine the role of a particular target gene for MLL-fusion mediated transformation, 
up-regulated target genes were knocked down in vitro. In order to establish whether 
modulating the identified transcriptional networks used by MLL-fusions would block 
leukaemia in vivo, we induced leukaemia using the conditional MLL-ENL cell lines. 
We then examined the dependence of the leukaemia on MLL-ENL expression. The 
aim of these experiments was to validate the targeting of transcription pathways 
activated by MLL-fusions, in order to treat established leukaemias. 
 
6.1.  Immortalised MLL-ENL cells induce AML in vivo 
 
Immortalised myeloid cells with either constitutive or conditional expression 
of MLL-ENL were generated and characterised in the same manner as the 
immortalised myeloid MLL-AF9 cell lines, described in Chapter III (generation of 
ME4 by myself, generation of all other immortalised MLL-ENL cell lines by Dr. 
Sarah Horton, Molecular Haematology and Cancer Biology Unit, UCL Institute of 
Child Health and Great Ormond Street Hospital). The relative expression levels of 
MLL-ENL in the cells and the tetracycline-transactivator dependent expression of 
MLL-ENL in conditional immortalised cells was measured by qPCR (Figure 49, 
experiment was performed by Dr. Sarah Horton). Total RNA was isolated from all 
selected cell lines cultured with or without 2µg/ml Doxycycline for 48 hours and 
used for qPCR analysis.    190
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Figure 49: Relative MLL-ENL mRNA expression in the presence and absence of 
Doxycycline 
The graph shows the relative level of MLL-ENL mRNA expression in ME4, ME5, 
ME7 and cME3 cells in the absence (black) or presence (grey bar or indicated by 
grey arrows) of 2µg/ml Doxycycline for 48 hours. Columns represent the mean of 
triplicate measurements, error bars the standard deviations.   191
Upon addition of Doxycycline to the cultures,  MLL-ENL expression was 
completely abrogated. As expected, treatment of the cME3 constitutive immortalised 
cells with Doxycycline did not have an effect on MLL-ENL expression. 
 
To determine if immortalised MLL-ENL cells could induce leukaemia in 
vivo, 1x10
6 cells of the conditional immortalised MLL-ENL cell lines ME4, ME5, 
ME7 or of the constitutive immortalised cell line cME3 were transplanted 
intravenously into sublethally γ-irradiated (6.5 Gy) C57BL/6 or C57BL/6-CD45.1 
mice (all transfers were performed by Dr. Owen Williams). After transplantation the 
primary recipients were closely monitored. The mice where immediately sacrificed 
as soon as they showed signs of distress such as hunched postures, abnormal 
breathing, weight loss, immobility and piloerection. When analysed, the recipients 
had pale bone marrow and had developed enlarged spleens, consistent with AML 
phenotype. To determine if the leukaemia could be transplanted into secondary 
recipients, 1x10
6 leukaemic splenocytes from primary recipients were injected 
intravenously into sublethally irradiated C57BL/6-CD45.1 or C57BL/6 (CD45.2) 
mice. Peripheral blood was analysed at regular intervals for the presence of donor-
derived leukaemic cells and recipients were sacrificed when they showed any signs 
of disease or at indicated time points (Figure 50). 
 
The survival of all recipients was monitored and in order to further 
characterise the leukaemia, organs of leukaemic secondary recipients were analysed. 
MLL-ENL immortalised cells induced leukaemia in primary as well as secondary 
recipients with similar latencies of 81.25±4.4 days (n=8) and 26.89±6.8 days (n=44), 
respectively (Figure 51).    192
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Figure 50: Experimental strategy for a conditional in vivo model of MLL-ENL 
leukaemia 
Recipient mice were sublethally γ-irradiated with 6.5 Gray 24 hours prior to 
injections. Primary recipients were injected with 1x106 immortalised cells. 
Secondary recipients were injected with 1x106 leukaemic splenocytes derived from 
leukaemic primary recipients. Recipients were sacrificed when they showed any 
signs of disease.   193
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Figure 51: Secondary recipients develop disease with a shorter latency 
The graph shows the survival curves of primary (filled symbols) and secondary 
(open symbols) recipients, transplanted with immortalised or leukaemic constitutive 
(cME3, diamonds, n=5) or conditional (ME4, circles, n=5) myeloid cells. In total 
MLL-ENL immortalised cells caused leukaemia in primary and secondary recipients 
with an average latency of 81.25±4.4 days (n=8) and 26.89±6.8 days (n=44), 
respectively.   194
Secondary recipients transplanted with leukaemic splenocytes from the 
primary recipients developed leukaemia with much shorter latencies than primary 
recipients transplanted with immortalised cells. In secondary recipients, leukaemic 
cells derived from conditionally immortalised cells could be identified by CD45.2 
and EGFP expression. Leukaemic cells derived from constitutively immortalised 
cells did not express EGFP and could only be identified by CD45.2 expression (left 
panel Figure 52 A). Flow cytometric analysis of cell surface antigen expression 
revealed that leukaemic splenocytes derived from secondary recipients expressed 
high levels of the myeloid lineage marker Mac-1 and intermediate to high levels of 
the myeloid marker Gr-1 (right panel Figure 52 A). This phenotype is consistent with 
the phenotype of immature myeloid progenitors as well as with the phenotype of the 
immortalised MLL-ENL and MLL-AF9 cell lines (data for MLL-AF9 cell lines 
shown in Chapter III). Sections of liver harvested from secondary recipients and 
normal liver from C57BL/6 mice were fixed in formalin, set in paraffin and stained 
with hematoxylin & eosin (histopathology was performed by Dr. Neil Sebire, 
Department of Histopathology, UCL Institute of Child Health and Great Ormond 
Street Hospital). Liver sections from secondary recipients showed extensive 
leukaemic cell infiltration (Figure 52 B). 
 
  A possible explanation for the shortened latencies in secondary recipients 
could be the in vivo selection for an outgrowth of a minor aggressive clone in the 
primary recipients. In this scenario, a clone present as a minor population of the 
original immortalised cell line would compose the bulk of leukaemic cells isolated 
from primary leukaemic mice.   195
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Figure 52: Spleen and liver analysis of diseased secondary recipients 
A) The left panel of the dot plots shows the expression of CD45.2 and EGFP in 
leukaemic cME3 and ME4 splenocytes of secondary recipients. The right panel of 
the dot plots shows the expression of the myeloid markers Gr-1 and Mac-1 also in 
leukaemic cME3 and ME4 splenocytes of secondary recipients. Numbers in the plots 
refer to the percentages of cells within each quadrant. B) Photomicrographs of 
hematoxylin & eosin stained sections of leukaemic cell infiltrated liver from 
secondary recipients and normal liver from C57BL6 control mice (original 
magnification x100).   196
In order to compare the retroviral integration pattern of all immortalised cell 
lines and their corresponding leukaemic cells, southern blot analysis of end-
fragments produced by BamHI digestion of integrated provirus and genomic DNA 
was performed (Figure 53 A). All leukaemic cell lines had the identical retroviral 
integration pattern as the immortalised cells from which they were derived (Figure 
53 B). This result suggests that the outgrowth of a minor clone in vivo was unlikely. 
 
Another possible cause of the shortened latencies could be that the 
immortalised cells became conditioned to the microenvironment in vivo. Hence, after 
transplanting those in vivo conditioned leukaemic cells into secondary recipients they 
were better able to interact with the bone marrow environment, engraft more 
efficiently and induced leukaemia at an accelerated rate. To test this hypothesis, 
splenocytes derived from primary leukaemic recipients were either directly 
transplanted into secondary recipients or cultured for one month in vitro before 
transplantation into secondary recipients (Figure 54 A). Prolonged culture of 
leukaemic cells in vitro would presumably lead to a loss of any acquired 
microenvironmental conditioning and the cells would have lost a possible 
engraftment advantage. However, the survival curves for mice transplanted with the 
leukaemic cells ME5a (Figure 54 B) show that leukaemic cells did not loose the 
ability to induce leukaemia with a shorter latency after one month in vitro culture 
prior to transplantation. Although there were some differences in latencies between 
ex vivo to post-culture transplanted leukaemic cells (Table 19), all leukaemic cells 
induced leukaemia with a shorter latency when compared to the immortalised 
parental cells. 
   197
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Figure 53: Leukaemic and immortalised cells have the same retroviral 
integration pattern 
A) The figure shows diagrams of the constitutive (pMSCV-neo-mod-fMLLENL) and 
conditional (pMSCV-neo-TRE-fMLLENL) retroviral constructs. The BamH1 
restriction endonuclease site and region corresponding to the probe (shown in grey) 
used in the southern blot analysis are indicated. B) Southern blot analysis of genomic 
DNA isolated from immortalised constitutive (cME3) and conditional (ME4, ME5 
and ME7) cells and their leukaemic progeny (cME3a, ME4a, ME4b, ME5a, ME7a 
and ME7b). Blots show 5’(ME4, ME5, ME7, ME4a, ME4b, ME5a, ME7a and 
ME7b) and 3’ (cME3 and cME3a) end-fragments produced by BamHI digestion of 
the integrated provirus and genomic DNA. 
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Figure 54: Cultured and freshly isolated leukaemic cells cause leukaemia in 
secondary recipients with similar latencies 
A) Brief overview of the experimental strategy used to assess the effect of in vitro 
culture of primary leukaemic cells on latency of leukaemia in secondary recipients. 
B) Survival curves of mice transplanted with ME5a leukaemic cells, either freshly 
isolated (open circles) or following 4 weeks culture in vitro (filled diamonds). In 
vitro culture of the leukaemic cells caused a small but significant increase in ME5a 
latency (p=0.038, Mantel Haenszel logrank test).   199
Table 19: Latencies of secondary leukaemias ex vivo or post-culture 
Leukaemic Cells  Latency of 2
nd ex vivo Latency of 2
nd post-culture  p-value 
ME4a  26.2 (±1.1, n=5)  17.8 (±9.2, n=5)  0.269 
ME5a  16.6 (±2.2, n=5)  22.0 (±9.5, n=10)  0.038 
ME7a  34.2 (±3.3, n=5)  14.2 (±3.3, n=5)  0.002 
 
The table shows a summary of the comparisons between ex vivo and post-culture induced secondary 
latencies. ME4a leukaemic cells showed no significant difference in latencies, ME5a leukaemic cells 
showed a small but significant increase in latencies and ME7a showed a significant decrease in 
latencies. 
 
  An alternative explanation could be the acquisition of additional mutations by 
the leukaemic cells resulting in shortened latencies. In order to examine if additional 
mutations have occurred, immortalised cells and leukaemic cells were karyotyped 
(GTG banding and analysis of metaphase spreads was performed by Steve Chatters, 
Paediatric Malignancies Cytogenetics Unit, Institute of Child Health and Great 
Ormond Street Hospital). The microscopic analysis of metaphase spreads showed an 
increase in single cell abnormalities within leukaemic cultures when compared to the 
parental immortalised cell lines (Table 20). Most of the observed mutations were 
single cell abnormalities, such as polyploidy and chromosomal breaks (Figure 55). 
However, one set of leukaemic cells (ME7a) harboured a clonal abnormality, 
identified by GTG-banding as a trisomy 6 (Figure 56). 
 
In the two cases of ME4b and ME7b, karyotyping could not reveal an 
increased number of mutations compared to the immortalised cell lines from which 
they were derived. A more sensitive approach was used to analyse changes in copy 
number of subchromosmal regions, by using array-based comparative genomic 
hybridisation (CGH) analysis (Agilent).    200
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Figure 55: Leukaemic ME4a cells have acquired single cell abnormalities 
Metaphase spread of ME4a cells (original magnification x1000) which shows a 
chromosome break (red arrow).    201
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Figure 56: Leukaemic ME7a cells have acquired a clonal Trisomy 6 
abnormality 
GTG-banded karyotype of the leukaemic cell line ME7a. Ideograms are shown next 
to the corresponding chromosome pair (original magnification x1000).    202
Table 20: Leukaemic cells have cytogenetic abnormalities 
Cell Line  Single Cell Abnormalities  Karyotype 
ME4    0/50 abnormal 
  0/50 polyoloid 
normal 
ME4a    2/50 abnormal 
14/50 polyoloid 
normal 
ME4b    2/50 abnormal 
  0/50 polyoloid 
normal 
ME5    0/30 abnormal 
  0/30 polyoloid 
normal 
ME5a    1/20 abnormal 
14/20 polyoloid 
normal 
ME7    5/50 abnormal 
  0/50 polyoloid 
normal 
ME7a    1/50 abnormal 
  0/50 polyoloid 
trisomy 6 
ME7b    1/18 abnormal 
  0/18 polyoloid 
normal 
cME3    0/50 abnormal 
  0/50 polyoloid 
normal 
cME3a    1/50 abnormal 
  0/50 polyoloid 
normal 
 
The table shows a summary of the karyotype and the frequency of additional single cell mutations in 
all analysed immortalised cell lines and leukaemic cells. 
 
Genomic DNA was isolated from leukaemic cells ME4b and ME7b and 
compared to genomic DNA from their parental immortalised cell lines, ME4 and 
ME7, respectively. Using this approach, changes in copy number could be detected. 
ME4b leukaemic cells showed a copy number increase of a region of chromosome 4 
as well as a copy number decrease of a region of chromosome 15, when compared to 
the parental ME4 immortalised cells (Figure 57).    203
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Figure 57: CGH analysis of ME4 and ME4b DNA samples 
A) The figure illustrates the increase in copy number profile across all chromosomes. 
The copy number increase (red bars) of a region of chromosome 4 and decrease 
(green bars) of a region of chromosome 15 in ME4b leukaemic cells when compared 
to ME4 immortalised cells is shown. B) Detailed view of chromosome 4 and 15. 
Each point on the graph represents the log2 ratio value of a single oligonucleotide 
probe. The shaded area and vertical line indicate an aberrant region identified by the 
Z-score algorithm (CGH Analytics v3.4, Agilent Technologies). Array analysis 
performed by Miltenyi Biotec.   204
ME7b leukaemic cells showed a copy number increase of a small region of 
chromosome 6, when compared to the parental ME7 immortalised cells (Figure 58). 
It is tempting to speculate that the genes, which are mapped to the detected aberrant 
regions, could potentially play an important role for MLL-ENL induced 
leukaemogenesis. This possibility will be investigated further in future work. 
 
If the provirus integration occurred at or proximal to the region of copy 
number alterations, this could result in either increased copy number of the MLL-
ENL provirus or cause increased expression of the oncogene. Hence, those increases 
may have impacted on the latencies of secondary leukaemias. To examine this, 
genomic DNA and total RNA was isolated from all immortalised cell lines and 
leukaemic cells. The relative level of MLL-ENL DNA copy number (Figure 59 A) 
and relative level of MLL-ENL mRNA expression (Figure 59 B) was measured by 
qPCR. No significant change could be detected in MLL-ENL DNA copy number and 
no consistent increase could be detected in MLL-ENL mRNA expression of 
leukaemic cells compared to their parental immortalised cell lines.  
 
6.2.  In vitro characterisation of leukaemic cells 
 
Leukaemic splenocytes were isolated from primary recipients and cultured in 
vitro in RPMI medium supplemented with 100 ng/ml SCF, 10 ng/ml IL-3 and 10 
ng/ml IL-6. Their rate of proliferation, growth factor requirements and response to 
Doxycycline was compared to the immortalised cells from which they were derived. 
Leukaemic cells proliferated steadily in vitro but in all cases analysed, showed a 
reduced rate of proliferation compared to the immortalised cells (Figure 60).    205
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Figure 58: CGH analysis of ME7 and ME7b DNA samples 
A) The figure illustrates the increase in copy number profile across all chromosomes. 
The copy number increase (red bars) of a region of chromosome 6 in ME7b 
leukaemic cells when compared to ME7 immortalised cells is shown. B) Detailed 
view of chromosome 6. Each point on the graph represents the log2 ratio value of a 
single oligonucleotide probe. The shaded area and vertical line indicate an aberrant 
region identified by the Z-score algorithm (CGH Analytics v3.4, Agilent 
Technologies). Array analysis performed by Miltenyi Biotec.   206
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Figure 59: Relative MLL-ENL DNA copy number and mRNA expression 
A) Relative MLL-ENL DNA copy numbers measured by qPCR. Copy numbers were 
calculated for ME4a and ME4b relative to ME4, for ME5a relative to ME5, for 
ME7a and ME7b relative to ME7 and for cME3a relative to cME3 and normalised to 
mouse β-Actin. Columns represent the mean of triplicate measurements, error bars 
represent the standard deviations. B) Relative level of MLL-ENL mRNA expression 
measured by qPCR shown for all cell lines normalised to ME4. Columns represent 
the mean of triplicate measurements, error bars represent the standard deviations.    207
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Figure 60: Leukaemic cells have a reduced proliferation rate in vitro 
The graph shows the fold accumulation (log10) in cell number of in vitro cell lines 
cME3, ME4, ME5 and ME7 (filled squares) and leukaemic cell lines cME3a, ME4a, 
ME5a, ME7a (open triangles), ME4b and ME7b (open diamonds).   208
To determine the cytokine requirements of the cell lines, cell proliferation 
assays were carried out. Data for all analysed cell lines are shown in Figure 61. The 
cells were cultured in various combinations of the cytokines SCF, IL-6, IL-3 and 
GM-CSF. The immortalised and the leukaemic cells remained growth factor 
dependent and showed a similar pattern of response to the cytokine combinations. 
 
In order to examine the response to Doxycycline upon loss of MLL-ENL 
expression, leukaemic cells and immortalised cell lines were cultured in the presence 
of 2μg/ml Doxycycline for seven days (Figure 62). Viable cells were counted using 
Trypan Blue exclusion after two, four and six or seven days. After two days, both the 
leukaemic and immortalised cells had a similar cell number in cultures with and 
without Doxycycline. By day four, all conditionally immortalised cells and their 
corresponding leukaemic progeny, cultured in the presence of Doxycycline, showed 
a decrease in proliferation and by day six or seven no viable cells could be detected. 
This response was similar for all conditional cells apart from immortalised ME4 
cells, which terminally differentiated by day four. As expected, addition of 
Doxycycline to the cultures of constitutively immortalised or leukaemic cells did not 
have an effect on their proliferation capacity. Analysis of Wright-Giemsa stained 
cytospin preparations showed that the leukaemic cells had the same myeloblastic 
morphology as the immortalised cells. Upon addition of Doxycycline to the cultures 
for four days most of the conditionally immortalised cells and their corresponding 
leukaemic progeny terminally differentiated into neutrophils, as shown by their 
lobular shaped nuclei (Figure 63). 
 
To confirm the terminal differentiation of the cells into neutrophils, 
neutrophil-specific granule gene expression was examined.    209
 
 
 
2.2
1.6
0
S
C
F
 
I
L
6
S
C
F
 
I
L
3
I
L
6
 
I
L
3
S
C
F
I
L
6
I
L
3
G
M
-
C
S
F
n
o
 
G
F
S
C
F
 
I
L
6
 
I
L
3
a
b
s
o
r
b
a
n
c
e
 
a
t
 
4
9
0
 
n
m
cME3 cME3a ME4 ME4a ME4b
0
S
C
F
 
I
L
6
S
C
F
 
I
L
3
I
L
6
 
I
L
3
S
C
F
I
L
6
I
L
3
G
M
-
C
S
F
n
o
 
G
F
S
C
F
 
I
L
6
 
I
L
3
0.8
1.6
0.8
ME5 ME5a
S
C
F
 
I
L
6
S
C
F
 
I
L
3
I
L
6
 
I
L
3
S
C
F
I
L
6
I
L
3
G
M
-
C
S
F
n
o
 
G
F
S
C
F
 
I
L
6
 
I
L
3 0
2.2
1.6
0.8
ME7 ME7a ME7b
S
C
F
 
I
L
6
S
C
F
 
I
L
3
I
L
6
 
I
L
3
S
C
F
I
L
6
I
L
3
G
M
-
C
S
F
n
o
 
G
F
S
C
F
 
I
L
6
 
I
L
3 0
2.2
1.6
0.8
 
 
 
 
Figure 61: Cell proliferation assay to test growth factor requirements of 
immortalised and leukaemic cells 
The graph shows the viability of cells cultured in various cytokine conditions (SCF, 
Il-6, IL-3 or GM-CSF) measured with an MTS assay at an absorbance of 490 nm. 
The cells were cultured for 72 hours in various cytokine combinations. The values 
are normalised to the growth of each cell line in the presence of SCF, IL-6 and IL-3. 
Bars represent means of triplicate values and error bars their standard deviations.    210
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Figure 62: Effect of Doxycycline on viability of immortalised and leukaemic 
cells in vitro 
The graph shows the fold accumulation (log10) in cell number following maintenance 
of the cells without (filled symbols) and with 2 μg/ml Doxycycline (open symbols). 
Viable cells were counted using Trypan Blue exclusion after 2, 4 and 6 or 7 days.   211
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Figure 63: Differentiation of immortalised and leukaemic cells in response to 
Doxycycline 
The figure shows the morphology of the cell lines following culture with and without 
2µg/ml Doxycycline for 4 days, assessed by cytospin preparation and Wright-
Giemsa staining (original magnification x 400).   212
Total RNA was isolated from the immortalised ME4 cells and the leukaemic 
ME4a cells cultured with or without 2μg/ml Doxycycline for 72 hours and used for 
qPCR analysis. In the presence of Doxycycline, the expression of the primary 
granule gene Myeloperoxidase (Mpo) was down-regulated while expression of the 
secondary granule gene Lactoferrin ( Ltf) and the tertiary granule gene 
Metalloproteinase 9 ( Mmp9) were increased (Figure 64). These changes in 
neutrophil granule gene expression are consistent with terminal differentiation. 
 
6.3.  Leukaemic cells require MLL-ENL expression in vivo 
 
 These  in vitro experiments suggested that leukaemic cells may also be 
sensitive to Doxycycline exposure in vivo. In order to examine this possibility, 
secondary recipient mice were transplanted with primary leukaemic splenocytes. 
Upon detection of donor derived leukaemic cells in the blood, one group of 
secondary recipients was treated with 200µg/ml Doxycycline and 5% sucrose in their 
drinking water for a specified period of time, and the other left untreated (Figure 65). 
Peripheral blood from secondary recipients was analysed at regular intervals for the 
presence of Mac-1
+EGFP
+ leukaemic cells. Cells were stained using PE- or APC-
conjugated antibodies to either c-Kit, Mac-1, Gr-1 or CD45.2 and used for flow 
cytometry analysis. (Experiments performed by myself, Dr. Sarah Horton and Dr. 
Owen Williams). Figure 66 illustrates an example of two mice transplanted with 
ME4a cells, one recipient treated with Doxycycline and one left untreated. An initial 
increase in the percentage of Mac-1
+EGFP
+ leukaemic cells was detected in the 
peripheral blood of untreated as well as treated recipients after six days of 
Doxycycline treatment.    213
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Figure 64: Neutrophil granule gene expression is changed in response to 
Doxycycline 
The graph shows the relative level of neutrophil granule gene mRNA expression, 
measured by qPCR, in ME4 and ME4a cells after culture without (black bars) and 
with (grey bars) 2 µg/ml Doxycycline for 3 days. Plots show a significant (p<0.001) 
decrease after treatment with Doxycycline in primary granule Mpo and an significant 
(p<0.001) increase in secondary granule Ltf and tertiary granule Mmp9 gene 
expression. Columns represent the mean of triplicate measurements, error bars 
represent the standard deviations.   214
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Figure 65: Experimental strategy for in vivo Doxycycline treatment 
Secondary recipients were injected with 1x106 leukaemic splenocytes derived from 
leukaemic primary recipients. Upon detection of leukaemic cells in the PBL 
Doxycycline was administered. Secondary recipients were divided into two groups 
and either administered 200 µg/ml Doxycycline and 5% sucrose or not in the 
drinking water. Mice were sacrificed when they showed any signs of disease.   215
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Figure 66: Elimination of conditional leukaemic cells from peripheral blood of 
Doxycycline treated mice 
The dot plots show the presence of Mac-1+EGFP+ leukaemic ME4a cells in the 
peripheral blood of recipient mice before (day -1) and after (day 6 and 34) their 
treatment (right panel), or not (left panel), with Doxycycline. Numbers in the top 
right quadrant represent Mac-1+EGFP+ cells as a percentage of total Mac-1+ cells. 
None of the recipients in the untreated group survived until the last time-point 
shown.   216
However, 34 days later, recipients which received Doxycycline treatment 
were still alive and Mac-1
+EGFP
+ leukaemic cells were completely eliminated from 
the peripheral blood. None of the untreated recipients survived until the last time 
point of analysis. All recipients which were transplanted with ME4a, ME5a and 
ME7c leukaemic cells, and which received Doxycycline treatment, survived for the 
entire period of the study (Figure 67). In all cases analysed, conditional leukaemic 
cells were completely eliminated from the peripheral blood (Figure 68). 
Interestingly, treatment duration for as little as seven days was sufficient to 
completely eliminate leukaemic cells from the peripheral blood (ME7c, Figure 67 
and Figure 68). As expected, Doxycycline treatment did not have an effect on the 
survival of recipients which were transplanted with constitutive cME3a leukaemic 
cells. Moreover, Doxycycline treatment had no effect on the accumulation of 
leukaemic cells in the peripheral blood of mice transplanted with constitutive cells.  
 
In order to examine the fate of Doxycycline treated leukaemic cells in vivo, 
bone marrow from secondary recipients was analysed. Bone marrow and spleen 
isolated from ME4b transfers with (n=3) and without (n=3) Doxycycline treatment 
showed loss of c-Kit expression (Figure 69 A). Leukaemic cells were further 
analysed for Gr-1 and c-Kit expression. Bone marrow from untreated transfers 
showed one population of cells with Gr-1
hic-Kit
lo expression and one population of 
cells with Gr-1
intc-Kit
hi expression (Figure 69 B, upper panel). Upon treatment with 
Doxycycline the population of cells with Gr-1
hic-Kit
lo expression increased and the 
population of cells with Gr-1
int expression showed reduced c-Kit expression 
indicating differentiation. An alternative possibility was that the cells underwent 
apoptosis in vivo as a direct result of MLL-ENL loss.    217
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Figure 67: Effect of Doxycycline on survival of recipients 
Recipients were transplanted with the indicated leukaemic cells and following their 
detection in the peripheral blood, one group was given Doxycycline in their water 
(open diamonds; cME3a n=6, ME4a n=5, ME5a n=5, ME7c n=4) and the other left 
untreated (filled circles; cME3a n=4, ME4a n=5, ME5a n=5, ME7c n=5). Red arrows 
indicate the point at which treatment started, red bars on the survival curves indicate 
the duration of treatment in each experiment. Doxycycline treated mice were still 
alive 350, 270 and 360 days after transplantation of ME4a, ME5a and ME7c cells, 
respectively.    218
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Figure 68: Effect of Doxycycline on the elimination of leukaemic cells from the 
peripheral blood 
Recipient mice were transplanted with the indicated leukaemic cells and following 
their detection in the peripheral blood, one group was given Doxycycline in their 
water (open red diamonds; cME3a n=6, ME4a n=5, ME5a n=5, ME7c n=4) and the 
other left untreated (filled black circles; cME3a n=4, ME4a n=5, ME5a n=5, ME7c 
n=5). Red arrows indicate the point at which DOX treatment started. For conditional 
cells leukaemic cells were identified as (Mac-1+EGFP+)/Mac-1. For constitutive cells 
leukaemic cells were identified as (Mac-1+CD45.2+)/Mac-1.   219
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Figure 69: Leukaemic cells are not apoptotic in response to Doxycycline 
A) Percentage of EGFP+ ME4b cells expressing c-Kit in the bone marrow and spleen 
of the recipient mice, treated (grey bars) or untreated (white bars) with Doxycycline. 
Bars represent mean values (n=3), error bars represent the standard deviations. B) 
Dot plots show Gr-1 and c-Kit expression (upper panel), and staining with 7AAD 
and Annexin-V (lower panel), on gated EGFP+ ME4b cells in the bone marrow of 
mice 18 days after transplantation with ME4b cells and 3 days after their treatment 
(right plot), or not (left plot), with Doxycycline. Numbers in the plots represent the 
percentage of cells in each quadrant (upper panel) and of apoptotic (7AAD-, 
Annexin-V+) EGFP+ cells (lower panel).   220
Therefore, bone marrow from ME4b transfers was also analysed for 7-amino-
actinomycinD (7AAD) and Annexin-V staining (Figure 69 B bottom panel). 
However, the cells showed no detectable apoptosis in response to Doxycycline in 
vivo. This was also shown for recipients transplanted with ME7c cells. Upon 
detection of leukaemic cells in the peripheral blood on day 18 after transfer, bone 
marrow from the first group of recipients (n=3) was harvested and analysed. On the 
same day Doxycycline treatment began for the remaining ME7c recipients. Bone 
marrow was then harvested and analysed three days as well as eight days after the 
beginning of Doxycycline treatment (Figure 70). At each time point, three individual 
ME7c recipients were sacrificed. Leukaemic CD45.2
+EGFP
+ cells with high c-Kit 
expression were detected in the bone marrow 18 days after transfer and before 
treatment with Doxycycline began. 21 days after the cells were transferred, and three 
days into Doxycycline treatment, the second group of ME7c recipients was 
sacrificed. Although leukaemic CD45.2
+EGFP
+ cells were still detected in the bone 
marrow, they expressed reduced levels of c-Kit. 26 days after the cells were 
transferred, and eight days into Doxycycline treatment, the third group of ME7c 
recipients was sacrificed. Leukaemic CD45.2
+EGFP
+ cells were almost completely 
eliminated from the bone marrow. Taken together with the in vitro data, this data 
suggested that loss of leukaemic cells results from terminal differentiation in vivo. 
 
In some recipients, leukaemic cells reappeared in the peripheral blood and the 
mice relapsed with leukaemia (Figure 71 upper panel). All five recipients 
transplanted with ME4c leukaemic cells relapsed while they were still on 
Doxycycline treatment. One recipient transplanted with ME4b relapsed, also while 
still on Doxycycline treatment, and one recipient relapsed 101 days after the transfer, 
and 41 days after Doxycycline treatment was stopped.    221
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Figure 70: Doxycycline causes leukaemic cells to differentiate in vivo 
The dot plots show the presence of c-Kit+EGFP+ leukaemic ME7c cells in the bone 
marrow of three individual recipients after their treatment with Doxycycline (day 0, 
day 3 and day 8). This data is representative for three recipients per time point.   222
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Figure 71: Some recipients relapsed during or after Doxycycline treatment 
Recipient mice were transplanted with the indicated leukaemic cells and following 
their detection in the peripheral blood, one group was given Doxycycline in their 
water (open diamonds; ME4b n=5, ME4c n=5) and the other left untreated (filled 
circles; ME4b n=5, ME4c n=5). Red arrows indicate the point at which treatment 
started, red bars on the survival curves indicate the duration of treatment in each 
experiment. All of the mice transplanted with ME4c leukaemic cells relapsed while 
on Doxycycline treatment and two of the ME4b recipients relapsed: one while on 
Doxycycline treatment and one 41 days after Doxycycline withdrawal.   223
In all cases, the complete elimination of leukaemic cells from the peripheral 
blood was initially achieved, prior to the relapse (Figure 71 lower panel). In order to 
examine the expression of MLL-ENL in the relapses that occurred while recipients 
where being treated with Doxycycline, total RNA was isolated from splenocytes of 
the ME4cI, ME4cII and ME4bI relapses (Figure 72 A). All three analysed relapses 
had much higher MLL-ENL expression when compared to the parental immortalised 
cell line ME4, cultured with Doxycycline. Leukaemic cells were also isolated from 
the two ME4b recipients which relapsed, while on Doxycycline (ME4bI) and after 
(ME4bII) Doxycycline treatment. The isolated leukaemic cells were cultured in 
RPMI medium supplemented with 100 ng/ml SCF, 10 ng/ml IL-3 and 10 ng/ml IL-6. 
MLL-ENL expression in response to Doxycycline treatment was analysed by qPCR 
(Figure 72 B). In both cases, the MLL-ENL expression was not abrogated by addition 
of Doxycycline. Although the ME4bII cell line, produced from the relapsed 
leukaemia, expressed relatively low levels of MLL-ENL, these were not reduced by 
Doxycycline treatment. In addition the low level of MLL-ENL expression in this cell 
line correlated with a particularly slow proliferation rate (data not shown). 
Furthermore, the relative level of MLL-ENL expression was much lower in ME4bII 
cells compared to ME4 and ME4bI, which could be a possible explanation for the 
much longer latency for the development of leukaemia in this case. These results 
suggested that MLL-ENL expression, in all of the relapsed leukaemias analysed had 
become Doxycycline-insensitive and treatment with Doxycycline could no longer 
abrogate the MLL-ENL expression.   224
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Figure 72: Leukaemic cells require MLL-ENL expression for survival in vivo 
A-B) Relative level of MLL-ENL mRNA expression in immortalized ME4 cells after 
treatment (open bars or indicated with arrow) or not (filled bars) for 48 hours with 2 
µg/ml Doxycycline. Also shown in panel A are levels of MLL-ENL mRNA 
expression in leukaemias isolated from the spleens of secondary recipient mice 54 
days (ME4cI and ME4cII) after transplantation with ME4c leukaemic cells or 60 
days (ME4bI) after transplantation with ME4b leukaemic cells (all on Doxycycline 
treatment). Also shown in panel B) are levels of MLL-ENL mRNA expression in 
ME4b leukaemias following culture in RPMI medium with (open bars) or without 
(filled bars) Doxycycline. The cells were isolated from the spleens of secondary 
recipient mice 60 days (ME4bI, on Doxycycline treatment) and 101 days (ME4bII, 
off Doxycycline treatment) after transplantation. Values determined by quantitative 
RT-PCR are normalised to untreated ME4 cells. Columns represent the mean of 
triplicate measurements, error bars represent the standard deviations.    225
6.4.  Discussion – Chapter VI 
 
Our study shows that constitutively and conditionally immortalised MLL-
ENL cell lines induced leukaemia in vivo and that this leukaemia was transplantable 
into subsequent recipients. We observed that although leukaemic cells acquired 
additional genetic abnormalities, continuous MLL-ENL expression was required for 
maintaining leukaemia in vivo. Furthermore, we have shown that the leukaemia 
completely regressed upon loss of MLL-ENL activity. In the absence of MLL-ENL, 
leukaemic and immortalised cells underwent terminal myeloid differentiation in vitro 
and in vivo. Leukaemic cells remained growth factor dependent in culture, to the 
same combination of growth factors as the immortalised cells from which they were 
derived. However, the immunophenotype of leukaemic cells showed intermediate to 
high expression of the myeloid differentiation marker Gr-1. This heterogeneous 
leukaemic cell population is slightly different to the more homogeneous population 
of immortalised cells from which they were derived. 
 
Some of the recipients relapsed with leukaemia after the complete elimination 
of leukaemic cells from the peripheral blood was initially achieved. Since all mice, 
apart from one case, that relapsed were still on Doxycycline treatment but 
nevertheless showed significant expression of MLL-ENL mRNA, it seems likely that 
MLL-ENL expression in these recipients had become tTA independent. Therefore, 
MLL-ENL expression could not be abrogated by addition of Doxycycline anymore. 
Two other in  vivo studies have described a similar loss of conditional oncogene 
expression in response to Doxycycline or Tetracycline treatment. Felsher et al. used 
a Tet-regulatory system for MYC expression in mice and showed that 10% of the 
mice relapsed despite continuous Doxycycline treatment (Felsher et al., 1999).   226
Furthermore, all the MYC expressing lymphoid tumours had acquired novel 
chromosomal rearrangements (Karlsson et al., 2003). Koschmieder et al. developed a 
transgenic model in which tTA was placed under the control of the murine stem cell 
leukaemia (SCL) gene regulatory elements and showed that conditional expression 
of BCR-ABL resulted in reversible chronic myeloid leukaemia (CML) and B 
lymphoid blast crisis (Koschmieder et al., 2005). However, one of these leukaemias 
did not regress upon Tetracycline treatment and tumour cells were shown to have 
retained BCR-ABL expression despite the presence of Tetracycline (Koschmieder et 
al., 2005). Our similar findings suggest an in vivo selection for leukaemic cells with 
Doxycycline-independent MLL-ENL expression, which results in continuous MLL-
ENL expression that cannot be abrogated. These data further support the critical 
importance of MLL-ENL expression for leukaemic progression in vivo. 
 
We showed that secondary recipients transplanted with leukaemic 
splenocytes developed leukaemia with much shorter latencies than primary recipients 
transplanted with immortalised cells. Other in vivo MLL-fusion studies have also 
reported that secondary recipients develop leukaemia with shortened latencies 
(Lavau et al., 1997; Krivtsov et al., 2006; Somervaille et al., 2006). However, the 
reason for this event has not been previously addressed. We analysed leukaemic cells 
from secondary recipients in order to examine whether the shortened latencies are 
caused by an outgrowth of a minor aggressive clone in the primary recipients, or are 
due to in vivo conditioning to microenvironmental signals, or due to additional 
acquired genetic abnormalities. Our data showed that immortalised and leukaemic 
cells have the same retroviral integration pattern, suggesting that the outgrowth of a 
minor clone in vivo was unlikely. We then showed that secondary recipients develop 
AML with similar latencies when comparing freshly isolated leukaemic splenocytes   227
to cells transplanted following culture for one month in vitro. This suggests that in 
vivo conditioning to microenvironmental signals does not cause shortened latencies. 
However, we have also shown that the leukaemic cells had acquired additional 
genetic abnormalities, which could not be detected in the immortalised cells from 
which they were derived. Additional secondary mutations have also been reported in 
human leukaemias associated with the MLL-ENL translocation but have not been 
reported in other murine studies (Moorman et al., 1998). Since we demonstrated 
gross additional genetic abnormalities, such as the observed trisomy, or gains and 
losses of chromosomal regions, it is possible that these may be responsible for the 
reduced latency of AML upon secondary transplantation. Further analysis of the 
genes which are mapped to the regions of chromosomal gains or losses is necessary 
in order to examine whether some of these genes could be involved in the process of 
oncogenic transformation mediated by MLL-fusion oncogenes. 
 
We and others have shown that cancer cells are still physiologically 
dependent on the continued activity of a specific oncogene for maintenance of their 
malignant phenotype (Felsher et al., 1999; Koschmieder et al., 2005; Horton, Walf-
Vorderwülbecke et al., 2009). Our data supports the theory of ‘oncogene addiction’ 
(Jonkers et al., 2004; Weinstein et al., 2006) suggesting that the immortalised and 
leukaemic cells are addicted to MLL-ENL expression. Since transcription factors, 
such as MLL-fusion oncogenes, are difficult to target with drugs, therapeutic 
approaches aiming to directly inhibit oncogene expression are unlikely to be 
effective. However, targeting downstream pathways which are regulated by MLL-
fusions may be a possible way of interfering with the oncogenic transformation and 
reversing immortalisation (Krivtsov et al., 2006; Wong et al., 2007). Using this 
model we will be able to validate the importance of target genes, identified by the   228
Affymetrix microarray screen, in vivo. It will be necessary to examine if abrogating 
identified and validated target genes such as c-Myb and Siah1a will interfere with 
MLL-ENL mediated transformation in vivo and cause established AML to regress. 
Despite additional chromosomal mutations we have shown that MLL-ENL 
expression is still necessary to maintain leukaemia in vivo, offering a valid approach 
to target MLL-fusion activity. This specific targeting of oncogenic pathways 
maintained by MLL-fusions would offer new possibilities for therapy of MLL-fusion 
induced leukaemias.   229
CHAPTER VII  - CONCLUSION 
 
It was shown that the intact MLL portion of the MLL-AF9 fusion gene was 
required to immortalise murine haematopoietic progenitor cells. Myeloid 
constitutively and conditionally immortalised MLL-AF9 and MLL-ENL cells were 
generated using a retroviral transduction assay and methylcellulose culture. Stable 
constitutive and conditional cell lines were established in liquid culture and were 
maintained indefinitely in the presence of the myeloid growth factors SCF, IL-6 and 
IL-3. MLL-AF9 protein and mRNA expression was down-regulated in conditional 
cell lines in the presence of Doxycycline, but was not affected in constitutive cells. 
Similar results were observed for MLL-ENL mRNA expression. All of the 
characterised cell lines had a similar immature myeloid phenotype (c-Kit
+Gr-1
+Mac-
1
hi) and myeloblastic morphology in the absence of Doxycycline. Upon loss of MLL-
fusion expression, conditionally immortalised cells differentiated into more mature 
myeloid cells (c-kit
-Gr-1
hiMac-1
hi). Constitutive cells were not affected by addition 
of Doxycycline to the cultures. 
 
The known MLL-AF9 and MLL-ENL target genes, HoxA9 and Meis1, were 
expressed in the characterised cell lines and their expression was down-regulated 
upon loss of MLL-fusion expression. Cell lines with similar expression levels of 
HoxA9 and Meis1, as well as similar levels of down-regulation of these genes in the 
presence of Doxycycline, were selected for the gene expression analysis. Three 
conditional MLL-AF9 (MA1, MA3, MA4) and MLL-ENL (ME4, ME5, ME7) cell 
lines as well as one constitutive MLL-AF9 (cMA3) and MLL-ENL (cME3) cell lines 
were picked for the gene expression study and grouped as replicates. Global gene 
expression analysis confirmed the up-regulation of known MLL-fusion target genes,   230
such as genes of the HoxA cluster, Meis1 and Mef2c, and identified a large number 
(2,934 genes) of differentially expressed MLL-fusion target genes. At least twelve 
up-regulated target genes were found to be associated with the Wnt signalling 
pathway. 
 
Thirteen up-regulated target genes were selected for knock-down including 
some of the Wnt signalling associated genes and its key regulator Ctnnb1, which was 
not among the differentially expressed MLL-fusion target genes. Immortalised cell 
lines were transduced with shRNA knocking down specific target gene expression. 
Knock-down of two genes, c-Myb and Msi2, had a marked effect on the transduced 
cells, whereas knock-down of Frat1 and c-Myc had a slight effect. Knock-down of 
all other selected target genes did not have any effect on the immortalised cells. In 
addition, down-regulation of HoxA9, c-Myb, c-Myc, Frat1, Msi2, Pontin and Reptin 
expression upon loss of MLL-fusion expression was confirmed by qPCR. Protein 
expression of c-Myb and Pontin was also validated by Western blot analysis. In 
contrast to the Affymetrix analysis, β-Catenin mRNA and protein expression were 
found to be down-regulated upon loss of MLL-fusion expression.  
 
The E3 ubiquitin ligase Siah1a was found to be down-regulated in the 
presence of MLL-fusions. Since Siah1a targets not only β-Catenin for proteasomal 
degradation but also AF4, a member of the MLL-fusion complex, and c-Myb, a 
down-stream mediator of MLL-fusion activity, it was selected for further analysis. It 
was shown that Siah1a mRNA expression decreased in the presence of MLL-fusion 
proteins and that this regulation correlated with an increase in AF4 protein 
expression, a Siah1a degradation target. In order to analyse the role of Siah1a and 
Wnt signalling in MLL-fusion mediated transformation, Hexachlorophene was used   231
to study induction of Siah1a function without abrogating the expression of MLL-AF9 
or MLL-ENL. It was shown that MLL-fusion immortalised cells differentiate in 
response to Hexachlorophene treatment at a drug concentration-dependent 
differentiation rate. The results suggested that MLL-fusion target genes, identified by 
the Affymetrix analysis, are also differentially regulated upon treatment with 
Hexachlorophene, presumably through induction of Siah1a activity. The 
consequence of induced Siah1a activity would be proteasomal degradation of its 
targets, such as AF4, c-Myb and β-Catenin. Therefore, the transcriptional elongation 
complex, recruited by AF4, could no longer remain active and MLL-fusion target 
gene expression would consequently be abrogated. However, further experiments are 
necessary in order to prove the direct induction of Siah1a activity by 
Hexachlorophene. Figure 73 illustrates a proposed model of oncogenic MLL-fusion 
activity. 
 
Conditionally immortalised MLL-ENL cell lines were found to induce 
leukaemia in vivo. Secondary recipients transplanted with leukaemic cells developed 
leukaemia with much shorter latencies than primary recipients transplanted with 
immortalised cells. It was shown that the shortened latencies were not caused by an 
outgrowth of a minor aggressive clone in the primary recipients or by in vivo 
conditioning to microenvironmental signals. However, we have shown that the 
leukaemic cells isolated from primary recipients had acquired additional genetic 
abnormalities. The leukaemic cells remained dependent on MLL-ENL expression in 
vitro and in  vivo and its ablation resulted in differentiation and regression of 
established leukaemias. We were able to show that MLL-ENL expression is still 
necessary to maintain leukaemia in vivo, validating the targeting of MLL-fusion 
transcriptional activity in leukaemic therapy.   232
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Figure 73: Proposed model of MLL-fusion activity 
Target genes are regulated at the level of transcription by MLL-fusion oncogenes and 
at the level of protein by MLL-fusion  induced Siah1a repression. 1) MLL-fusion up-
regulate target genes, such as HoxA9, c-Myb, Ctnnb1; 2) level of c-Myb and Ctnnb1 
protein expression are increased; 3) MLL-fusion down-regulate Siah1a mRNA 
expression; 4) Siah1a activity is decreased in the presence of MLL-fusions; 5) 
proteasomal degradation of Siah1a targets, such as c-Myb, Ctnnb1, AF4, is 
decreased; 6) transcription elongation complex recruits AF4 and remains active in 
the presence of MLL-fusions.   233
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Figure 74: Determination of the viral titre of pMSCV-neo-TRE-fMLLAF9 
The viral titre was determined by titration on NIH-3T3 cells and was calculated using 
the following formula: 
viral titre (infectious particles/ml) = (number of colonies x dilution factor)/2   256
 
 
 
 
 
 
 
5’-….CCCCGCC CAAGTATCCCTGTAAAACAAAAACCA  AAAGA
AAAGATTCTTGAAGTGAAAAGTCCAATAAAGCA AAGCAAAT
CAGATAAGCAAATAAAGAATGGTGAATG TGACAAGGCA.…-’3
forward primer
probe
reverse primer
 
 
 
 
 
 
 
 
Figure 75: MLL-AF9 qPCR assay 
The figure illustrates the location of the MLL binding forward primer, the AF9 
binding reverse primer and the probe, which binds across the MLL-AF9 breakpoint. 
The MLL part of the construct shown in this figure is highlighted in green, the AF9 
part of the construct shown in this figure is highlighted in red. The location of the 
breakpoint in this construct is underlined in grey.   257
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Figure 76: MLL-AF9 qPCR assay, primer and probe optimisation 
A specific primer and probe set spanning the MLL-AF9 breakpoint region was 
designed and optimised to measure relative expression levels of MLL-AF9 by qPCR. 
A) The optimal primer concentration and B) the optimal probe concentration were 
determined by plotting the cycle threshold (CT) value versus primer or probe 
concentration. Columns represent the mean of triplicates, error bars represent the 
standard deviations.   258
 
 
 
 
 
MLL-AF9 18S
Log [cDNA concentration (ng)]
C
T
v
a
l
u
e
slope = -3.2668
y intercept = 26.088
R2 = 0.9943
slope = -3.3129
y intercept = 18.774
R2 = 0.97
0 0.5 1 1.5 2
10
15
20
25
30
 
 
 
 
 
 
Figure 77: Standard curve for MLL-AF9 and 18S qPCR assays 
The graph shows the standard curves for MLL-AF9 (black triangles) and for 18S 
(grey diamonds) generated by qPCR of serially diluted cDNA (0.39 ng to 50 ng). 
The slope reflects the efficiency of the assay, the y intercept reflects the sensitivity 
and R2 indicated the reproducibility of the assay at low and high cDNA 
concentrations.   259 
Table 21: List of all hairpin oligonucleotides designed and tested in this study 
 
No
. 
Gene Name  Accession No.  Sequence (5’-miR30senseloopantisensemiR30-3’) Design  tool 
1  Meis1  NM_010789 TGCTGTTGACAGTGAGCGCGTGTCCTATCTTAGCATTTAATAGTGAAGC
CACAGATGTATTAAATGCTAAGATAGGACACATGCCTACTGCCTCGGA 
 
Kathadin 
2  Meis1  NM_010789 TGCTGTTGACAGTGAGCGCCTGGATAACTTGATGATTCAATAGTGAAGC
CACAGATGTATTGAATCATCAAGTTATCCAGTTGCCTACTGCCTCGGA 
 
Kathadin 
3  Meis1  NM_010789 TGCTGTTGACAGTGAGCGCCCACACTATGTGTGTTGTTTCTAGTGAAGC
CACAGATGTAGAAACAACACACATAGTGTGGATGCCTACTGCCTCGGA 
 
Kathadin 
4  Zfhx1b  NM_015753 TGCTGTTGACAGTGAGCGCGCAAGAAATGTATTGGTTTAATAGTGAAGC
CACAGATGTATTAAACCAATACATTTCTTGCTTGCCTACTGCCTCGGA 
 
RNAi codex  
5  Zfhx1b  NM_015753 TGCTGTTGACAGTGAGCGCCCACTAGACTTCAATGACTATTAGTGAAGC
CACAGATGTAATAGTCATTGAAGTCTAGTGGTTGCCTACTGCCTCGGA 
 
RNAi codex  
6  Zfhx1b  NM_015753 TGCTGTTGACAGTGAGCGAAGACTGTAGCTTATCCTTTATTAGTGAAGC
CACAGATGTAATAAAGGATAAGCTACAGTCTGTGCCTACTGCCTCGGA 
 
Katahdin 
7  P2ry2  NM_008773 TGCTGTTGACAGTGAGCGCGCTGGCAAATGTCAAACCATTTAGTGAAGC
CACAGATGTAAATGGTTTGACATTTGCCAGCATGCCTACTGCCTCGGA 
 
RNAi codex  
8  P2ry2  NM_008773 TGCTGTTGACAGTGAGCGAGCCAATCCTATTTCAATTTAATAGTGAAGC
CACAGATGTATTAAATTGAAATAGGATTGGCCTGCCTACTGCCTCGGA 
 
RNAi codex  
9  P2ry2  NM_008773 TGCTGTTGACAGTGAGCGCGGGAACCATAACTTATATGAATAGTGAAG
CCACAGATGTATTCATATAAGTTATGGTTCCCATGCCTACTGCCTCGGA 
RNAi codex  
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10  Hpgd  NM_008278 TGCTGTTGACAGTGAGCGAGGTGTAAGACTGAATGTCATTTAGTGAAGC
CACAGATGTAAATGACATTCAGTCTTACACCGTGCCTACTGCCTCGGA 
 
RNAi codex  
11  Hpgd  NM_008278 TGCTGTTGACAGTGAGCGATTCCTGTATCTGATGTTAATATAGTGAAGC
CACAGATGTATATTAACATCAGATACAGGAAGTGCCTACTGCCTCGGA 
 
Katahdin 
12  Hpgd  NM_008278 TGCTGTTGACAGTGAGCGATCACTCAGACTGCATCTTTACTAGTGAAGC
CACAGATGTAGTAAAGATGCAGTCTGAGTGAGTGCCTACTGCCTCGGA 
 
Katahdin 
13  Frat1  NM_008043 TGCTGTTGACAGTGAGCGAGGAAACAAGAGTGGACTTAATTAGTGAAG
CCACAGATGTAATTAAGTCCACTCTTGTTTCCCTGCCTACTGCCTCGGA 
 
RNAi codex  
14  Frat1  NM_008043 TGCTGTTGACAGTGAGCGACCAGGACTTAGGTTTGTTTAATAGTGAAGC
CACAGATGTATTAAACAAACCTAAGTCCTGGGTGCCTACTGCCTCGGA 
 
RNAi codex  
15  Frat1  NM_008043 TGCTGTTGACAGTGAGCGCCGGCTCAGCCTGCTATGGAACTAGTGAAGC
CACAGATGTAGTTCCATAGCAGGCTGAGCCGATGCCTACTGCCTCGGA 
 
Katahdin 
16  Frat2  NM_177603 TGCTGTTGACAGTGAGCGCGGGCTTCTAACAATACTTGAATAGTGAAGC
CACAGATGTATTCAAGTATTGTTAGAAGCCCTTGCCTACTGCCTCGGA 
 
RNAi codex  
17  Frat2  NM_177603 TGCTGTTGACAGTGAGCGCCCTGATTTATAGGATTCATAATAGTGAAGC
CACAGATGTATTATGAATCCTATAAATCAGGATGCCTACTGCCTCGGA 
 
RNAi codex  
18  Frat2  NM_177603 TGCTGTTGACAGTGAGCGCGGTGGTCCTGATTTATAGGATTAGTGAAGC
CACAGATGTAATCCTATAAATCAGGACCACCATGCCTACTGCCTCGGA 
 
RNAi codex  
19  Fzd7  NM_008057 TGCTGTTGACAGTGAGCGCCCGGCTAGGGCCTAAGGGAAATAGTGAAG
CCACAGATGTATTTCCCTTAGGCCCTAGCCGGTTGCCTACTGCCTCGGA 
 
RNAi codex  
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20  Fzd7  NM_008057 TGCTGTTGACAGTGAGCGACCTTGTCAAGTGGTGGTCAAATAGTGAAGC
CACAGATGTATTTGACCACCACTTGACAAGGGTGCCTACTGCCTCGGA 
 
RNAi codex  
21  Fzd7  NM_008057 TGCTGTTGACAGTGAGCGATGCGAGGCGCTCATGAACAAGTAGTGAAG
CCACAGATGTACTTGTTCATGAGCGCCTCGCAGTGCCTACTGCCTCGGA 
 
Katahdin 
22  c-myb  NM_010848 TGCTGTTGACAGTGAGCGACCCTTGCAGCTCAAGAAATTATAGTGAAGC
CACAGATGTATAATTTCTTGAGCTGCAAGGGCTGCCTACTGCCTCGGA 
 
RNAi codex  
23  c-myb  NM_010848 TGCTGTTGACAGTGAGCGAGGGAAACTTCTTCTGCTCAAATAGTGAAGC
CACAGATGTATTTGAGCAGAAGAAGTTTCCCGTGCCTACTGCCTCGGA 
 
RNAi codex  
24  c-myb  NM_010848 TGCTGTTGACAGTGAGCGCAGAGACTCGGTGTTAGATAACTAGTGAAG
CCACAGATGTAGTTATCTAACACCGAGTCTCTTTGCCTACTGCCTCGGA 
 
Katahdin 
25  Msi2  NM_054043 TGCTGTTGACAGTGAGCGACCAGCAAGTGTAGATAAAGTATAGTGAAG
CCACAGATGTATACTTTATCTACACTTGCTGGGTGCCTACTGCCTCGGA 
 
RNAi codex  
26  Msi2  NM_054043 TGCTGTTGACAGTGAGCGCGCAAGTGTAGATAAAGTATTATAGTGAAG
CCACAGATGTATAATACTTTATCTACACTTGCTTGCCTACTGCCTCGGA 
 
RNAi codex  
27  Msi2  NM_054043 TGCTGTTGACAGTGAGCGAACCCAGCAAGTGTAGATAAAGTAGTGAAG
CCACAGATGTACTTTATCTACACTTGCTGGGTCTGCCTACTGCCTCGGA 
 
Katahdin 
28  Sox4  NM_009238 TGCTGTTGACAGTGAGCGACGCTCGATCGGGACCTGGATTTAGTGAAGC
CACAGATGTAAATCCAGGTCCCGATCGAGCGCTGCCTACTGCCTCGGA 
 
RNAi codex  
29  Sox4  NM_009238 TGCTGTTGACAGTGAGCGCGGTTTATAGCTGTTGTGTTTATAGTGAAGC
CACAGATGTATAAACACAACAGCTATAAACCTTGCCTACTGCCTCGGA 
 
RNAi codex  
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30  Sox4  NM_009238 TGCTGTTGACAGTGAGCGACGAGATGATCTCGGGAGATTGTAGTGAAG
CCACAGATGTACAATCTCCCGAGATCATCTCGCTGCCTACTGCCTCGGA 
 
Katahdin 
31  Gata2  NM_008090 TGCTGTTGACAGTGAGCGCGCCGCCATTACTGTGAATATTTAGTGAAGC
CACAGATGTAAATATTCACAGTAATGGCGGCATGCCTACTGCCTCGGA 
 
RNAi codex  
32  Gata2  NM_008090 TGCTGTTGACAGTGAGCGAGGAGAGTGTTTGTTTGGAGAGTAGTGAAG
CCACAGATGTACTCTCCAAACAAACACTCTCCGTGCCTACTGCCTCGGA 
 
Katahdin 
33  Gata2  NM_008090 TGCTGTTGACAGTGAGCGAGGCCTCTGTCTGTTTACCCAGTAGTGAAGC
CACAGATGTACTGGGTAAACAGACAGAGGCCCTGCCTACTGCCTCGGA 
 
Katahdin 
34  Ctnnb1  NM_007614 TGCTGTTGACAGTGAGCGCGGACCAGGTGGTAGTTAATAATAGTGAAG
CCACAGATGTATTATTAACTACCACCTGGTCCTTGCCTACTGCCTCGGA 
 
RNAi codex  
35  Ctnnb1  NM_007614 TGCTGTTGACAGTGAGCGACCAGTGTGGGTGAATACTTTATAGTGAAGC
CACAGATGTATAAAGTATTCACCCACACTGGCTGCCTACTGCCTCGGA 
 
RNAi codex  
36  Ctnnb1  NM_007614 TGCTGTTGACAGTGAGCGCACTGTTGGATTGATTCGAAACTAGTGAAGC
CACAGATGTAGTTTCGAATCAATCCAACAGTTTGCCTACTGCCTCGGA 
 
Katahdin 
 
All hairpin oligonucleotides were designed against the sense strand of the target gene, using either Katahdin prediction software (http://katahdin.cshl.org: 
9331/siRNA/RNAi.cgi?type=shRNA) or sequences published on RNAi codex web site (http://codex.cshl.edu). 
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Table 22: 41 up-regulated genes picked by rank and publication 
 
Gene Symbol  Accession Number  Fold Change  Product 
Hpgd  1419906_at  34.11  Hydroxyprostaglandin dehydrogenase 15  
Cited4  1425400_a_at 12.2  Cbp/p300-interacting  transactivator, with Glu/Asp-rich carboxy-terminal domain4 
Ascl2  1422396_s_at  10.93  achaete-scute complex homolog-like 2 (Drosophila) 
Sox4  1419156_at  8.23  SRY-box containing gene 4 
P2ry2  1450318_a_at 7.474  purinergic  receptor P2Y, G-protein coupled 2 
Frat2  1455220_at  6.627  frequently rearranged in advanced T-cell lymphomas 2 
Znrf3  1435608_at  5.839  zinc and ring finger 3 
Six4  1425767_a_at 5.831  sine  oculis-related homeobox 4 homolog (Drosophila) 
Ppan  1423703_at  4.829  peter pan homolog (Drosophila) 
Zfp248  1436473_at  4.775  zinc finger protein 248 
Six1  1427277_at  3.968  sine oculis-related homeobox 1 homolog (Drosophila) 
Hmgn1  1422495_a_at  3.924  high mobility group nucleosomal binding domain 1 
Pontin  1416585_at  3.916  RuvB-like protein 1 
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Eif1a  1424343_a_at 3.822  eukaryotic translation initiation factor 1A 
Pa2g4  1435372_a_at 3.779  proliferation-associated  2G4 
Gas5  1455904_at  3.776  growth arrest specific 5 
Zfhx1b  1442393_at  3.754  Zinc finger homeobox 1b 
Tceal8  1418171_at  3.745  transcription elongation factor A (SII)-like 8 
Nle1  1424731_at  3.726  notchless homolog 1 (Drosophila) 
c-Myc  1424942_a_at 3.724  myelocytomatosis oncogene 
Reptin  1422482_at  3.614  RuvB-like protein 2 
Angptl4  1417130_s_at 3.587  angiopoietin-like  4 
Pdcd4  1418840_at  3.571  programmed cell death 4 
Mybbp1a  1423430_at  3.462  MYB binding protein (P160) 1a 
c-Myb  1423430_at  3.462  MYB binding protein (P160) 1a 
Nr4a2  1455034_at 3.151 Nuclear  receptor  subfamily 4, group A, member 2 (Nr4a2) 
Taf4b  1435303_at  3.144  TAF4B RNA polymerase II, TATA box binding protein (TBP)-associated factor 
Frat1  1449814_at  3.047  frequently rearranged in advanced T-cell lymphomas 
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Aatf  1432394_a_at  3.042  apoptosis antagonizing transcription factor 
Tcf4  1424089_a_at  3.04  transcription factor 4 
Eef1d  1428135_a_at 3.038  eukaryotic translation elongation factor 1 delta 
Tada2l  1452310_at  2.994  transcriptional adaptor 2 (ADA2 homolog, yeast)-like 
Pdrg1  1428309_s_at 2.855  p53  and  DNA damage regulated 1 
Eif2b3  1434524_at 2.855 eukaryotic translation initiation factor 2B, subunit 3 
Msi2  1435521_at  2.786  Musashi homolog 2 (Drosophila) 
Ptch1  1428853_at  2.767  patched homolog 1 
Cnksr3  1433983_at  2.764  Cnksr family member 3 
Gata2  1450333_a_at  2.744  GATA binding protein 2 
Tnfrsf11a  1430259_at 2.602 tumor  necrosis factor receptor superfamily, member 11a 
Fzd7  1450044_at  2.46  frizzled homolog 7 (Drosophila) 
Rab34  1416590_a_at 2.411  RAB34,  member of RAS oncogene family 
 
The table lists 41 genes which were selected by rank and publication from the list of genes that were up-regulated in the presence of MLL-fusions. The entries in the list 
are sorted by fold change. 
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